FedInvent™ Patent Applications
Application Details for Thursday, September 15, 2022
This page was updated on Thursday, September 15, 2022 at 08:21 PM GMT
Department of Health and Human Services (HHS)
| US 20220287583 | Rubinsky et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Boris Rubinsky (El Cerrito, California); Cesar A. GONZALEZ (Anahuac, Mexico) |
| ABSTRACT | A method and apparatus of determining the condition of a bulk tissue sample, by: positioning a bulk tissue sample between a pair of induction coils (or antennae); passing a spectrum of alternating current (or voltage) through a first of the induction coils (or antennae); measuring spectrum of alternating current (or voltage) produced in the second of the induction coils (or antennae); and comparing the phase shift between the spectrum of alternating currents (or voltages) in the first and second induction coils (or antennae), thereby determining the condition of the bulk tissue sample. |
| FILED | Monday, September 20, 2021 |
| APPL NO | 17/479640 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/05 (20130101) A61B 5/053 (20130101) A61B 5/0205 (20130101) A61B 5/413 (20130101) A61B 5/443 (20130101) A61B 5/0537 (20130101) Original (OR) Class A61B 5/725 (20130101) A61B 5/02042 (20130101) A61B 5/4064 (20130101) A61B 5/4244 (20130101) A61B 5/4519 (20130101) A61B 5/4869 (20130101) A61B 5/4878 (20130101) A61B 5/7225 (20130101) A61B 5/7228 (20130101) A61B 2562/143 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 27/026 (20130101) Measuring Electric Variables; Measuring Magnetic Variables G01R 33/34 (20130101) G01R 33/36 (20130101) G01R 33/483 (20130101) G01R 33/4828 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287603 | Zand et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | SURGISENSE CORPORATION (BETHESDA, Maryland) |
| ASSIGNEE(S) | SURGISENSE CORPORATION (BETHESDA, Maryland) |
| INVENTOR(S) | Jason Matthew Zand (Washington, District of Columbia); Gregory Scott Fischer (Jamaica Plain, Massachusetts); Justin Thomas Knowles (Fairfax, Virginia) |
| ABSTRACT | Apparatus, systems, and methods are provided that generate in vivo maps of oxygenation measurements of biological tissue. These may include surgical instruments and stand-alone imaging systems with incorporated oxygen sensing capability. Oxygenation maps can be determined via fluorescent or phosphorescent lifetime imaging of an injectable probe with an oxygen-dependent optical response. Probe configuration and methods and apparatus of injecting the probe into the tissue are provided. Methods and apparatus for temperature compensation of temperature-dependent lifetime measurements are provided to improve oxygenation measurement accuracy. Oxygen maps may be registered with visible light images to assist in assessing tissue viability or localize anomalies in the tissue. Resulting oxygen images may be used for various applications including, but not limited to, guiding surgical procedures such as colorectal resection through use of intraoperative sensing, enhanced endoscopic imaging for identifying suspect lesions during colonoscopy, and external imaging of tissue such as assessing peripheral vascular disease. |
| FILED | Thursday, October 21, 2021 |
| APPL NO | 17/507015 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 1/0005 (20130101) A61B 1/005 (20130101) A61B 1/00009 (20130101) A61B 1/018 (20130101) A61B 1/043 (20130101) A61B 1/0125 (20130101) A61B 1/0676 (20130101) A61B 5/015 (20130101) A61B 5/0035 (20130101) A61B 5/0071 (20130101) A61B 5/0084 (20130101) A61B 5/1459 (20130101) A61B 5/14556 (20130101) Original (OR) Class A61B 2560/0247 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287648 | Cannesson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Maxime Cannesson (Los Angeles, California); Brian Hill (Los Angeles, California); Eran Halperin (Santa Monica, California); Ira Hofer (Los Angeles, California); Nadav Rakocz (Los Angeles, California) |
| ABSTRACT | Systems and methods for training a signal generation model and generating imputed physiological waveform signals in accordance with embodiments of the invention are illustrated. One embodiment includes a method for measuring physiological waveform signals. The method includes steps for receiving a set of one or more input physiological waveform signals, processing the set of input physiological waveform signals, generating an output physiological waveform signal using a signal generation model, and providing outputs based on the generated output signal. |
| FILED | Wednesday, August 19, 2020 |
| APPL NO | 17/753126 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/308 (20210101) A61B 5/318 (20210101) A61B 5/742 (20130101) A61B 5/02416 (20130101) A61B 5/7203 (20130101) A61B 5/7267 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287658 | Viola et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wayne State University (Detroit, Michigan) |
| ASSIGNEE(S) | Wayne State University (Detroit, Michigan); Wayne State University (Detroit, Michigan) |
| INVENTOR(S) | Nerissa Viola (Canton, Michigan); Heather Gibson (Ferndale, Michigan) |
| ABSTRACT | Compositions and methods for in vivo immunoimaging IL-12 as a marker of IL-12—producing activated antigen presenting cells (APCs) in a subject are provided according to aspects of the present disclosure which include: administering a labeled-antibody conjugate to a subject, wherein the labeled-antibody conjugate includes 1) an antibody or antibody fragment that specifically binds to IL-12, and 2) a detection label conjugated to the antibody or antibody fragment, wherein the detection label is a radionuclide tracer, fluorophore, or nanoparticle, and wherein the labeled-antibody conjugate specifically binds to IL-12; and detecting the presence of the labeled-antibody conjugate in the subject in vivo by imaging. According to embodiments of the present disclosure, the subject is human and the antibody or antibody fragment specifically binds to human IL-12. |
| FILED | Wednesday, August 19, 2020 |
| APPL NO | 17/636107 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 6/037 (20130101) Original (OR) Class A61B 6/4417 (20130101) Preparations for Medical, Dental, or Toilet Purposes A61K 31/164 (20130101) A61K 38/193 (20130101) A61K 51/1021 (20130101) A61K 51/1093 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) A61P 39/04 (20180101) Peptides C07K 16/244 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287758 | Yang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Trustees of Boston University (Boston, Massachusetts) |
| ASSIGNEE(S) | Trustees of Boston University (Boston, Massachusetts) |
| INVENTOR(S) | Chen Yang (Newton, Massachusetts); Ji-Xin Cheng (Newton, Massachusetts); Nan Zheng (Allston, Massachusetts); Yueming Li (Brighton, Massachusetts); Ying Jiang (Brighton, Massachusetts); Lu Lan (Allston, Massachusetts); Linli Shi (Allston, Massachusetts) |
| ABSTRACT | A tapered fiber optoacoustic emitter includes a nanosecond laser configured to emit laser pulses and an optic fiber. The optic fiber includes a tip configured to guide the laser pulses. The tip has a coating including a diffusion layer and a thermal expansion layer, wherein the diffusion layer includes epoxy and zinc oxide nanoparticles configured to diffuse the light while restricting localized heating. The thermal expansion layer includes carbon nanotubes (CNTs) and Polydimethylsiloxane (PDMS) configured to convert the laser pulses to generate ultrasound. The frequency of the ultrasound is tuned with a thickness of the diffusion layer and a CNT concentration of the expansion layer. |
| FILED | Wednesday, March 09, 2022 |
| APPL NO | 17/690948 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 18/04 (20130101) Original (OR) Class Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 19/10 (20130101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 30/00 (20130101) B82Y 40/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287883 | Mbagwu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California); The United States of America as represented by The Department Of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael Mbagwu (Mountain View, California); David Buickians (Glendale, California); David Myung (Saratoga, California) |
| ABSTRACT | Precise concentric, symmetric, and repeatable circular scoring (cutting) of Descemet's membrane is made possible by a handheld surgical ophthalmic device. The precision of the cut is provided by a stabilizing point on a stabilizing arm as well the anchoring insertion point at the limbus. Stabilization through the insertion point and the stabilizing arm provides a two-point fixation thereby establishing a cutting plane. The cutting plane allows for precise depth of cut whereas the rotating blade's consistent radius allows for circularity of the cut. The stabilization arm fixates on tissue, and is then removed when the procedure is completed. Consistent torque and contact pressure of the cutting blade is provided through rotational control via the depression of a button on a handle thereby removing the need to “free-hand” the desemetorhexis. |
| FILED | Tuesday, March 15, 2022 |
| APPL NO | 17/695484 |
| CURRENT CPC | Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits A61F 9/0133 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287969 | Sayour et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Inc. (Gainesville, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Elias Sayour (Newberry, Florida); Hector Ruben Mendez-Gomez (Gainesville, Florida); Duane Mitchell (Gainesville, Florida); Carlos Rinaldi (Gainesville, Florida) |
| ABSTRACT | The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided. |
| FILED | Friday, July 17, 2020 |
| APPL NO | 17/626674 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/1272 (20130101) Original (OR) Class A61K 39/39 (20130101) A61K 48/0033 (20130101) A61K 2039/53 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/88 (20130101) C12N 15/113 (20130101) C12N 2310/351 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287983 | Traverso et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts); The Brigham and Women's Hospital, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts); The Brigham and Women's Hospital, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Carlo Giovanni Traverso (Newton, Massachusetts); Ameya R. Kirtane (Cambridge, Massachusetts); Robert S. Langer (Newton, Massachusetts); Hyunjoon KIM (Cambridge, Massachusetts); Gary W. Liu (Cambridge, Massachusetts); James Byrne (Boston, Massachusetts); Daniel Reker (Durham, North Carolina); Yunhua Shi (Arlington, Massachusetts); Grace Junyue Zhong (Cambridge, Massachusetts); Netra Rajesh (Brampton, Canada) |
| ABSTRACT | The present disclosure provides branched poly(β-amino esters) (PBAEs) of Formula (I) made by reacting primary amines with diacrylates. Further provided herein are compositions comprising the polymers of Formula (I), and methods of using the compositions and polymers as described herein for the treatment of disease. L-(R)n (I) |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689314 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5153 (20130101) Original (OR) Class A61K 39/0011 (20130101) A61K 48/0041 (20130101) A61K 2039/53 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 63/685 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287995 | SIRYAPORN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (OAKLAND, California) |
| ASSIGNEE(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (OAKLAND, California) |
| INVENTOR(S) | Albert SIRYAPORN (IRVINE, California); Michelle DIGMAN (IRVINE, California); Jenu VARGHESE CHACKO (IRVINE, California); Kumar PERINBAM (IRVINE, California); Anerudh KANNAN (IRVINE, California); Allon HOCHBAUM (IRVINE, California); Katrine WHITESON (IRVINE, California) |
| ABSTRACT | Compositions and methods for inhibiting bacterial virulence, as well as methods and materials for use in rapid assessment of antibiotic susceptibility are described. A method for inhibiting bacterial virulence comprises exposing a site containing or suspected of containing virulent bacteria to a carbon source, wherein the carbon source produces a low g value. Examples of such carbon sources include pyruvate, citrate, oxaloacetate, malate, and fumarate. The carbon source can be applied to a surface or administered to a subject. A device for testing antibiotic susceptibility of bacteria comprises a fluorescence lifetime imaging microscopy (FLIM) apparatus that emits an excitation pulse of light directed at a receiving surface; a detector that collects time-correlated fluorescence emitted from individual bacteria immobilized on the receiving surface; an analyzer that generates a FLIM-phasor profile; and an analyzer that correlates the FLIM-phasor profile to the status of the antibiotic susceptibility of the bacteria. |
| FILED | Thursday, July 30, 2020 |
| APPL NO | 17/597922 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/19 (20130101) A61K 31/194 (20130101) Original (OR) Class Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/025 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288001 | Yang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Lili Yang (Los Angeles, California); Stefano Di Biase (Los Angeles, California) |
| ABSTRACT | As disclosed herein, we have discovered that creatine is a critical molecule buffering ATP levels in cancer-targeting CD8 T cells through maintaining a readily available high-energy phosphate reservoir. Building upon this discovery, we have designed a number of methods for modulating energy metabolism in a population of tumor-infiltrating CD8 T cells, methods that can be adapted for use in therapeutic regimens for the treatment of cancer. Illustrative embodiments of the invention include methods for enhancing tumor-infiltrating CD8 T cells ability to mount and sustain a response to tumor cells comprising increasing the concentrations of creatine available for tumor-infiltrating CD8 T cells energy metabolism, thereby enhancing the ability of the tumor-infiltrating CD8 T cells to mount and sustain a response to the tumor cells. |
| FILED | Thursday, September 24, 2020 |
| APPL NO | 17/763583 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/198 (20130101) Original (OR) Class A61K 31/337 (20130101) A61K 31/555 (20130101) A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 16/2809 (20130101) C07K 16/2818 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288011 | Brosnan |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Robert J. Brosnan (Davis, California) |
| ABSTRACT | The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods. |
| FILED | Monday, November 02, 2020 |
| APPL NO | 17/087365 |
| CURRENT CPC | Veterinary Instruments, Implements, Tools, or Methods A61D 7/04 (20130101) Preparations for Medical, Dental, or Toilet Purposes A61K 9/007 (20130101) A61K 31/02 (20130101) A61K 31/08 (20130101) A61K 31/025 (20130101) A61K 31/045 (20130101) A61K 31/341 (20130101) A61K 31/351 (20130101) Original (OR) Class A61K 31/357 (20130101) Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 16/01 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288024 | ALEXANDER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Melinta Subsidiary Corp. (Morristown, New Jersey) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Elizabeth ALEXANDER (Maplewood, New Jersey); Jeffrey S. LOUTIT (Los Altos, California); Michael N. DUDLEY (San Diego, California) |
| ABSTRACT | Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy. |
| FILED | Friday, May 27, 2022 |
| APPL NO | 17/826712 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 31/69 (20130101) A61K 31/407 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/04 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
20220288028 — A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS
| US 20220288028 | Dana et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Schepens Eye Research Institute, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Reza Dana (Newton, Massachusetts); Yihe Chen (Somerville, Massachusetts) |
| ABSTRACT | Disclosed are methods of treating a non-infectious ocular immunoinflammatory disorder in a subject. Methods of reducing a symptom, e.g., ocular redness, of a non-infectious ocular immunoinflammatory disorder in a subject, and pharmaceutical composition containing an SP blocker, an SP antagonist, an SP receptor blocker or an SP receptor antagonist as an active component and a pharmaceutically acceptable carrier or excipient are also described. |
| FILED | Friday, May 29, 2020 |
| APPL NO | 17/613467 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0048 (20130101) A61K 31/41 (20130101) Original (OR) Class A61K 31/404 (20130101) A61K 31/439 (20130101) A61K 31/451 (20130101) A61K 31/4035 (20130101) A61K 31/5377 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 27/02 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288032 | Kyba et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, Minnesota) |
| ASSIGNEE(S) | REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, Minnesota) |
| INVENTOR(S) | Michael Kyba (Minneapolis, Minnesota); Darko Bosnakovski (Minneapolis, Minnesota) |
| ABSTRACT | A method for treating a cancer involving one or more translocations generating an oncogenic fusion transcription factor that requires p300/CBP for activity in an animal, comprising administering a compound of formula (I): or a pharmaceutically acceptable salt thereof to the animal. |
| FILED | Thursday, March 10, 2022 |
| APPL NO | 17/691305 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/4184 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288037 | Edagwa et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (Lincoln, Nebraska) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Benson Edagwa (Omaha, Nebraska); Howard Gendelman (Omaha, Nebraska) |
| ABSTRACT | The present invention provides prodrugs and methods of use thereof. |
| FILED | Friday, August 21, 2020 |
| APPL NO | 17/631955 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/426 (20130101) Original (OR) Class A61K 31/675 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/12 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288051 | Mitsiades et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Constantine S. MITSIADES (Brookline, Massachusetts); Ryosuke SHIRASAKI (, None); Geoffrey M. MATTHEWS (Malvern East, Australia); Sara GANDOLFI (Carnago, Italy); Ricardo DE MATOS SIMOE (Boston, Massachusetts); Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Constantine S. Mitsiades (Brookline, Massachusetts); Ryosuke Shirasaki (, None); Geoffrey M. Matthews (Malvern East, Australia); Sara Gandolfi (Carnago, Italy); Ricardo de Matos Simoes (Boston, Massachusetts) |
| ABSTRACT | The present invention relates, in part, to methods for treating cancer using serial administration of E3 ubiquitin ligase degraders. |
| FILED | Friday, September 11, 2020 |
| APPL NO | 17/641288 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/551 (20130101) A61K 31/4545 (20130101) Original (OR) Class A61K 45/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288059 | Castor |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Trevor P. CASTOR (Woburn, Massachusetts) |
| ASSIGNEE(S) | Aphios Corporation (Woburn, Massachusetts) |
| INVENTOR(S) | Trevor Percival Castor (Arlington, Massachusetts) |
| ABSTRACT | Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids, naltrexone and a combination of cannabinoids and naltrexone as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized sphere having a diameter of about 100 to 500 nanometers having a shell comprising a biodegradable polymer containing a cannabinoid, naltrexone and a combination of a cannabinoid and naltrexone in a deareated buffer. A featured cannabinoid is cannabidiol (CBD). |
| FILED | Saturday, August 15, 2020 |
| APPL NO | 17/635694 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/19 (20130101) A61K 9/5153 (20130101) A61K 9/5192 (20130101) A61K 31/05 (20130101) A61K 31/485 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288071 | Wang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stantord, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xinnan Wang (Redwood City, California); Chung-Han Hsieh (Palo Alto, California); Li Li (Palo Alto, California); Kong Nguyen (Moraga, California) |
| ABSTRACT | Methods and compositions are provided for the treatment of Parkinson's Disease. Aspects of the methods include administering Miro1 reducer. Also provided are reagents and kits for practicing the subject methods. In some embodiments, a method is provided for reducing undesirable levels of Miro1 in a cell having depolarized or otherwise damaged mitochondria. In some embodiments the cell is in vivo, e.g. in an animal model for PD, in an individual diagnosed with PD, in a clinical trial for treatment of PD, and the like. |
| FILED | Friday, September 04, 2020 |
| APPL NO | 17/638676 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/13 (20130101) A61K 31/198 (20130101) A61K 31/506 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/16 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
20220288079 — SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY
| US 20220288079 | ALLEN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| INVENTOR(S) | Joshua E. ALLEN (Cambridge, Massachusetts); Gen Sheng WU (Troy, Michigan); Wafik S. EL-DEIRY (Bryn Mawr, Pennsylvania) |
| ABSTRACT | Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof. |
| FILED | Monday, March 21, 2022 |
| APPL NO | 17/655646 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 9/0053 (20130101) A61K 31/337 (20130101) A61K 31/513 (20130101) A61K 31/519 (20130101) Original (OR) Class A61K 31/4188 (20130101) A61K 31/4545 (20130101) A61K 39/3955 (20130101) A61K 39/39558 (20130101) A61K 45/06 (20130101) A61K 2039/505 (20130101) Peptides C07K 16/22 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6863 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288099 | DREW et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF ALASKA FAIRBANKS (Fairbanks, Alaska) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kelly DREW (Fairbanks, Alaska); Bernard LAUGHLIN (Fairbanks, Alaska) |
| ABSTRACT | The present disclosure provides a pharmaceutical composition comprising i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic. Kits utilizing i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic are also provided, as well as methods utilizing the described pharmaceutical compositions and kits. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692383 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/7076 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 9/02 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288104 | Blanchard et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Joel Blanchard (Arlington, Massachusetts); Manolis Kellis (Boston, Massachusetts); Li-Huei Tsai (Cambridge, Massachusetts); Jose Davila Velderrain (Saltillo, Mexico); Leyla Akay (Cambridge, Massachusetts); Djuna Von Maydell (Somerville, Massachusetts); Audrey Effenberger (Cambridge, Massachusetts); Matheus Victor (Cambridge, Massachusetts) |
| ABSTRACT | The present disclosure provides methods of inhibiting amyloid synthesis in a subject using cyclodextrin and analogs thereof. Small molecules (cyclodextrin) reverse APOE4-associated cholesterol phenotypes and lead to significantly improved myelination both human in vitro cultures and APOE4 targeted replacement mice. This demonstrates that APOE4 alters cholesterol synthesis and transport in oligodendrocytes which impairs myelination. Collectively, this work uncovers a pathogenic role of APOE4 in oligodendrocytes and myelination and enables therapeutic opportunities for Alzheimer's Disease. |
| FILED | Monday, March 14, 2022 |
| APPL NO | 17/694630 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/724 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/28 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288105 | Machielse et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mandos LLC (West Hollywood, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernardus Nicolaas Machielse (North Potomac, Maryland); Allan Darling (North Potomac, Maryland) |
| ABSTRACT | This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745481 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/08 (20130101) A61K 9/0019 (20130101) A61K 9/0085 (20130101) A61K 31/724 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288106 | Machielse et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mandos LLC (West Hollywood, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernardus Nicolaas Machielse (North Potomac, Maryland); Allan Darling (North Potomac, Maryland) |
| ABSTRACT | This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745516 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/08 (20130101) A61K 9/0019 (20130101) A61K 9/0085 (20130101) A61K 31/724 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288109 | SZULC et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (Charleston, South Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Zdzislaw M. SZULC (Charleston, South Carolina); Besim OGRETMEN (Mount Pleasant, South Carolina); Natalia OLEINIK (Charleston, South Carolina) |
| ABSTRACT | Ionic conjugates of selenite anions and cationic ceramide analogs are described. For instance, conjugates can comprise ionic conjugates of selenite anions and pyridinium-substituted ceramide analogs. Also described is the use of the ionic conjugates in treating cancer, such as head and neck cancer and brain cancer. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/637129 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/4425 (20130101) A61K 33/04 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288124 | HE et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (Augusta, Georgia) |
| ASSIGNEE(S) | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (Augusta, Georgia) |
| INVENTOR(S) | Yukai HE (Martinez, Georgia); Leidy D. CARABALLO GALVA (Augusta, Georgia); Xiatao JIANG (Augusta, Georgia) |
| ABSTRACT | Chimeric antigen receptor T cell (CARTs) compositions and methods of their use are provided. One embodiment provides a chimeric antigen receptor T cell composition including 8F8 chimeric antigen receptor T cells. Another embodiment provides a chimeric antigen receptor T cell composition including 6G11 chimeric antigen receptor T cells. Still another embodiment provide a chimeric antigen receptor T cell composition including 12D7 chimeric antigen receptor T cells. The disclosed CARTs can be used to treat cancer, for example hepatocellular carcinoma. |
| FILED | Monday, September 21, 2020 |
| APPL NO | 17/762186 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/17 (20130101) Original (OR) Class A61K 2039/5156 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 14/7051 (20130101) C07K 16/303 (20130101) C07K 2317/34 (20130101) C07K 2317/92 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0636 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288127 | Lagasse |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania) |
| INVENTOR(S) | Eric Lagasse (Pittsburgh, Pennsylvania) |
| ABSTRACT | The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain. |
| FILED | Friday, October 29, 2021 |
| APPL NO | 17/514136 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/22 (20130101) A61K 35/26 (20130101) Original (OR) Class A61K 35/30 (20130101) A61K 35/38 (20130101) A61K 35/39 (20130101) A61K 35/42 (20130101) A61K 35/55 (20130101) A61K 2035/122 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288141 | McCOWN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (CHAPEL HILL, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Thomas McCOWN (Carrboro, North Carolina); Marc WEINBERG (Carrboro, North Carolina) |
| ABSTRACT | The invention relates to products and methods for transdifferentiating oligodendrocytes and/or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions. |
| FILED | Friday, December 03, 2021 |
| APPL NO | 17/542150 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 31/713 (20130101) A61K 31/7105 (20130101) A61K 35/76 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/00 (20180101) A61P 25/14 (20180101) A61P 25/16 (20180101) A61P 25/28 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0619 (20130101) C12N 5/0622 (20130101) C12N 15/86 (20130101) C12N 15/113 (20130101) C12N 2310/11 (20130101) C12N 2310/14 (20130101) C12N 2310/111 (20130101) C12N 2310/122 (20130101) C12N 2310/141 (20130101) C12N 2330/51 (20130101) C12N 2750/14141 (20130101) C12N 2750/14143 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288157 | Tsai et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Li-Huei Tsai (Cambridge, Massachusetts); Joel Blanchard (Arlington, Massachusetts) |
| ABSTRACT | The present disclosure provides methods of inhibiting amyloid synthesis in a subject using small molecule inhibitors. The invention also includes methods of treating disease associated with amyloid synthesis, such as Alzheimer's disease. The small molecule inhibitors disclosed herein are compounds which are non-immunosuppressant cyclosporin including the pharmaceutically acceptable salts thereof. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692821 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/436 (20130101) A61K 38/13 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/28 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288162 | YEO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana) |
| ASSIGNEE(S) | PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana) |
| INVENTOR(S) | Yoon YEO (West Lafayette, Indiana); Simseok YUK (Lafayette, Indiana) |
| ABSTRACT | The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis. |
| FILED | Friday, August 21, 2020 |
| APPL NO | 17/636453 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5123 (20130101) A61K 31/7032 (20130101) A61K 33/26 (20130101) A61K 38/12 (20130101) A61K 38/1709 (20130101) Original (OR) Class A61K 47/10 (20130101) A61K 47/36 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 37/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288169 | McDougal |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Supervisors of Louisiana State University and Agriculyural andMechanical College (Baton Rouge, None) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David McDougal (Springfield, Louisiana) |
| ABSTRACT | This invention is directed to compositions and methods for the treatment and prevention of hypoglycemic complications. Specifically, aspects of the invention are drawn to the use of leptin for the treatment and prevention of hypoglycemic complications. |
| FILED | Sunday, May 26, 2019 |
| APPL NO | 17/612979 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/28 (20130101) A61K 38/2264 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 3/08 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288181 | Mirkin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NORTHWESTERN UNIVERSITY (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Chad A. Mirkin (Wilmette, Illinois); Michelle Hope Teplensky (Evanston, Illinois); Max Everett Distler (Evanston, Illinois); Caroline Danielle Kusmierz (San Antonio, Texas); Cassandra Elizabeth Callmann (Evanston, Illinois) |
| ABSTRACT | Spherical Nucleic Acids (SNAs) are chemically well-defined nanoscale architectures comprised of nucleic acids densely arranged around a spherical nanoparticle core in a highly oriented fashion. SNAs are highly modular structures produced by chemical synthesis and programmed assembly, allowing for their rapid modification to incorporate novel viral antigens. The present disclosure provides a SNA comprising (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a viral antigen encapsulated in the nanoparticle core. |
| FILED | Tuesday, March 01, 2022 |
| APPL NO | 17/684269 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/39 (20130101) A61K 39/001192 (20180801) Original (OR) Class A61K 2039/55555 (20130101) A61K 2039/55561 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1138 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288188 | Mittal |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Suresh Kumar Mittal (West Lafayette, Indiana) |
| ABSTRACT | Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production. |
| FILED | Friday, March 12, 2021 |
| APPL NO | 17/199972 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/145 (20130101) Original (OR) Class A61K 2039/5256 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/16 (20180101) A61P 37/04 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 2710/10334 (20130101) C12N 2710/10343 (20130101) C12N 2710/10352 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288191 | PICKER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | OREGON HEALTH and SCIENCE UNIVERSITY (Portland, Oregon) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Louis J. PICKER (Portland, Oregon); Michael A. JARVIS (Portland, Oregon); Jay A. NELSON (Lake Oswego, Oregon) |
| ABSTRACT | Particular aspects provide for use of the β-herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV, SIV or TB, comprising infection of a subject in need thereof with at least one recombinant CMV-based vector (e.g., HCMV or RhCMV) comprising an expressible HIV/SIV/TB antigen or a variant or fusion protein thereof. In particular embodiments of the method, infection is of an to immunocompetent, HCMV or RhCMV seropositive subject. Additional aspects provide for RhCMV- and HCMV-based vaccine vectors, and versions thereof with suicide or safety means. Further aspects provide pharmaceutical compositions comprising the inventive CMV-based vaccine vectors. |
| FILED | Thursday, June 17, 2021 |
| APPL NO | 17/350891 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/04 (20130101) A61K 39/12 (20130101) A61K 39/21 (20130101) Original (OR) Class A61K 2039/53 (20130101) Peptides C07K 14/005 (20130101) C07K 16/088 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 7/00 (20130101) C12N 15/86 (20130101) C12N 2740/16034 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288197 | Geiger et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Children’s Hospital Medicai Center (Cincinnati, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Hartmut Geiger (Cincinnati, Ohio); Yi Zhang (Cincinnati, Ohio) |
| ABSTRACT | Embodiments disclosed herein relate to methods for prolonging or regulating aspects of a subject's life or immunizing a subject. In particular, methods are provided for increasing or regulating longevity, survival time, life span, and health span comprising, administering to a subject in need of treatment an effective amount of at least one Cdc42-specific inhibitor. Additionally, methods are provided for immunizing a subject comprising, administering to a subject in need of immunization an effective amount of at least one Cdc42-specific inhibitor and administering to said subject one or more immunization dosages. Methods are described that further comprise identifying a subject as one that will benefit from increased longevity, increased survival time, increased life span, increased health span, or immunization. The subject is identified on the basis of the subject's age, the subject's present medical condition, the subject's present medical treatment, or the subject's Cdc42 activity. |
| FILED | Thursday, August 13, 2020 |
| APPL NO | 17/635655 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/403 (20130101) A61K 31/4985 (20130101) A61K 39/39 (20130101) Original (OR) Class A61K 2039/55511 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 37/04 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288210 | Kobayashi et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human (Bethesda, Maryland) |
| ASSIGNEE(S) | THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human (Bethesda, Maryland) |
| INVENTOR(S) | Hisataka Kobayashi (Laurel, Maryland); Peter Choyke (Rockville, Maryland) |
| ABSTRACT | The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods. |
| FILED | Tuesday, May 17, 2022 |
| APPL NO | 17/746740 |
| CURRENT CPC | Personal Adornments, e.g Jewellery; Coins A44C 15/00 (20130101) Preparations for Medical, Dental, or Toilet Purposes A61K 31/704 (20130101) A61K 41/0071 (20130101) A61K 45/06 (20130101) Original (OR) Class A61K 47/6803 (20170801) A61K 47/6869 (20170801) A61K 49/0032 (20130101) A61K 49/0058 (20130101) Peptides C07K 16/30 (20130101) C07K 16/32 (20130101) C07K 16/2863 (20130101) C07K 16/3069 (20130101) C07K 2317/77 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5011 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288223 | Whitney et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael A. Whitney (San Diego, California); Stephen Adams (Poway, California); Qing Xiong (San Diego, California); Dina Hin-Gorani (San Diego, California) |
| ABSTRACT | Disclosed herein, the invention pertains to methods and compositions involving activatable specific binding member complex(es). |
| FILED | Thursday, March 12, 2020 |
| APPL NO | 17/438364 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/60 (20170801) A61K 47/6849 (20170801) Original (OR) Class Peptides C07K 16/2863 (20130101) C07K 2317/24 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288225 | Wu |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NORTHWESTERN UNIVERSITY (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jennifer D. Wu (Wilmette, Illinois) |
| ABSTRACT | Described herein are Natural Killer Group 2D (NKG2D) agonist complexes comprising a soluble MHC I Chain-related molecule (sMIC) and a non-blocking sMIC-neutralizing antibody. Methods for activating CD8 T cells and methods for treating MIC-negative cancers and viral infections using such complexes are also provided. |
| FILED | Friday, August 21, 2020 |
| APPL NO | 17/635444 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/3955 (20130101) A61K 47/6811 (20170801) A61K 47/6849 (20170801) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288227 | Chattaraj et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of the University of Pennsylvania (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Rajarshi Chattaraj (Philadelphia, Pennsylvania); Daeyeon Lee (Wynnewood, Pennsylvania); Chandra M Sehgal (Wayne, Pennsylvania); Daniel A Hammer (Villanova, Pennsylvania) |
| ABSTRACT | A microbubble composition, comprising: a plurality of microbubbles, a microbubble comprising a noble gas and/or perfluorocarbon encapsulated within a shell that comprises one or more of a lipid, a protein, or a polymer, and a microbubble optionally defining a cross-sectional dimension in the range of from about 0.5 to about 20 micrometers. A method, comprising forming a composition according to the present disclosure. A method, comprising administering a microbubble composition according to the present disclosure to a subject, the composition optionally comprising echogenic phospholipid microbubbles. A method, comprising: (a) identifying, with the application of energy, the location of a microbubble composition according to the present disclosure, the energy optionally being ultrasound, (b) controllably effecting rupture of microbubbles of a microbubble composition of the present disclosure, the rupture optionally being effected by application of ultrasound, or both (a) and (b). |
| FILED | Tuesday, March 15, 2022 |
| APPL NO | 17/695612 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0009 (20130101) A61K 41/0033 (20130101) A61K 45/06 (20130101) A61K 47/6925 (20170801) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288235 | ZAKHARENKO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | St. Jude Children's Research Hospital, Inc. (Memphis, Tennessee) |
| ASSIGNEE(S) | St. Jude Children's Research Hospital, Inc. (Memphis, Tennessee) |
| INVENTOR(S) | Stanislav S. ZAKHARENKO (Collierville, Tennessee); Prakash DEVARAJU (Memphis, Tennessee) |
| ABSTRACT | Described is a method for treating a social memory deficit in a subject with a neuropsychiatric disease is treated by administering a peptide encoded by 2510002D24Rik or Atp23 genes, a vector expressing such peptide, or an agent capable of increasing the level or activity of such peptide. The method may be used to treat schizophrenia or autism. The peptide, vector or agent can be administered directly to the hippocampus, such as by transcranial surgical injection. |
| FILED | Wednesday, August 19, 2020 |
| APPL NO | 17/636152 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 48/0058 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/18 (20180101) Peptides C07K 14/47 (20130101) C07K 2319/42 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 2750/14143 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288241 | Moses et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Children's Medical CenterCorporation (Boston, Massachusetts) |
| ASSIGNEE(S) | Children's Medical CenterCorporation (Boston, Massachusetts) |
| INVENTOR(S) | Marsha A. Moses (Brookline, Massachusetts); Peng Guo (Boston, Massachusetts); Golnaz Morad (Boston, Massachusetts); Jing Huang (Natick, Massachusetts) |
| ABSTRACT | Provided herein are methods of producing exosome mimetics that are homogenous in size and are akin to native exosomes in structure and/or biological function. Also provided herein are the use of the EMs as delivery vehicles to deliver agents (e.g., therapeutic agents or diagnostic agents) for treating or diagnosing a disease. |
| FILED | Thursday, August 13, 2020 |
| APPL NO | 17/635409 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5068 (20130101) A61K 49/1896 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288273 | Annabi et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nasim Annabi (Los Angeles, California); Ehsan Shirzaei Sani (Los Angeles, California) |
| ABSTRACT | The present invention relates in part to a hydrogel composition and a method of fabricating the hydrogel composition comprising the steps of providing a solution comprising a polymer comprising crosslinkable groups; providing a solution comprising a crosslinking agent; mixing the solution comprising a polymer comprising crosslinkable groups and the solution comprising the crosslinking agent to form a combined solution; and crosslinking the combined solution. The invention also relates in part to a methods of treatment using the hydrogel composition. |
| FILED | Friday, June 12, 2020 |
| APPL NO | 17/618390 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 27/34 (20130101) A61L 27/042 (20130101) A61L 27/045 (20130101) A61L 27/047 (20130101) A61L 27/52 (20130101) A61L 27/54 (20130101) A61L 27/222 (20130101) Original (OR) Class A61L 2300/25 (20130101) A61L 2300/404 (20130101) A61L 2300/412 (20130101) A61L 2430/12 (20130101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 5/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288279 | Song et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Massachusetts (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jie Song (Shrewsbury, Massachusetts); Pingsheng Liu (Worcester, Massachusetts) |
| ABSTRACT | The invention provides a novel approach in which zwitterionic networks are used to sequester and deliver ionic biomolecules, such as proteins, without compromising their native conformation and bioactivity. Zwitterionic networks are designed to effectively retain and deliver ionic or polar biomolecules for guided tissue regeneration. The invention represents a conceptual advance and enables a novel strategy for the utilization of zwitterionic motifs as therapeutics delivery vehicles and tissue engineering scaffolds. |
| FILED | Wednesday, March 16, 2022 |
| APPL NO | 17/695964 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/18 (20130101) A61K 38/30 (20130101) A61K 38/1875 (20130101) Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 27/14 (20130101) A61L 27/18 (20130101) A61L 27/50 (20130101) A61L 27/52 (20130101) A61L 27/54 (20130101) A61L 27/58 (20130101) Original (OR) Class A61L 2300/414 (20130101) A61L 2430/02 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288309 | Patel et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Beta Bionics, Inc. (Irvine, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Himanshu Patel (Rancho Santa Margarita, California); Edward R. Damiano (Acton, Massachusetts); Firas H. El-Khatib (Allston, Massachusetts); Michael J. Rosinko (Las Vegas, Nevada) |
| ABSTRACT | Systems and methods presented herein relate to managing ambulatory medical device data access. A computing system of a networked computing environment can establish a direct end-to-end data connection to an ambulatory medical device via a wireless wide area network. A public key of the computing system may be transmitted to the ambulatory medical device permitting the ambulatory medical device to encrypt data to be transmitted to the computing system. The computing system may receive, via the direct end-to-end data connection, encrypted data from the ambulatory medical device, and upon decrypting the data can generate a therapy report based at least in part on the therapy data. This therapy report may include time-series therapy data relating to the therapy delivered by the ambulatory medical device over a particular time period. The computing system can restrict access to the therapy report to authorized users. |
| FILED | Wednesday, January 19, 2022 |
| APPL NO | 17/579419 |
| CURRENT CPC | Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 5/142 (20130101) A61M 5/172 (20130101) Original (OR) Class A61M 5/1723 (20130101) A61M 5/14244 (20130101) A61M 5/14248 (20130101) A61M 5/16831 (20130101) A61M 2205/18 (20130101) A61M 2205/52 (20130101) A61M 2205/3553 (20130101) A61M 2230/201 (20130101) Electric Digital Data Processing G06F 3/04847 (20130101) G06F 3/04883 (20130101) G06F 8/61 (20130101) G06F 8/65 (20130101) G06F 8/656 (20180201) G06F 21/31 (20130101) G06F 21/84 (20130101) G06F 21/305 (20130101) G06F 21/6245 (20130101) Signalling or Calling Systems; Order Telegraphs; Alarm Systems G08B 21/18 (20130101) G08B 21/0453 (20130101) G08B 25/00 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 10/60 (20180101) G16H 20/17 (20180101) G16H 40/40 (20180101) G16H 40/60 (20180101) G16H 40/67 (20180101) G16H 50/30 (20180101) G16H 80/00 (20180101) Transmission of Digital Information, e.g Telegraphic Communication H04L 9/30 (20130101) H04L 9/088 (20130101) H04L 63/101 (20130101) H04L 67/34 (20130101) Wireless Communication Networks H04W 76/10 (20180201) H04W 76/14 (20180201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288357 | Rafiee et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Telltale LLC (Andover, Massachusetts); The National Institutes of Health (NIH) (Bethseda, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nasser Rafiee (Andover, Massachusetts); Robert J. Lederman (Bethseda, Maryland); Rany Busold (Andover, Massachusetts); Morgan House (Andover, Massachusetts); Jaffar Khan (Bethseda, Maryland); Toby Rogers (Bethseda, Maryland); Christopher G. Bruce (Bethseda, Maryland) |
| ABSTRACT | The disclosure provides various embodiments of systems to facilitate the cutting of luminal tissue structures percutaneously. |
| FILED | Thursday, March 31, 2022 |
| APPL NO | 17/710149 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 90/39 (20160201) Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 25/09 (20130101) Original (OR) Class A61M 25/0108 (20130101) A61M 2025/09166 (20130101) A61M 2025/09175 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288418 | GUHA et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Montefiore Medical Center (Bronx, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Chandan GUHA (Scarsdale, New York); Talicia SAVAGE (New York, New York); Sanjay PANDEY (New York, New York) |
| ABSTRACT | Methods and systems are provided for treating a cancer in a subject, the method comprising providing an ablative dose of radiation therapy to a first region comprising the cancer followed by a sub-ablative dose to a second region, wherein the sub-ablative dose is administered within 1 hour to 4 days after the ablative dose. |
| FILED | Wednesday, August 26, 2020 |
| APPL NO | 17/635985 |
| CURRENT CPC | Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 5/1038 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288589 | Schwartz et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin); University of Leiden (Leiden, Netherlands); University of Chicago (Chicago, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David Charles Schwartz (Madison, Wisconsin); Kristy L. Kounovsky-Shafer (Kearney, Nebraska); Juan Pablo Hernandez-Ortiz (Madison, Wisconsin); Konstantinos Dimitrios Potamousis (Madison, Wisconsin); Juan Jose De Pablo (Chicago, Illinois); Theo Odijk (Leiden, Netherlands); Kyubong Jo (Seoul, South Korea) |
| ABSTRACT | Devices, systems, and methods for en masse patterning of nucleic acid molecule structures are disclosed. The devices can include microchannels and nanoslits. The microchannels and nanoslits can be connected by parking chambers. The systems and methods can utilize the geometry of the devices in coordination with a voltage application routine to park nucleic acid molecules in the parking chambers and subsequently inject the nucleic acid molecules into the nanoslits. The methods can be utilized to present nucleic acid molecules in a fashion suitable for genomic analysis. The methods can also be utilized to provide size selection of the nucleic acid molecules. |
| FILED | Monday, December 20, 2021 |
| APPL NO | 17/556100 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502761 (20130101) Original (OR) Class B01L 2200/0663 (20130101) B01L 2300/0645 (20130101) B01L 2300/0896 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 27/44791 (20130101) G01N 33/48721 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288822 | Rodriguez et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (Livermore, California); The Texas A and M University System (College Station, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jennifer N. Rodriguez (Lathrop, California); Duncan J. Maitland (College Station, Texas); Thomas S. Wilson (San Leandro, California) |
| ABSTRACT | Polymeric based closed cell foams, such as shape memory polymer foams, contain bubbles. Making these bubbles continuous is called reticulation. Disclosed are embodiments of a device and method to controllably reticulate polymer-based closed cell foams by puncturing the membranes of these polymer-based closed cell foams. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/752275 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 31/06 (20130101) A61L 31/146 (20130101) Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing B29C 44/5663 (20130101) Original (OR) Class Indexing Scheme Associated With Subclasses B29B, B29C or B29D, Relating to Moulding Materials or to Materials for Reinforcements, Fillers or Preformed Parts, e.g Inserts B29K 2075/00 (20130101) Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form B32B 5/18 (20130101) B32B 5/32 (20130101) B32B 2266/08 (20130101) B32B 2266/0278 (20130101) B32B 2535/00 (20130101) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 18/73 (20130101) C08G 18/3228 (20130101) C08G 18/3278 (20130101) C08G 18/3284 (20130101) Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H C08J 9/38 (20130101) C08J 2205/052 (20130101) C08J 2207/10 (20130101) C08J 2375/04 (20130101) Compositions of Macromolecular Compounds C08L 75/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289673 | Tansey et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Vanderbilt University (Nashville, Tennessee) |
| ASSIGNEE(S) | |
| INVENTOR(S) | William P. Tansey (Brentwood, Tennessee); Stephen W. Fesik (Nashville, Tennessee); Shaun R. Stauffer (Brentwood, Tennessee); Alex G. Waterson (Nashville, Tennessee); Changho Han (Nashville, Tennessee); Joseph R. Alvarado (Cleveland Heights, Ohio); Jonathan D. MacDonald (Nashville, Tennessee); Selena Chacon Simon (Nashville, Tennessee); Sameer S. Nikhar (Nashville, Tennessee); Alexey Kuznetsov (Nashville, Tennessee) |
| ABSTRACT | Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation. |
| FILED | Wednesday, July 29, 2020 |
| APPL NO | 17/631114 |
| CURRENT CPC | Acyclic or Carbocyclic Compounds C07C 311/21 (20130101) Original (OR) Class C07C 311/29 (20130101) C07C 311/39 (20130101) C07C 311/43 (20130101) C07C 317/34 (20130101) C07C 317/38 (20130101) C07C 317/48 (20130101) C07C 323/49 (20130101) C07C 381/00 (20130101) Heterocyclic Compounds C07D 205/04 (20130101) C07D 207/08 (20130101) C07D 207/12 (20130101) C07D 207/27 (20130101) C07D 211/48 (20130101) C07D 213/40 (20130101) C07D 213/56 (20130101) C07D 213/64 (20130101) C07D 215/36 (20130101) C07D 233/36 (20130101) C07D 239/26 (20130101) C07D 241/04 (20130101) C07D 249/14 (20130101) C07D 265/30 (20130101) C07D 305/08 (20130101) C07D 307/14 (20130101) C07D 307/18 (20130101) C07D 307/22 (20130101) C07D 307/52 (20130101) C07D 307/79 (20130101) C07D 309/04 (20130101) C07D 309/10 (20130101) C07D 309/14 (20130101) C07D 309/22 (20130101) C07D 333/20 (20130101) C07D 333/24 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289688 | Weeks et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (Chapel Hill, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kevin Weeks (Carrboro, North Carolina); Jeffrey Aubé (Chapel Hill, North Carolina); Kelin Li (Chapel Hill, North Carolina); Meredith Zeller (Durham, North Carolina) |
| ABSTRACT | The disclosure is directed to compounds that bind to a target RNA molecule, such as a TPP riboswitch, compositions comprising the compounds, and methods of making and using the same. The compounds contain two structurally different fragments that allow for binding with the target RNA at two different binding sites thereby producing a higher affinity binding ligand compared to compounds that only bind to a single RNA binding site. |
| FILED | Wednesday, August 05, 2020 |
| APPL NO | 17/632695 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/498 (20130101) A61K 47/00 (20130101) Heterocyclic Compounds C07D 241/42 (20130101) Original (OR) Class C07D 401/12 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289689 | Huigens, III et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Incorporated (Gainesville, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Robert William Huigens, III (Williston, Florida); Hongfen Yang (Gainesville, Florida) |
| ABSTRACT | The present invention provides phenazine derivatives, such as compounds of Formula (I). The compounds of the invention are expected to be antimicrobial agents and may act by a microbial warfare strategy (e.g., a reactive oxygen species (ROS)-based competition strategy). The present invention also provides compositions, kits, uses, and methods that involve the compounds of the invention, which may be useful in preventing or treating a microbial infection (e.g., a bacterial infection or mycobacterial infection) in a subject, inhibiting the growth and/or reproduction of a microorganism (e.g., a bacterium or mycobacterium), killing a microorganism (e.g., a bacterium or mycobacterium), inhibiting the formation and/or growth of a biofilm, reducing or clearing a biofilm, and/or disinfecting a surface. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692536 |
| CURRENT CPC | Heterocyclic Compounds C07D 241/46 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289707 | REIGAN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, A Body Corporate (Denver, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Philip REIGAN (Denver, Colorado); Christopher J. MATHESON (Newcastle upon Tyne, United Kingdom); Craig JORDAN (Aurora, Colorado) |
| ABSTRACT | The present disclosure relates to compounds of Formula (I): stereoisomers thereof, prodrugs thereof, and pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., to inhibit AMP-Activated protein kinase (AMPK) and treat cancer in a subject. |
| FILED | Thursday, July 02, 2020 |
| APPL NO | 17/620317 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/02 (20180101) Heterocyclic Compounds C07D 401/06 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289720 | TURKSON et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF HAWAII (Honolulu, Hawaii) |
| ASSIGNEE(S) | |
| INVENTOR(S) | James TURKSON (Honolulu, Hawaii); Francisco LOPEZ-TAPIA (Honolulu, Hawaii); Marcus TIUS (Honolulu, Hawaii); Peibin YUE (Honolulu, Hawaii); Christine BROTHERTON-PLEISS (Sunnyvale, California); Wenzhen FU (Honolulu, Hawaii) |
| ABSTRACT | The present disclosure provides pharmaceutical compositions comprising aryl sulfonamide Stat3 small molecule inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use for treating cancer. |
| FILED | Wednesday, July 22, 2020 |
| APPL NO | 17/628513 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Acyclic or Carbocyclic Compounds C07C 317/36 (20130101) C07C 2601/16 (20170501) Heterocyclic Compounds C07D 205/04 (20130101) C07D 213/81 (20130101) C07D 237/32 (20130101) C07D 401/12 (20130101) C07D 401/14 (20130101) C07D 403/12 (20130101) Original (OR) Class C07D 403/14 (20130101) C07D 405/14 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289750 | Movassaghi et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Mohammad Movassaghi (Lincoln, Massachusetts); Bradley L. Pentelute (Cambridge, Massachusetts); Carly Schissel (Cambridge, Massachusetts); Kyan Anthony D'Angelo (Cambridge, Massachusetts) |
| ABSTRACT | The present disclosure provides compounds of Formula I, methods of preparing the compounds, compositions, kits, and methods of using the compounds for treating or preventing microbial infections. |
| FILED | Thursday, December 23, 2021 |
| APPL NO | 17/561680 |
| CURRENT CPC | General Methods of Organic Chemistry; Apparatus Therefor C07B 2200/05 (20130101) C07B 2200/07 (20130101) Heterocyclic Compounds C07D 209/86 (20130101) C07D 487/04 (20130101) Original (OR) Class C07D 487/14 (20130101) C07D 487/22 (20130101) C07D 498/22 (20130101) C07D 519/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289775 | LI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Lingyin LI (Menlo Park, California); Mark Smith (San Francisco, California); Jacqueline Ann CAROZZA (Palo Alto, California); Volker BOEHNERT (Palo Alto, California) |
| ABSTRACT | Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response. |
| FILED | Thursday, January 30, 2020 |
| APPL NO | 17/423389 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/44 (20130101) A61K 31/69 (20130101) A61K 31/517 (20130101) A61K 31/675 (20130101) A61K 31/4706 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 215/46 (20130101) C07D 401/04 (20130101) Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium C07F 5/02 (20130101) C07F 9/60 (20130101) C07F 9/65128 (20130101) Original (OR) Class C07F 9/65583 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289798 | Fuqua et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Louisville Research Foundation, Inc. (Louisville, Kentucky) |
| ASSIGNEE(S) | University of Louisville Research Foundation, Inc. (Louisville, Kentucky); The United States of America, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland) |
| INVENTOR(S) | Joshua Fuqua (Pewee Valley, Kentucky); Krystal Hamorsky (Owensboro, Kentucky); Barry R. O'Keefe (Frederick, Maryland); Tinoush Moulaei (Burlingame, California); Kenneth E. Palmer (Anchorage, Kentucky) |
| ABSTRACT | Provided herein are GRFT variants and methods of using such GRFT variants. The GRFT variants described herein can be PEGylated, which significantly improves the pharmacokinetics and decreases the immunogenicity of the GFRT composition. |
| FILED | Thursday, September 10, 2020 |
| APPL NO | 17/641264 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 9/0031 (20130101) A61K 38/168 (20130101) A61K 47/10 (20130101) Peptides C07K 14/405 (20130101) Original (OR) Class Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/8203 (20130101) C12N 15/8257 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289800 | GOLDSTEIN |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Steven Alan GOLDSTEIN (Chicago, Illinois) |
| ABSTRACT | The present invention provides novel agents for modulation of Hv1 channels. The present invention provides agents for activating and/or inhibiting Hv1 channel function and/or activity, and reagents and methods relating thereto. |
| FILED | Tuesday, March 01, 2022 |
| APPL NO | 17/684346 |
| CURRENT CPC | Peptides C07K 14/705 (20130101) C07K 14/43518 (20130101) Original (OR) Class C07K 14/43522 (20130101) C07K 2319/02 (20130101) C07K 2319/41 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289802 | ARORA et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NEW YORK UNIVERSITY (New York, New York); CORNELL UNIVERSITY (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Paramjit S. ARORA (Cold Spring Harbor, New York); Ethel CESARMAN (Jersey City, New Jersey); Michael G. WUO (Brooklyn, New York); Jouliana SADEK (Roosevelt Island, New York) |
| ABSTRACT | This invention relates to macrostructures (and pharmaceutical formulations containing them) that include a parallel coiled-coil structure, wherein the parallel coiled-coil comprises a first coil of Formula I and a second coil of Formula II: T1-f0-g0-a1-b1-c1-d1-e1-f1-g1-a2-b2-c2-d2-e2-f2-g2-a3-b3-c3-d3-e3-T2 (I) T3-g′0-a′1-b′1-c′1-d′1-e′1-f′1-g′1-a′2-b′2-c′2-d′2-e′2-f′2-g′2-a′3-b′3-c′3-d′3-e′3-f′3-T4 (II), as described in the present application. Methods of using these macrostructures are also disclosed. |
| FILED | Tuesday, April 19, 2022 |
| APPL NO | 17/723921 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 45/06 (20130101) A61K 47/65 (20170801) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Acyclic or Carbocyclic Compounds C07C 49/04 (20130101) Heterocyclic Compounds C07D 227/02 (20130101) C07D 255/02 (20130101) C07D 333/02 (20130101) Peptides C07K 7/02 (20130101) C07K 7/08 (20130101) C07K 14/4702 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289809 | Schwartzman et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania) |
| INVENTOR(S) | David S. Schwartzman (Pittsburgh, Pennsylvania); Sanjeev G. Shroff (Pittsburgh, Pennsylvania); Guy Salama (Pittsburgh, Pennsylvania); Charles F. McTiernan (Pittsburgh, Pennsylvania) |
| ABSTRACT | Disclosed herein are methods of using relaxin polypeptides and analogs, or nucleic acid molecules encoding such polypeptides to treat or inhibit atrial fibrillation. |
| FILED | Friday, November 05, 2021 |
| APPL NO | 17/519838 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/2221 (20130101) A61K 45/06 (20130101) Peptides C07K 14/575 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289829 | Sievers et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | California Institute of Technology (Pasadena, California); The Rockefeller University (New York, New York) |
| ASSIGNEE(S) | California Institute of Technology (Pasadena, California); The Rockefeller University (New York, New York) |
| INVENTOR(S) | Stuart A. Sievers (Encino, California); Jennifer Keeffe (Pasadena, California); Michel C. Nussenzweig (New York, New York); Pamela J. Bjorkman (La Canada, California) |
| ABSTRACT | This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g, reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection. |
| FILED | Wednesday, July 08, 2020 |
| APPL NO | 17/625247 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/42 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/18 (20180101) Peptides C07K 16/1045 (20130101) Original (OR) Class C07K 2317/31 (20130101) C07K 2317/565 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289840 | Connolly et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Denise C. Connolly (Philadelphia, Pennsylvania); Alana M. O'Reilly (Philadelphia, Pennsylvania); Tiffiney R. Hartman (Philadelphia, Pennsylvania); Valerie L. Sodi (Philadelphia, Pennsylvania) |
| ABSTRACT | The present disclosure provides antibodies specifically binding N-terminal or C-terminal regions of Cell Adhesion Molecule-Related/Down-Regulated By Oncogenes (CDON) polypeptide, methods of making the same, and methods of treating humans having tumors by administering the antibody. |
| FILED | Wednesday, February 12, 2020 |
| APPL NO | 17/430227 |
| CURRENT CPC | Peptides C07K 16/2803 (20130101) Original (OR) Class C07K 2317/34 (20130101) C07K 2317/73 (20130101) C07K 2317/76 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/57449 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289841 | THOMAS-TIKHONENKO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, Pennsylvania) |
| INVENTOR(S) | Andrei THOMAS-TIKHONENKO (Philadelphia, Pennsylvania); Sisi ZHENG (Philadelphia, Pennsylvania) |
| ABSTRACT | The present disclosure is directed to antibodies binding to CD22-Del.ex5-6 protein and methods of using such antibodies to treat cancers that express or overexpress CD22-Del.ex5-6 protein. Specifically, the disclosure provides a method of treating cancer comprising contacting a cancer cell in a subject with an antibody or antibody derivative that binds selectively to CD22-Del.ex5-6 protein, or to a peptide having the sequence of QLNVKHPPKKVTTVIQNP (SEQ ID NO: 1). |
| FILED | Wednesday, July 29, 2020 |
| APPL NO | 17/630361 |
| CURRENT CPC | Peptides C07K 14/7051 (20130101) C07K 16/30 (20130101) C07K 16/2803 (20130101) Original (OR) Class C07K 2317/24 (20130101) C07K 2317/34 (20130101) C07K 2317/569 (20130101) C07K 2319/03 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/16 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289854 | Freeman et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Gordon J. Freeman (Brookline, Massachusetts); Apoorvi Chaudhri (Houston, Texas) |
| ABSTRACT | The present invention relates, in part, to methods of treating cancers using combinations of anti-CX3CR1 and anti-immune checkpoint therapies. |
| FILED | Friday, April 24, 2020 |
| APPL NO | 17/606585 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 2039/585 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/02 (20180101) Peptides C07K 16/2866 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289855 | Ginsberg et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Mark Ginsberg (LaJolla, California); Hao Sun (La Jolla, California); Jailal Ablack (La Jolla, California) |
| ABSTRACT | Antibodies against CD25 engineered with dysfunctional constant regions used to bind T regulatory cells to activate integrin to inhibit immune responses and for treatment of autoimmune diseases such as systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, in addition to transplantation rejection. The invention demonstrates that treatment of CD4+ T cells with CD25 antibody results in rapid activation of multiple integrins as measured by soluble ligand binding. |
| FILED | Monday, August 10, 2020 |
| APPL NO | 17/633912 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 37/02 (20180101) Peptides C07K 16/2866 (20130101) Original (OR) Class C07K 2317/55 (20130101) C07K 2317/71 (20130101) C07K 2317/524 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289863 | Marasco et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Wayne A. Marasco (Wellesley, Massachusetts); Elizabeth Magnotti (Ashburn, Virginia); Matthew Chang (Brookline, Massachusetts) |
| ABSTRACT | MUC1 is overexpressed in many cancers, including those of the lung, colon, breast, ovary, and pancreas. Aspects of the invention are directed towards the discovery of monoclonal antibodies and fragments thereof, such as a human single chain variable fragment (scFv), that recognizes human MUC1-SEA. |
| FILED | Monday, June 15, 2020 |
| APPL NO | 17/618363 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 14/7051 (20130101) C07K 16/3092 (20130101) Original (OR) Class C07K 2317/21 (20130101) C07K 2317/565 (20130101) C07K 2317/622 (20130101) C07K 2319/03 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289866 | CRAIK et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Charles S. CRAIK (San Francisco, California); Kevan M. SHOKAT (San Francisco, California); Ziyang ZHANG (San Francisco, California); Peter J. ROHWEDER (San Francisco, California) |
| ABSTRACT | The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer. |
| FILED | Friday, July 10, 2020 |
| APPL NO | 17/626459 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/39558 (20130101) A61K 39/39583 (20130101) A61K 47/50 (20170801) A61K 47/6843 (20170801) A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 16/44 (20130101) Original (OR) Class C07K 16/2809 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/574 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290092 | Jovanovich et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | S2 Genomics, Inc. (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Stevan Bogdan Jovanovich (Livermore, California); Kaiwan Chear (Livermore, California); Bruce Leisz (San Jose, California); David Eberhart (Santa Clara, California); John Bashkin (Fremont, California) |
| ABSTRACT | A system, methods, and apparatus are described to collect and prepare single cells, nuclei, subcellular components, and biomolecules from specimens including tissues and in some embodiments use the single cells to form organoids or microtissues. The system can perform enzymatic and/or physical disruption of the tissue to dissociate it into single-cells and then use a hanging droplet method to form organoids or microtissues. |
| FILED | Saturday, June 01, 2019 |
| APPL NO | 15/734128 |
| CURRENT CPC | Apparatus for Enzymology or Microbiology; C12M 41/12 (20130101) C12M 45/02 (20130101) Original (OR) Class C12M 45/06 (20130101) C12M 45/09 (20130101) C12M 45/20 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 1/31 (20130101) G01N 1/286 (20130101) G01N 1/4077 (20130101) G01N 2001/4088 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290104 | Shah |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Brigham and Women`s Hospital, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dhvanit I. Shah (Chestnut Hill, Massachusetts) |
| ABSTRACT | In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the HE and/or endothelial cells under conditions sufficient for stimulating formation of HSCs. |
| FILED | Tuesday, May 31, 2022 |
| APPL NO | 17/828393 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/28 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0647 (20130101) Original (OR) Class C12N 2501/999 (20130101) C12N 2506/28 (20130101) C12N 2527/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290115 | Liu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | President and Fellows of Harvard College (Cambridge, Massachusetts) |
| ASSIGNEE(S) | President and Fellows of Harvard College (Cambridge, Massachusetts) |
| INVENTOR(S) | David R. Liu (Cambridge, Massachusetts); Kevin Tianmeng Zhao (Cambridge, Massachusetts); Yongjoo Kim (Cambridge, Massachusetts) |
| ABSTRACT | Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins comprise a Gam protein, a napDNAbp, and a cytidine deaminase. In some embodiments, the fusion proteins further comprise a UGI domain. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a Gam protein, a cytidine deaminase and nucleic acid editing proteins or domains, are provided. |
| FILED | Monday, March 21, 2022 |
| APPL NO | 17/700109 |
| CURRENT CPC | Peptides C07K 2319/09 (20130101) C07K 2319/80 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 9/78 (20130101) Original (OR) Class C12N 15/62 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290121 | Joung et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The General Hospital Corporation (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | J. Keith Joung (Winchester, Massachusetts); Ronghao Zhou (Charlestown, Massachusetts); Julian Grunewald (Charlestown, Massachusetts) |
| ABSTRACT | Engineered bifunctional adenine and cytosine base editor (BACE) variants that enable expanded amino acid modifications and methods of using the same. Described herein are fusion proteins containing adenosine deaminases, cytidine deaminases, catalytically impaired CRISPR-Cas proteins (e.g., Cas9, CasX or Cas12 nucleases), linkers, nuclear localization signals (NLSs) and uracil-n-glycosylase inhibitors (UGIs) that enable the CRISPR-guided programmable introduction of simultaneous A-to-G (T-to-C) and C-to-T (G-to-A) substitutions in DNA. |
| FILED | Monday, August 31, 2020 |
| APPL NO | 17/638133 |
| CURRENT CPC | Peptides C07K 2319/09 (20130101) C07K 2319/80 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 9/78 (20130101) C12N 15/102 (20130101) Original (OR) Class C12N 2310/20 (20170501) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 19/34 (20130101) C12P 21/02 (20130101) Enzymes C12Y 305/04004 (20130101) C12Y 305/04005 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290122 | Kory et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Whitehead Institute for Biomedical Research (Cambridge, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nora Kory (Allston, Massachusetts); David M. Sabatini (Cambridge, Massachusetts) |
| ABSTRACT | Disclosed herein are methods and compositions for modulating MCART1 expression and activity to treat diseases such as cancer and age related conditions. Also disclosed are methods of screening for MCART1 modulation agents. |
| FILED | Wednesday, February 19, 2020 |
| APPL NO | 17/432479 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1006 (20130101) Original (OR) Class Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 2600/178 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5011 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290126 | Awasthi |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Regents of The University of Texas System (Austin, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sanjay Awasthi (Lubbock, Texas) |
| ABSTRACT | Partial depletion of RLIP76 in p53 deficient living subject has shown many health benefits. In one embodiment, partical Rlip depletion is used to prevent or treat cancer in p53 deficient living subjects. In another embodiment, partial Rlip depletion is used for reversion of DNA-methylation abnormalities caused by the lack of p53 to normal in p53 deficient living subjects. In yet another embodiment, partial Rlip depletion is used in reduction of blood glucose, insulin-resistance, hyperlipidemina, or any combination thereof in p53 deficient living subjects. Methods of using liposome containing anti-sense nucleic acid or double stranded siRNA to partially deplete RLIP76 and thus treat p53 deficient subject are disclosed. The approaches described herein can be especially helpful in preventing cancer in Li-Fraumeni patients. |
| FILED | Wednesday, June 01, 2022 |
| APPL NO | 17/829768 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 16/40 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0693 (20130101) C12N 9/00 (20130101) C12N 11/18 (20130101) C12N 15/11 (20130101) C12N 15/113 (20130101) C12N 15/1024 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290127 | Rodgers et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Regents of the University of Oklahoma (Norman, Oklahoma) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Karla Rodgers (Edmond, Oklahoma); Walker HOOLEHAN (Oklahoma City, Oklahoma) |
| ABSTRACT | Compositions, kits, systems, and methods are disclosed for use in analysis of DNA sequence-specificity in V(D)J recombination or other types of recombination. |
| FILED | Tuesday, March 01, 2022 |
| APPL NO | 17/683744 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0687 (20130101) C12N 9/22 (20130101) C12N 15/85 (20130101) C12N 15/1065 (20130101) Original (OR) Class C12N 15/1093 (20130101) C12N 2800/107 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 19/34 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) C12Q 1/6869 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290138 | Miller et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Washington University (St. Louis, Missouri) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Timothy M. Miller (St. Louis, Missouri); Mariah Lawler Hoye (St. Louis, Missouri); Ted Hyman (St. Louis, Missouri); Erica Koval (St. Louis, Missouri); Joseph Dougherty (St. Louis, Missouri) |
| ABSTRACT | The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS). |
| FILED | Thursday, January 13, 2022 |
| APPL NO | 17/575410 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/7105 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/28 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/111 (20130101) C12N 15/113 (20130101) Original (OR) Class C12N 2310/141 (20130101) C12N 2320/10 (20130101) C12N 2320/30 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6883 (20130101) C12Q 2600/178 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290147 | Yen et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Baylor College of Medicine (Houston, Texas) |
| ASSIGNEE(S) | Baylor College of Medicine (Houston, Texas); Baylor College of Medicine (Houston, Texas) |
| INVENTOR(S) | Laising Yen (Pearland, Texas); Liming Luo (Pearland, Texas); Jocelyn Duen-Ya Jea (Houston, Texas) |
| ABSTRACT | Compositions and methods relating to regulation of gene expression are described. In some embodiments, the present disclosure provides compositions and methods for the regulation of gene expression using nucleic acid constructs. In some embodiments, the present disclosure recognizes the utility of alternative splicing in regulation of gene expression in a nucleic acid construct. In some embodiments, the present disclosure recognizes the utility of regulating gene expression utilizing ligand-binding aptamers. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/638619 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/63 (20130101) C12N 15/115 (20130101) Original (OR) Class C12N 2310/16 (20130101) C12N 2830/50 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290159 | Zakharenko et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | St. Jude Children's Research Hpspital, Inc. (Memphis, Tennessee) |
| ASSIGNEE(S) | St. Jude Children's Research Hpspital, Inc. (Memphis, Tennessee) |
| INVENTOR(S) | Stanislav S. Zakharenko (Collierville, Tennessee); Tae-Yeon Eom (Memphis, Tennessee) |
| ABSTRACT | The invention is directed to methods and compositions for treating a disease associated with ventricular enlargement such as 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-382-3p and/or miR-674-3p or inhibition of dopamine receptor Drd1 in ependymal cells. |
| FILED | Thursday, July 23, 2020 |
| APPL NO | 17/629211 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0085 (20130101) A61K 31/7088 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1138 (20130101) Original (OR) Class C12N 2310/141 (20130101) C12N 2320/30 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290161 | JAFFREY et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CORNELL UNIVERSITY (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Samie R. JAFFREY (New York, New York); Jiahui WU (New York, New York) |
| ABSTRACT | The present disclosure is directed to RNA-regulated fusion proteins comprising a protein of interest and an RNA-regulated destabilization domain. Also disclosed are RNA aptamers that bind specifically to a RNA-regulated destabilization domain. Nucleic acid molecules encoding the RNA-regulated fusion proteins and RNA aptamers and methods of use thereof are also disclosed. |
| FILED | Monday, August 31, 2020 |
| APPL NO | 17/637940 |
| CURRENT CPC | Peptides C07K 2319/60 (20130101) C07K 2319/61 (20130101) C07K 2319/85 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0602 (20130101) C12N 15/52 (20130101) C12N 15/62 (20130101) Original (OR) Class C12N 15/85 (20130101) C12N 15/115 (20130101) C12N 2310/16 (20130101) C12N 2800/107 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6816 (20130101) Enzymes C12Y 111/01011 (20130101) C12Y 113/12013 (20130101) C12Y 201/01043 (20130101) C12Y 603/0401 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290196 | MOORE et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bradley S. MOORE (La Jolla, California); Hanna LUHAVAYA (Oakland, California) |
| ABSTRACT | Provided herein, inter alia, are genetically engineered microbes and methods of use thereof for producing L-4-chlorokynrenine from L-Tryptophan. The genetically engineered microbes include, inter alia, one or more exogenous nucleic acids or enzymes for producing L-4-chlorokynrenine. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/638596 |
| CURRENT CPC | Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 13/22 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290209 | Makrigiorgos |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Gerassimos Makrigiorgos (Chestnut Hill, Massachusetts) |
| ABSTRACT | Presently described are compositions and methods for performing genome-wide enrichment of DNA microsatellites (e.g., homopolymers) containing deletions and facilitating their detection via sequencing or other downstream methodologies. Additionally, disclosed herein are compositions and methods for selecting the genomic fraction containing poly-adenine/poly-thymidine homopolymer repeats and other A:T-rich sequences of low melting temperature from the genome, so that very little sequencing is required to detect the enriched homo-polymer deletions. |
| FILED | Thursday, August 20, 2020 |
| APPL NO | 17/636881 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) Original (OR) Class C12Q 1/6809 (20130101) C12Q 1/6813 (20130101) C12Q 2537/16 (20130101) C12Q 2537/159 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290213 | Robison et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Brigham Young University (Provo, Utah) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Richard A. Robison (Provo, Utah); Taalin Hoj (Provo, Utah) |
| ABSTRACT | Provided herein are a composition, system, and kit for the rea-time pentaplex amplification and detection of DNA from at least one of beta-lactamase genes Klebsiella pneumoniae carbapenemase (KPC); New Delhi metallo-beta-lactamase (NDM); cefotaximase-Munich (CTX); cephamycin AmpC beta-lactamase (CMY); and oxacillinase-48 (OXA-48). |
| FILED | Friday, February 11, 2022 |
| APPL NO | 17/670221 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/689 (20130101) Original (OR) Class C12Q 1/6806 (20130101) C12Q 1/6853 (20130101) C12Q 2600/16 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290224 | LIEBERMAN AIDEN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); BAYLOR COLLEGE OF MEDICINE (Houston, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Erez LIEBERMAN AIDEN (Houston, Texas); Suhas RAO (Medfield, Massachusetts); Elena STAMENOVA (Reading, Massachusetts); Olga DUDCHENKO (Houston, Texas); Eric LANDER (Cambridge, Massachusetts) |
| ABSTRACT | Disclosed is an in situ method for detecting spatial proximity relationships between nucleic acid sequences, such as DNA, in a cell. The method includes: providing a sample of one or more cells comprising nucleic acids; fragmenting the nucleic acids present in the cells that leaves 5′ overhanging ends; filling in the overhanging ends with at least one labeled nucleotide; joining the filled in end of the fragmented nucleic acids that are in close physical proximity to create one or more end joined nucleic acid fragments having a junction; isolating the one or more end joined nucleic acid fragments using the labeled nucleotide; and determining the sequence at the junction of the one or more end joined nucleic acid fragments. |
| FILED | Thursday, February 10, 2022 |
| APPL NO | 17/669211 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) C12Q 1/6869 (20130101) Original (OR) Class C12Q 2521/501 (20130101) C12Q 2525/117 (20130101) C12Q 2535/122 (20130101) C12Q 2563/131 (20130101) Combinatorial Chemistry; Libraries, e.g Chemical Libraries C40B 20/00 (20130101) C40B 30/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290227 | Ju et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of Columbia University in the City of New York (New York, New York) |
| ASSIGNEE(S) | The Trustees of Columbia University in the City of New York (New York, New York) |
| INVENTOR(S) | Jingyue Ju (Englewood Cliffs, New Jersey); Dae Hyun Kim (Northbrook, Illinois); Jia Guo (Chandler, Arizona); Qinglin Meng (Foster City, California); Zengmin Li (Flushing, New York); Huanyan Cao (Changzhou City, China PRC) |
| ABSTRACT | This invention provides a process for sequencing nucleic acids using 3′ modified deoxynucleotide analogues or 3′ modified deoxyinosine triphosphate analogues, and 3′ modified dideoxynucleotide analogues having a detectable marker attached thereto. |
| FILED | Friday, January 14, 2022 |
| APPL NO | 17/576184 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/70 (20130101) Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids C07H 19/04 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6869 (20130101) C12Q 1/6874 (20130101) Original (OR) Class C12Q 1/6876 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290231 | SALK et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (Seattle, Washington) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jesse SALK (Seattle, Washington); Lawrence A. LOEB (Bellevue, Washington); Michael SCHMITT (Seattle, Washington) |
| ABSTRACT | Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands. |
| FILED | Friday, October 22, 2021 |
| APPL NO | 17/451919 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) C12Q 1/6869 (20130101) C12Q 1/6876 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290235 | Targan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CEDARS-SINAI MEDICAL CENTER (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Stephan R. Targan (Santa Monica, California); Marla C. Dubinsky (Los Angeles, California); Carol J. Landers (Los Angeles, California); Ling Mei (Pasadena, California); Jerome I. Rotter (Los Angeles, California); Kent D. Taylor (Ventura, California) |
| ABSTRACT | This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC. |
| FILED | Friday, January 28, 2022 |
| APPL NO | 17/588089 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6883 (20130101) Original (OR) Class C12Q 2600/156 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6893 (20130101) G01N 2800/50 (20130101) G01N 2800/065 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290238 | Abecassis et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NORTHWESTERN UNIVERSITY (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael M. Abecassis (Highland Park, Illinois); Josh Levitsky (Evanston, Illinois) |
| ABSTRACT | The present disclosure is directed to materials and methods for predicting and diagnosing acute rejection in liver transplant recipients. Methods of the disclosure are useful, in various embodiments, for adjusting or initiating therapies (e.g., immunosuppressive (IS) therapy) in patients who would benefit therefrom. |
| FILED | Friday, August 21, 2020 |
| APPL NO | 17/637410 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6883 (20130101) Original (OR) Class C12Q 2600/106 (20130101) C12Q 2600/118 (20130101) C12Q 2600/158 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290241 | MCGOVERN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Cedars-Sinai Medical Center (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dermot MCGOVERN (Los Angeles, California); Michelle KHROM (Northridge, California); Talin HARITUNIANS (Los Angeles, California) |
| ABSTRACT | Provided are methods, systems, and kits for identifying a patient who has or has a likelihood of developing an extra-intestinal manifestation of inflammatory bowel disease. |
| FILED | Thursday, May 26, 2022 |
| APPL NO | 17/825580 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/573 (20130101) A61K 45/06 (20130101) A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 37/06 (20180101) Peptides C07K 16/241 (20130101) C07K 16/2866 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6883 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290245 | Elnitski et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland) |
| ASSIGNEE(S) | The United States of America, as represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland) |
| INVENTOR(S) | Laura L. Elnitski (Germantown, Maryland); Gennady Margolin (Rockville, Maryland) |
| ABSTRACT | The present application provides methods for the detection and classification of cancer. In one aspect, the application provides a method for detecting the presence of cancer in a subject or identifying a biological sample as from a subject with cancer by detecting the methylation status of a panel of eight genomic DNA segments. In another aspect, the application provides a method for classifying a cancer type in a subject or classifying a biological sample as from a subject with a particular cancer type by detecting the methylation status of a panel of 39 genomic DNA segments. |
| FILED | Friday, September 11, 2020 |
| APPL NO | 17/632783 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6886 (20130101) Original (OR) Class C12Q 2600/154 (20130101) Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology G16B 20/20 (20190201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290247 | FONG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Lawrence FONG (San Francisco, California); Chun Jimmie YE (San Francisco, California); David Y. OH (San Francisco, California) |
| ABSTRACT | The present disclosure relates generally to, inter alia, therapeutic and diagnostic methods and compositions for treatment of bladder cancer. In particular, the disclosure relates to defining pre-treatment gene signatures that are predictive of response to anti-PD-L1 therapy and to the use of such gene signatures as biomarkers to identify individuals having or suspected of having bladder cancer who are most likely to respond to an anti-PD-L1 therapy. In some embodiments, various methods for the treatment of bladder cancer in individuals identified by the diagnostic methods disclosed herein are also provided. |
| FILED | Thursday, August 06, 2020 |
| APPL NO | 17/633922 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 16/2827 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0637 (20130101) C12N 5/0638 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) C12Q 1/6813 (20130101) C12Q 1/6886 (20130101) Original (OR) Class C12Q 2600/106 (20130101) C12Q 2600/158 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290251 | YANG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | St. Jude Children's Research Hospital, Inc. (Memphis, Tennessee) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jun J. YANG (Memphis, Tennessee); Jiyang YU (Memphis, Tennessee) |
| ABSTRACT | Nucleic acid- and protein-based methods for identifying a patient sensitive to treatment with a tyrosine kinase inhibitor are provided, as is a method for treating a subject with a T-lineage hematological malignancy. Specifically, the method comprising determining activity levels of LCK nucleic acid or protein in a biological sample from a patient with a T-lineage hematological malignancy, wherein an increase in the activity levels of the LCK nucleic acid or protein in the biological sampled compared to a reference level indicates that the patient is sensitive to treatment with a tyrosine kinase inhibitor. |
| FILED | Monday, August 24, 2020 |
| APPL NO | 17/637510 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/506 (20130101) A61K 31/5025 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/02 (20180101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6886 (20130101) Original (OR) Class C12Q 2600/106 (20130101) C12Q 2600/158 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/57484 (20130101) G01N 2333/912 (20130101) G01N 2440/14 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290257 | LUO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania) |
| INVENTOR(S) | Jianhua LUO (Wexford, Pennsylvania); Zhanghui CHEN (Huzhou City, China PRC); Yanping YU (Wexford, Pennsylvania); George MICHALOPOULOS (Pittsburgh, Pennsylvania); Joel B. NELSON (Pittsburgh, Pennsylvania) |
| ABSTRACT | The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer. |
| FILED | Monday, May 23, 2022 |
| APPL NO | 17/751152 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/4545 (20130101) A61K 31/5377 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 7/00 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1137 (20130101) C12N 2310/14 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6886 (20130101) Original (OR) Class C12Q 2600/106 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291094 | Hewitt et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America, as represented by the Secretary, Dept of Health and Human Services (Bethesda, Maryland) |
| ASSIGNEE(S) | The United States of America, as represented by the Secretary, Dept. of Health and Human Services (Bethesda, Maryland) |
| INVENTOR(S) | Stephen M. Hewitt (Potomac, Maryland); Joon-Yong Chung (Rockville, Maryland); Candice D. Perry (Gaithersburg, Maryland); Robert A. Star (Bethesda, Maryland) |
| ABSTRACT | Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid. |
| FILED | Friday, April 08, 2022 |
| APPL NO | 17/716606 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 1/30 (20130101) Original (OR) Class G01N 2001/307 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291142 | Mookherjea et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); California Institute of Technology (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shayan Mookherjea (San Diego, California); Xiaoxi Wang (San Diego, California); Boris A. Korzh (Altadena, California); Matthew D. Shaw (Los Angeles, California) |
| ABSTRACT | Methods, systems, and devices for testing an electro-optic device such as a modulator or a switch are disclosed. In one implementation, an apparatus includes an optical source to generate light, a first light transmission structure to route the light into the electro-optic device through a first guide segment structured to guide optical waves and optically couplable to the electro-optic device, an electrical probe to apply one or more electrical modulation signals to the electro-optic device to generate modulated light by modulating the light routed into the electro-optic device, a second light transmission structure to collect at least part of the modulated light from a second guide segment structured to guide optical waves and optically couplable to the electro-optic device, a detector to generate an electrical output signal corresponding to the collected light, and a signal processing device to record times at which each photon corresponding to the collected light is detected by processing the electrical output signal. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/654561 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/9503 (20130101) G01N 21/9505 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291166 | Schwartz et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin); University of Leiden (Leiden, Netherlands); University of Chicago (Chicago, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David C. Schwartz (Madison, Wisconsin); Kristy Kounovsky-Shafer (Kearney, Nebraska); Juan Hernandez-Ortiz (Medellin, Colombia); Theo Odijk (Leiden, Netherlands); Juan DePablo (Chicago, Illinois); Kyubong Jo (Seoul, South Korea) |
| ABSTRACT | Systems and methods for presenting nucleic acid molecules for analysis are provided. The nucleic acid molecules have a central portion that is contained within a nanoslit. The nanoslit contains an ionic buffer. The nucleic acid molecule has a contour length that is greater than a nanoslit length of the nanoslit. An ionic strength of the ionic buffer and electrostatic or hydrodynamic properties of the nanoslit and the nucleic acid molecule combining to provide a summed Debye length that is greater than or equal to the smallest physical dimension of the nanoslit. |
| FILED | Monday, May 03, 2021 |
| APPL NO | 17/306288 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502761 (20130101) B01L 2200/0663 (20130101) B01L 2300/0816 (20130101) B01L 2300/0896 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 27/44791 (20130101) Original (OR) Class G01N 33/48721 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291209 | Reya |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Tannishtha Reya (La Jolla, California) |
| ABSTRACT | Disclosed are methods for identifying small molecule modulators of protein-RNA interactions that could potentially function as therapeutic agents in cancer treatment. Methods of identifying inhibitors of the RNA-binding functions of MSI2, as well as inhibitors identified thereof, are also disclosed. |
| FILED | Thursday, January 06, 2022 |
| APPL NO | 17/647342 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/02 (20180101) Peptides C07K 14/36 (20130101) C07K 2319/21 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/6428 (20130101) G01N 33/542 (20130101) Original (OR) Class G01N 33/582 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291212 | Celedon et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Scanogen Inc. (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Alfredo A. Celedon (Columbia, Maryland); Joseph Patrick Russell (Odenton, Maryland) |
| ABSTRACT | The present application relates to detection units and methods for detecting one or more target analytes in a sample using a complex formed by a target and first and second probes, wherein the first probe is coupled to a detectable piece, the target is coupled to the first probe and the second probe, and the second probe is coupled to a solid support. Specific binding of the detectable piece to the target analyte can be distinguished from non-specific binding of the detectable piece by measuring the number of detectable pieces that leave their initial location after exposure to a disruptor that uncouples the detectable piece from the solid support. |
| FILED | Monday, May 23, 2022 |
| APPL NO | 17/750987 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/54306 (20130101) Original (OR) Class G01N 33/54313 (20130101) G01N 33/54393 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291216 | KAELIN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Dana Farber Cancer Institute, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | Dana Farber Cancer Insitute, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | William G. KAELIN (Boston, Massachusetts); Mircea IVAN (Indianapolis, Indiana) |
| ABSTRACT | Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions. |
| FILED | Friday, November 20, 2020 |
| APPL NO | 17/100272 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/00 (20130101) A61K 31/70 (20130101) A61K 38/44 (20130101) A61K 38/1709 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/26 (20130101) Enzymes C12Y 114/11002 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/573 (20130101) Original (OR) Class G01N 2333/90245 (20130101) G01N 2500/02 (20130101) G01N 2500/04 (20130101) G01N 2500/20 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291222 | Ilyuk et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Tymora Analytical Operations, Inc. (West Lafayette, Indiana) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Anton Ilyuk (West Lafayette, Indiana); Weiguo A. Tao (West Lafayette, Indiana); BRUNO BOCKORNY (West Lafayette, Indiana); LING HUANG (West Lafayette, Indiana); LAKSHMI MUTHUSWAMY (West Lafayette, Indiana); MANUEL HIDALGO (West Lafayette, Indiana); SENTHIL MUTHUSWAMY (West Lafayette, Indiana) |
| ABSTRACT | Methods and products for the identification and detection of new pancreatic cancer biomarkers based on proteins in biofluids, such as plasma and serum extracellular vesicles. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692377 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/57438 (20130101) Original (OR) Class G01N 33/57488 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291226 | BOYDEN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Edward BOYDEN (Cambridge, Massachusetts); Adam Henry MARBLESTONE (Cambridge, Massachusetts); Samuel Gordon RODRIQUES (Cambridge, Massachusetts) |
| ABSTRACT | The invention, in part, includes methods of single molecule protein sequencing that include using weak binding spectra in the amino acid identification. |
| FILED | Wednesday, May 25, 2022 |
| APPL NO | 17/824073 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/37 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/76 (20130101) G01N 21/6428 (20130101) G01N 21/6458 (20130101) G01N 33/6824 (20130101) Original (OR) Class G01N 2333/948 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291231 | Noth |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Virginia Patent Foundation (Charlottesville, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Imre Noth (Charlottesville, Virginia) |
| ABSTRACT | Provided are methods for generating prognostic signatures for subject diagnosed with Idiopathic Pulmonary Fibrosis (IPF) with respect to decline in lung Forced Vital Capacity (FVC). The methods can include determining first expression levels for one or more genes as set forth herein in a first biological sample obtained from a subject diagnosed with IPF, determining a second expression level for the same one or more genes in a second biological sample obtained from the subject, and comparing the first and second expression levels for the one or more genes to provide a prognostic signature. The first and second biological samples can include peripheral blood mononuclear cells (PBMCs) and/or nucleic acids extracted from PBMCs. Also provided are methods for classifying subjects with IPF as being at risk for FVC decline, for identifying and treating at risk subjects, and for monitoring the progress of treatments. |
| FILED | Monday, January 13, 2020 |
| APPL NO | 17/422033 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6893 (20130101) Original (OR) Class G01N 2800/12 (20130101) G01N 2800/52 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291240 | Dawson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Johns Hopkins University (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ted M. Dawson (Baltimore, Maryland); Liana Rosenthal (Baltimore, Maryland); Saurav Brahmachari (Baltimore, Maryland); Tae-In Kam (Baltimore, Maryland); Valina L. Dawson (Baltimore, Maryland) |
| ABSTRACT | The invention relates to methods for diagnosis, monitoring progression, and treatment of neurodegenerative disorders. In particular, biomarkers for diagnosis, monitoring progression, and treatment of neurodegenerative disorders are provided. In some embodiments, methods for diagnosis, monitoring progression, and treatment of synucleinopathies and related disorders are provided. |
| FILED | Wednesday, August 26, 2020 |
| APPL NO | 17/633917 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6896 (20130101) Original (OR) Class G01N 2440/14 (20130101) G01N 2800/2835 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291241 | Caughey et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The U.S.A., as represented by the Secretary, Department of Health and Human Services (Bethesda, Maryland) |
| ASSIGNEE(S) | The U.S.A., as represented by the Secretary, Department of Health and Human Services (Bethesda, Maryland) |
| INVENTOR(S) | Byron Winslow Caughey (Hamilton, Montana); Bradley Richard Groveman (Hamilton, Montana); Christina Doriana Groveman (Hamilton, Montana); Lynne DePuma Raymond (Hamilton, Montana); Andrew Gregory Hughson (Hamilton, Montana) |
| ABSTRACT | Methods are disclosed for determining whether a subject has a synucleinopathy. Methods are also disclosed for detecting misfolded alpha synuclein (αSyn) in a biological sample or fraction thereof. These methods include the use of an αSyn seeding assay. |
| FILED | Wednesday, March 30, 2022 |
| APPL NO | 17/708560 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/543 (20130101) G01N 33/6896 (20130101) Original (OR) Class G01N 2800/2814 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291400 | Shirley |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Kairos Sensors LLC (Corvallis, Oregon) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kendon Robert Shirley (Corvallis, Oregon) |
| ABSTRACT | Provided herein are technologies relating to detecting x-rays and particularly, but not exclusively, to compositions, devices, systems, and methods for x-ray imaging using a direct-conversion x-ray sensor comprising a perovskite composition that minimizes and/or eliminates in-sensor k-fluorescence in photon energy channels used for medical imaging. Exemplary perovskite compositions described are those that comprise a structure of ABX3, in which A represents an inorganic and/or organic cation, B represents a heavy metal cation, and X represents a halide. |
| FILED | Tuesday, October 12, 2021 |
| APPL NO | 17/498937 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 6/4208 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 23/046 (20130101) Measurement of Nuclear or X-radiation G01T 1/247 (20130101) Original (OR) Class Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 27/14658 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291401 | Shirley |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Kairos Sensors LLC (Corvallis, Oregon) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kendon Robert Shirley (Corvallis, Oregon) |
| ABSTRACT | Provided herein are technologies relating to detecting x-rays and particularly, but not exclusively, to compositions, devices, systems, and methods for x-ray imaging using a direct-conversion x-ray sensor comprising a perovskite composition that minimizes and/or eliminates in-sensor k-fluorescence in photon energy channels used for medical imaging. Exemplary perovskite compositions described are those that comprise a structure of ABX3, in which A represents an inorganic and/or organic cation, B represents a heavy metal cation, and X represents a halide. |
| FILED | Wednesday, December 22, 2021 |
| APPL NO | 17/559731 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 6/4208 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 23/046 (20130101) Measurement of Nuclear or X-radiation G01T 1/247 (20130101) Original (OR) Class Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 27/14658 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292637 | Huang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mayo Foundation for Medical Education and Research (Rochester, Minnesota) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Chengwu Huang (Rochester, Minnesota); Shigao Chen (Rochester, Minnesota) |
| ABSTRACT | Systems and methods for high spatial and temporal resolution ultrasound imaging of microvessels in a subject are described. Ultrasound data are acquired from a region-of-interest in a subject who has been administered a microbubble contrast agent. The ultrasound data are acquired while the microbubbles are moving through, or otherwise present in, the region-of-interest. The region-of-interest may include, for instance, microvessels or other microvasculature in the subject. By imaging microbubbles, a cross-correlation map between each microbubble image and a point spread function of the system can be generated. Accumulation of power-based cross-correlation maps may then be used to generate a high-resolution high-contrast image of the microvasculature. |
| FILED | Tuesday, June 15, 2021 |
| APPL NO | 17/634769 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 8/06 (20130101) A61B 8/469 (20130101) A61B 8/481 (20130101) A61B 8/0891 (20130101) A61B 8/5207 (20130101) A61B 8/5269 (20130101) Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 7/52039 (20130101) G01S 15/8977 (20130101) Image Data Processing or Generation, in General G06T 3/4007 (20130101) G06T 3/4053 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292641 | Wang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Ge Wang (Loudonville, New York); Qing Lyu (Troy, New York); Hongming Shan (Troy, New York) |
| ASSIGNEE(S) | Rensselaer Polytechnic Institute (Troy, New York) |
| INVENTOR(S) | Ge Wang (Loudonville, New York); Qing Lyu (Troy, New York); Hongming Shan (Troy, New York) |
| ABSTRACT | A deep neural network for motion artifact reduction includes a transformer neural network, and a synthesis neural network. The transformer neural network is configured to receive input image data comprising a target image, a prior image, and a subsequent image. The transformer neural network is configured to mitigate a temporal aspect of the motion artifact, and to provide a transformer output related to the input data. The synthesis neural network is configured to receive the transformer output, and to provide at least one output image having a reduced motion artifact relative to the input image data. |
| FILED | Friday, March 04, 2022 |
| APPL NO | 17/686819 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 3/0445 (20130101) G06N 3/0454 (20130101) Image Data Processing or Generation, in General G06T 3/4046 (20130101) G06T 5/001 (20130101) Original (OR) Class G06T 2207/10081 (20130101) G06T 2207/10088 (20130101) G06T 2207/20081 (20130101) G06T 2207/20084 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292657 | CLARK et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | TERRAN BIOSCIENCES, INC. (New York, New York); THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, New York); THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (Menands, New York) |
| ASSIGNEE(S) | TERRAN BIOSCIENCES, INC. (NEW YORK, New York); THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (NEW YORK, New York); THE RESEARCH FOUNDATION FOR MENTAL HEALTH HYGIENE, INC. (MENANDS, New York) |
| INVENTOR(S) | Samuel CLARK (New York, New York); Kenneth WENGLER (New York, New York); Guillermo HORGA HERNANDEZ (New York, New York) |
| ABSTRACT | An exemplary system, method and computer-accessible medium for harmonizing neuromelanin (NM) data using combat directly on a NM database or using combat generated coefficients to harmonize future data can include, for example, receiving imaging information of a brain of the patient(s), from one MRI scanner, receiving imaging information of a brain of the patient(s), from a second MRI scanner and using combat to harmonize the data between scanners against a reference dataset. The Neuromelanin (NM) concentration of the patient(s) can then be determined based on the harmonized data. The NM concentration can be determined using a voxel-wise analysis procedure. The voxel-wise analysis procedure can be used to determine a topographical pattern(s) within a substantia nigra (SN) of the brain of the patient(s). |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/693166 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/055 (20130101) Image Data Processing or Generation, in General G06T 5/007 (20130101) G06T 5/50 (20130101) Original (OR) Class G06T 7/0014 (20130101) G06T 2207/10088 (20130101) G06T 2207/20081 (20130101) G06T 2207/30016 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 50/20 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292819 | Raychaudhuri et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| ASSIGNEE(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| INVENTOR(S) | Dipankar Raychaudhuri (Princeton Junction, New Jersey); Wuyang Zhang (Bellevue, Washington); Yanyong Zhang (Metuchen, New Jersey); Yunxin Liu (Haidian District, China PRC); Marco Gruteser (Princeton, New Jersey) |
| ABSTRACT | Computer vision systems and methods for acceleration of high-resolution mobile deep vision with content-aware parallel offloading are provided. The system allows for acceleration of deep vision applications running on mobile devices via offloading of machine learning computations on edge cloud infrastructure, and speeds up computation via parallel processing on the edge cloud, employing one or more of the following processes: recurrent region proposal prediction, region proposal centric frame partitioning, and resource-aware offloading to multiple processors. Mobile deep vision applications can utilize the systems and methods disclosed herein to accelerate application processing. The system offloads computation to multiple servers to minimize the end-to-end latency, and includes a high-resolution mobile deep vision task acceleration system that offloads computation to multiple (edge located) servers. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689089 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 3/4046 (20130101) G06T 7/11 (20170101) G06T 11/00 (20130101) G06T 2207/20021 (20130101) G06T 2207/20084 (20130101) Image or Video Recognition or Understanding G06V 10/22 (20220101) G06V 10/74 (20220101) G06V 10/82 (20220101) G06V 20/20 (20220101) Original (OR) Class G06V 2201/10 (20220101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293210 | Higgins et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The General Hospital Corporation (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | John M. Higgins (Cambridge, Massachusetts); Anwesha Chaudhury (Boston, Massachusetts) |
| ABSTRACT | A method includes receiving data representing a first complete blood count (CBC) measured from a first sample of red blood cells (RBCs) from a subject and data representing a second CBC measured from a second sample of RBCs from the subject, each of the first and second CBCs including a volume and a hemoglobin content of each of the RBCs in the respective sample, the first and second samples being different samples corresponding to different times. Parameters representing RBC population dynamics for the subject are calculated based on the volume and the hemoglobin content for the RBCs in each of the first and second samples and a time between the first and second samples. A pathophysiological state of the subject is determined based on the one or more parameters representing the RBC population dynamics. |
| FILED | Thursday, August 20, 2020 |
| APPL NO | 17/636272 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 33/26 (20130101) Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology G16B 5/20 (20190201) Original (OR) Class Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 10/40 (20180101) G16H 50/20 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293215 | Xavier et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); THE GENERAL HOSPITAL CORPORATION (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ramnik Xavier (Boston, Massachusetts); Daniel B. Graham (Cambridge, Massachusetts); Chengwei Luo (Cambridge, Massachusetts) |
| ABSTRACT | A system and method for prediction of immunodominant epitopes is provided herein. MHCII peptidomics was used to discover complex bacterial epitopes and host antigen processing pathways. Novel insights into the features of antigenicity are leveraged to build an algorithm for prediction of immunodominant epitopes. Use of immunodominant epitopes is described. |
| FILED | Wednesday, June 27, 2018 |
| APPL NO | 16/627193 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/0208 (20130101) A61K 2039/605 (20130101) Peptides C07K 14/195 (20130101) Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology G16B 15/30 (20190201) G16B 20/30 (20190201) Original (OR) Class G16B 35/20 (20190201) G16B 40/20 (20190201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293224 | Katritch et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Vsevolod Katritch (Irvine, California); Arman Sadybekov (San Diego, California) |
| ABSTRACT | This disclosure provides for modular synthon-based screening for rapid drug discovery. Such screening includes initially docking a pre-built set of fragment-like compounds representing library reaction scaffolds and corresponding synthons. Best selected scaffold and synthon combinations from the initial docking are used to enumerate a further library, which is screened again to produce fully enumerated compounds. Such an iterative approach focuses on a subset of synthons at each screening, thereby reducing the combinatorial chemical space for docking and facilitating more rapid drug discovery. |
| FILED | Thursday, March 10, 2022 |
| APPL NO | 17/691958 |
| CURRENT CPC | Computational Chemistry; Chemoinformatics; Computational Materials Science G16C 20/50 (20190201) Original (OR) Class G16C 20/64 (20190201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293243 | Callcut et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Rachael Callcut (Oakland, California); Michael Blum (Oakland, California); Matthew O'Brien (Oakland, California) |
| ABSTRACT | Provided are systems and methods for analyzing sonograms of abdomen to identify presence or absence of free fluid in the abdomen. The systems and methods are useful for performing or assisting with point of care diagnosis of presence of internal bleeding in trauma patients without requiring input from a radiologist or another clinician trained to analyze sonograms for presence or absence of free fluid. Also provided are methods and system for training a medical imaging system for analyzing sonograms of abdomen to identify presence or absence of free fluid in the abdomen. |
| FILED | Friday, September 18, 2020 |
| APPL NO | 17/641279 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 8/085 (20130101) Computer Systems Based on Specific Computational Models G06N 3/08 (20130101) Image Data Processing or Generation, in General G06T 7/0012 (20130101) G06T 2207/10132 (20130101) G06T 2207/20021 (20130101) G06T 2207/20081 (20130101) G06T 2207/20084 (20130101) G06T 2207/30004 (20130101) Image or Video Recognition or Understanding G06V 10/82 (20220101) G06V 10/764 (20220101) G06V 10/774 (20220101) G06V 2201/10 (20220101) G06V 2201/031 (20220101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 30/20 (20180101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293244 | Leuthardt et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Washington University (St. Louis, Missouri) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Eric Leuthardt (St. Louis, Missouri); Joshua Shimony (St. Louis, Missouri); Patrick Luckett (St. Louis, Missouri); John Lee (St. Louis, Missouri) |
| ABSTRACT | A method for mapping brain function of a subject includes receiving a dataset of resting state fMRI (RS-fMRI) three dimensional (3D) image frames of the subject's brain, and inputting the 3D image frames to a deep learning artificial neural network. For each voxel of each 3D image frame and for each resting state network of a plurality of resting state networks, the deep learning artificial neural network calculates a probability that the voxel belongs to the resting state network. The deep learning artificial neural network is trained beforehand using a plurality of 3D image frames including previously defined resting state networks obtained from a plurality of calibration subjects. The method includes generating one or more functional map of the plurality of resting state networks of the subject's brain using the probabilities calculated by the artificial neural network. |
| FILED | Wednesday, March 09, 2022 |
| APPL NO | 17/654190 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 3/08 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 30/20 (20180101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293279 | Baronov et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Etiometry, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | Etiometry, Inc. (Boston, Massachusetts); Etiometry, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Dimitar V. Baronov (Weston, Massachusetts); Evan J. Butler (New Haven, Connecticut); Jesse M. Lock (Winchester, Massachusetts); Michael F. McManus (Pembroke, Massachusetts) |
| ABSTRACT | A risk-based patient monitoring system for critical care patients combines data from multiple sources to assess the current and the future risks to the patient, thereby enabling providers to review a current patient risk profile and to continuously track a clinical trajectory. A physiology observer module in the system utilizes multiple measurements to estimate Probability Density Functions (PDF) of a number of Internal State Variables (ISVs) that describe a components of the physiology relevant to the patient treatment and condition. A clinical trajectory interpreter module in the system utilizes the estimated PDFs of ISVs to identify under which probable patient states the patient can be currently categorized and assign a probability value that the patient will be in each of the identified states. The combination of patient states and their probabilities is defined as the clinical risk to the patient. |
| FILED | Tuesday, May 17, 2022 |
| APPL NO | 17/745969 |
| CURRENT CPC | Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 50/20 (20180101) G16H 50/30 (20180101) Original (OR) Class G16H 50/50 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
National Science Foundation (NSF)
| US 20220287299 | Kaeppler et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shawn Kaeppler (Middleton, Wisconsin); Heidi Kaeppler (Middleton, Wisconsin); Michael William Petersen (Merrimac, Wisconsin); Brian Joseph Martinell (Mount Horeb, Wisconsin); Frank McFarland (Middleton, Wisconsin) |
| ABSTRACT | The present invention provides pollen compositions, methods and kits for making said compositions, and methods of using said compositions to fertilize a plant. The pollen within these compositions has increased longevity and can be used to fertilize plants for an extended period of time as compared to pollen prepared using conventional methods. Also provided are methods of collecting pollen from a maize plant by maturing individual tassel branches off of the plant and vessels for collecting the pollen from these individual branches. |
| FILED | Monday, March 14, 2022 |
| APPL NO | 17/694200 |
| CURRENT CPC | New Plants or Processes for Obtaining Them; Plant Reproduction by Tissue Culture Techniques A01H 5/10 (20130101) A01H 6/4684 (20180501) Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 3/00 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287648 | Cannesson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Maxime Cannesson (Los Angeles, California); Brian Hill (Los Angeles, California); Eran Halperin (Santa Monica, California); Ira Hofer (Los Angeles, California); Nadav Rakocz (Los Angeles, California) |
| ABSTRACT | Systems and methods for training a signal generation model and generating imputed physiological waveform signals in accordance with embodiments of the invention are illustrated. One embodiment includes a method for measuring physiological waveform signals. The method includes steps for receiving a set of one or more input physiological waveform signals, processing the set of input physiological waveform signals, generating an output physiological waveform signal using a signal generation model, and providing outputs based on the generated output signal. |
| FILED | Wednesday, August 19, 2020 |
| APPL NO | 17/753126 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/308 (20210101) A61B 5/318 (20210101) A61B 5/742 (20130101) A61B 5/02416 (20130101) A61B 5/7203 (20130101) A61B 5/7267 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288104 | Blanchard et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Joel Blanchard (Arlington, Massachusetts); Manolis Kellis (Boston, Massachusetts); Li-Huei Tsai (Cambridge, Massachusetts); Jose Davila Velderrain (Saltillo, Mexico); Leyla Akay (Cambridge, Massachusetts); Djuna Von Maydell (Somerville, Massachusetts); Audrey Effenberger (Cambridge, Massachusetts); Matheus Victor (Cambridge, Massachusetts) |
| ABSTRACT | The present disclosure provides methods of inhibiting amyloid synthesis in a subject using cyclodextrin and analogs thereof. Small molecules (cyclodextrin) reverse APOE4-associated cholesterol phenotypes and lead to significantly improved myelination both human in vitro cultures and APOE4 targeted replacement mice. This demonstrates that APOE4 alters cholesterol synthesis and transport in oligodendrocytes which impairs myelination. Collectively, this work uncovers a pathogenic role of APOE4 in oligodendrocytes and myelination and enables therapeutic opportunities for Alzheimer's Disease. |
| FILED | Monday, March 14, 2022 |
| APPL NO | 17/694630 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/724 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/28 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288334 | Hawkes et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Elliot W. Hawkes (Goleta, California); David A. Haggerty (Goleta, California); David R. Drover (Stanford, California) |
| ABSTRACT | An everting vine robot intubation device capable of automatically and autonomously intubating the trachea and producing a lumen through which artificial ventilation may be conducted. The device includes an everting primary vine robot attached to a mouthpiece and a smaller diameter everting intubation vine robot associated with the primary everting vine robot. The primary vine robot is shaped and sized to extend to the back of a patient's laryngopharynx when fully actuated and the intubation everting vine robot is shaped and sized to extend from the primary vine robot into the patient's trachea when fully actuated. |
| FILED | Wednesday, July 29, 2020 |
| APPL NO | 17/632335 |
| CURRENT CPC | Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 16/049 (20140204) Original (OR) Class A61M 16/1005 (20140204) A61M 2205/0266 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288508 | Culberson |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Georgia Tech Research Corporation (Atlanta, Georgia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Austin Lance Culberson (Atlanta, Georgia) |
| ABSTRACT | An embodiment of the disclosed technology provides a microfluidic cooling device including a microfluidic pathway and a thermoelectric cooling element. The microfluidic pathway can include an inlet to receive a sample at a first temperature and an outlet to output a first phase and second phase of the sample at a second temperature. The sample can include a first liquid, a second liquid, and a plurality of soluble particles. The first phase can include the first liquid and a portion of the soluble particles that is more soluble in the first liquid than second liquid. The second phase can include the second liquid and a portion of the soluble particles that more soluble in the second liquid than first liquid. The thermoelectric cooling element can be in thermal communication with the microfluidic pathway and can transition the sample from the first temperature to the second temperature. |
| FILED | Friday, July 31, 2020 |
| APPL NO | 17/597953 |
| CURRENT CPC | Separation B01D 17/005 (20130101) Original (OR) Class B01D 17/12 (20130101) Chemical or Physical Laboratory Apparatus for General Use B01L 3/502761 (20130101) B01L 7/52 (20130101) B01L 2200/0652 (20130101) B01L 2300/1894 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288576 | LI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Honda Motor Co., Ltd. (Tokyo, Japan); The Trustees of Columbia University in the City of New York (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xufan LI (Fremont, California); Avetik HARUTYUNYAN (Santa Clara, California); Xiangye LIU (Xi'an, China PRC); Baiching LI (New York, New York); James Curtis HONE (New York, New York); Daniel V. ESPOSITO (New York, New York) |
| ABSTRACT | Aspects of the present disclosure generally relate to catalyst compositions including metal chalcogenides, processes for producing such catalyst compositions, processes for enhancing catalytic active sites in such catalyst compositions, and uses of such catalyst compositions in, e.g., processes for producing conversion products. In an aspect, a process for forming a catalyst composition is provided. The process includes introducing an electrolyte material and an amphiphile material to a metal chalcogenide to form the catalyst composition. In another aspect, a catalyst composition is provided. The catalyst composition includes a metal chalcogenide, an electrolyte material, and an amphiphile material. Devices for hydrogen evolution reaction are also provided. |
| FILED | Thursday, March 11, 2021 |
| APPL NO | 17/199129 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 27/043 (20130101) B01J 27/051 (20130101) B01J 27/0573 (20130101) B01J 27/0576 (20130101) B01J 37/344 (20130101) Original (OR) Class Electrolytic or Electrophoretic Processes for the Production of Compounds or Non-metals; Apparatus Therefor C25B 1/04 (20130101) C25B 11/075 (20210101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288586 | SINGER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northeastern University (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Brenna SINGER (Gansevoort, New York); Bridget BERGSTROM (Maple Grove, Minnesota); Sarah M. DUNBAR (Brookhaven, New York); Francheska TORRES (Charlton, Massachusetts); Alana PERSING (Allston, Massachusetts); Kelsey M. DUPONT (Revere, Massachusetts); Timothy LANNIN (Hopkinton, Massachusetts); Jeffrey RUBERTI (Lexington, Massachusetts) |
| ABSTRACT | Devices and methods for automated liquid handling and reagent processing to provide labelling and detection of bacteria and viruses are provided. Labelling reactions are performed rapidly and with essentially no generation of hazardous waste or use of consumables. Highly sensitive detection is performed by measuring fluorescence on a rotating sample plate. |
| FILED | Thursday, March 10, 2022 |
| APPL NO | 17/692078 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502715 (20130101) Original (OR) Class B01L 3/502723 (20130101) B01L 2200/16 (20130101) B01L 2200/0684 (20130101) B01L 2300/161 (20130101) B01L 2300/0663 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/6428 (20130101) G01N 33/582 (20130101) G01N 2800/26 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288780 | Wu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of South Florida (Tampa, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Lei Wu (Tampa, Florida); Redwan Alqasemi (Wesley Chapel, Florida); Rajiv Dubey (Tampa, Florida) |
| ABSTRACT | Disclosed is an intuitive robotic device control reference frame with hybrid inverse kinematics having a natural and easier human-robot interface. A system for controlling a robot can include a robotic device that performs tasks, an input device that receives user input indicating desired movement of the robotic device to perform the tasks, and a controller that controls the robotic device based on the user input. The controller can receive signals identifying the user input, determine a ground reference frame and an end-effector reference frame for controlling movement of the robotic device, generate, based on the ground reference frame and the end-effector reference frame, an intuitive reference frame for controlling movement of the robotic device, determine controls to move the robotic device in the intuitive reference frame, generate instructions for controlling movement of the robotic device, and execute the instructions to control movement of the robotic device. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689534 |
| CURRENT CPC | Manipulators; Chambers Provided With Manipulation Devices B25J 9/023 (20130101) B25J 9/1607 (20130101) B25J 9/1664 (20130101) Original (OR) Class B25J 9/1689 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289902 | Martin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | David C. Martin (Lincoln University, Pennsylvania); Samadhan Suresh Nagane (Maharashtra, India); Peter Sitarik (Fleetwood, Pennsylvania) |
| ASSIGNEE(S) | University of Delaware (Newark, Delaware) |
| INVENTOR(S) | David C. Martin (Lincoln University, Pennsylvania); Samadhan Suresh Nagane (Maharashtra, India); Peter Sitarik (Fleetwood, Pennsylvania) |
| ABSTRACT | Disclosed herein are functionalized 3,4-alkylenedioxythiophene (ADOT+) monomers represented by a chemical formula (CR1R2)(CR3R4)(CR4R6)xO2H2S, wherein x=0 or 1; wherein each of R1, R2, R3, R4, R5, and R6 is independently selected from hydrogen, a hydrocarbyl moiety, and a heteroatom-containing functional group; and wherein at least one of R1, R2, R3, R4, R5, and R6 comprises the heteroatom-containing functional group selected from an aldehyde, a maleimide, and their derivatives thereof. Also, disclosed herein are aldehyde derivatives represented by (ADOT-CH2—NH)pY and a maleimide derivative represented by (ADOT-(CH2)q—N)pZ where p=1-2 and each of Y and Z is a hydrocarbyl moiety or a biofunctional hydrocarbyl moiety. In an embodiment of the ADOT+ monomers, one of R1, R2, R3, R4, R5, and R6 is replaced by a direct bond to an amide group, an azide group, or an ester group of a biofunctional hydrocarbyl moiety. Also, disclosed herein are polymers and copolymers made therefrom. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/637108 |
| CURRENT CPC | Heterocyclic Compounds C07D 495/04 (20130101) C07D 519/00 (20130101) Steroids C07J 33/002 (20130101) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 61/126 (20130101) Original (OR) Class C08G 2261/44 (20130101) C08G 2261/94 (20130101) C08G 2261/122 (20130101) C08G 2261/148 (20130101) C08G 2261/334 (20130101) C08G 2261/1424 (20130101) C08G 2261/1426 (20130101) C08G 2261/1428 (20130101) C08G 2261/1432 (20130101) Cables; Conductors; Insulators; Selection of Materials for Their Conductive, Insulating or Dielectric Properties H01B 1/124 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289981 | CARTER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, Minnesota) |
| ASSIGNEE(S) | REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, Minnesota) |
| INVENTOR(S) | Clay Jeremy CARTER (Minneapolis, Minnesota); Adrian HEGEMAN (Minneapolis, Minnesota) |
| ABSTRACT | The invention provides a compound of formula (I): wherein R1, R2, and R3 have any of the values described in the specification, as well as compositions comprising a compound of formula (I), methods for preparing compounds of formula (I), and methods for detecting the presence of an amine in a sample. The compounds are useful as pigments. |
| FILED | Friday, August 21, 2020 |
| APPL NO | 17/636729 |
| CURRENT CPC | Acyclic or Carbocyclic Compounds C07C 251/16 (20130101) C07C 251/30 (20130101) Heterocyclic Compounds C07D 207/20 (20130101) C07D 207/22 (20130101) C07D 207/44 (20130101) C07D 209/08 (20130101) C07D 209/20 (20130101) C07D 209/42 (20130101) C07D 233/64 (20130101) Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids C07H 5/04 (20130101) Organic Dyes or Closely-related Compounds for Producing Dyes; Mordants; Lakes C09B 23/06 (20130101) Original (OR) Class Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 31/22 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290043 | Tharkur et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Central Florida Research Foundation, Inc. (Orlando, Florida) |
| ASSIGNEE(S) | University of Central Florida Research Foundation, Inc. (Orlando, Florida) |
| INVENTOR(S) | Jeremy Tharkur (Miami, Florida); Swadeshmukul Santra (Orlando, Florida) |
| ABSTRACT | A method for preparing a light sensitive particle that uses at least one metal precursor material and at least one dopant precursor material mixed in solution absent a surfactant. Upon an optional adjustment of pH to about 3 to about 6, a light-sensitive particle comprising a metal-dopant material may be formed and separated from the solution. The light-sensitive particle may comprise a Q-dot particle. Also described are the particles themselves. |
| FILED | Tuesday, May 31, 2022 |
| APPL NO | 17/828510 |
| CURRENT CPC | Materials for Miscellaneous Applications, Not Provided for Elsewhere C09K 11/574 (20130101) Original (OR) Class C09K 11/0805 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290224 | LIEBERMAN AIDEN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); BAYLOR COLLEGE OF MEDICINE (Houston, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Erez LIEBERMAN AIDEN (Houston, Texas); Suhas RAO (Medfield, Massachusetts); Elena STAMENOVA (Reading, Massachusetts); Olga DUDCHENKO (Houston, Texas); Eric LANDER (Cambridge, Massachusetts) |
| ABSTRACT | Disclosed is an in situ method for detecting spatial proximity relationships between nucleic acid sequences, such as DNA, in a cell. The method includes: providing a sample of one or more cells comprising nucleic acids; fragmenting the nucleic acids present in the cells that leaves 5′ overhanging ends; filling in the overhanging ends with at least one labeled nucleotide; joining the filled in end of the fragmented nucleic acids that are in close physical proximity to create one or more end joined nucleic acid fragments having a junction; isolating the one or more end joined nucleic acid fragments using the labeled nucleotide; and determining the sequence at the junction of the one or more end joined nucleic acid fragments. |
| FILED | Thursday, February 10, 2022 |
| APPL NO | 17/669211 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) C12Q 1/6869 (20130101) Original (OR) Class C12Q 2521/501 (20130101) C12Q 2525/117 (20130101) C12Q 2535/122 (20130101) C12Q 2563/131 (20130101) Combinatorial Chemistry; Libraries, e.g Chemical Libraries C40B 20/00 (20130101) C40B 30/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291128 | RUBERTI |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northeastern University (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jeffrey RUBERTI (Lexington, Massachusetts) |
| ABSTRACT | Methods and devices for continuous flow monitoring of a liquid sample for presence of an airborne microbial pathogen are provided. The liquid sample can be derived from environmental air. The methods and devices provide for continuous labeling of a targeted pathogen in the liquid sample with a fluorescent probe. A customized fluorescence detector is provided that can detect labeled pathogens during continuous flow. |
| FILED | Thursday, March 10, 2022 |
| APPL NO | 17/692034 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502715 (20130101) B01L 2200/10 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/6428 (20130101) Original (OR) Class G01N 21/6454 (20130101) G01N 33/582 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291142 | Mookherjea et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); California Institute of Technology (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shayan Mookherjea (San Diego, California); Xiaoxi Wang (San Diego, California); Boris A. Korzh (Altadena, California); Matthew D. Shaw (Los Angeles, California) |
| ABSTRACT | Methods, systems, and devices for testing an electro-optic device such as a modulator or a switch are disclosed. In one implementation, an apparatus includes an optical source to generate light, a first light transmission structure to route the light into the electro-optic device through a first guide segment structured to guide optical waves and optically couplable to the electro-optic device, an electrical probe to apply one or more electrical modulation signals to the electro-optic device to generate modulated light by modulating the light routed into the electro-optic device, a second light transmission structure to collect at least part of the modulated light from a second guide segment structured to guide optical waves and optically couplable to the electro-optic device, a detector to generate an electrical output signal corresponding to the collected light, and a signal processing device to record times at which each photon corresponding to the collected light is detected by processing the electrical output signal. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/654561 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/9503 (20130101) G01N 21/9505 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291163 | XIAO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | YI XIAO (MIAMI, Florida); JUAN CANOURA (HIALEAH GARDENS, Florida) |
| ASSIGNEE(S) | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (MIAMI, Florida) |
| INVENTOR(S) | YI XIAO (MIAMI, Florida); JUAN CANOURA (HIALEAH GARDENS, Florida) |
| ABSTRACT | The subject invention provides materials and methods for single-step fluorescence and electrochemical detection of small molecules, e.g., fentanyl and its analogs, in a sample. The subjection invention provides nucleic acids materials, e.g., aptamers (nucleic acid oligonucleotides) that can bind to fentanyl and its analogs with nanomolar affinity and high specificity against illicit drugs, adulterants, and cutting agents commonly existing in seized samples. The method for detecting fentanyl and/or its analogs in a sample comprises contacting the sample with an aptamer-based sensor selective for fentanyl and its analogs, and sensitively, specifically, and rapidly detecting fentanyl and/or its analogs in the sample. |
| FILED | Friday, May 27, 2022 |
| APPL NO | 17/826891 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/115 (20130101) C12N 2310/16 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/6428 (20130101) G01N 27/3276 (20130101) Original (OR) Class G01N 27/3277 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291166 | Schwartz et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin); University of Leiden (Leiden, Netherlands); University of Chicago (Chicago, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David C. Schwartz (Madison, Wisconsin); Kristy Kounovsky-Shafer (Kearney, Nebraska); Juan Hernandez-Ortiz (Medellin, Colombia); Theo Odijk (Leiden, Netherlands); Juan DePablo (Chicago, Illinois); Kyubong Jo (Seoul, South Korea) |
| ABSTRACT | Systems and methods for presenting nucleic acid molecules for analysis are provided. The nucleic acid molecules have a central portion that is contained within a nanoslit. The nanoslit contains an ionic buffer. The nucleic acid molecule has a contour length that is greater than a nanoslit length of the nanoslit. An ionic strength of the ionic buffer and electrostatic or hydrodynamic properties of the nanoslit and the nucleic acid molecule combining to provide a summed Debye length that is greater than or equal to the smallest physical dimension of the nanoslit. |
| FILED | Monday, May 03, 2021 |
| APPL NO | 17/306288 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502761 (20130101) B01L 2200/0663 (20130101) B01L 2300/0816 (20130101) B01L 2300/0896 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 27/44791 (20130101) Original (OR) Class G01N 33/48721 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291201 | Ozbolat et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ibrahim Tarik Ozbolat (Boalsburg, Pennsylvania); Monika Hospodiuk (State College, Pennsylvania); Dino Joseph Ravnic (Hershey, Pennsylvania); Bugra Ayan (State College, Pennsylvania); Srinivas Koduru (Mechanicsburg, Pennsylvania) |
| ABSTRACT | This document provides materials and methods for making and using functional (e.g., vascularized) organ models (e.g., pancreas models). For example, functional pancreas models including an ECM containing a plurality (e.g., two or more) of pancreatic islets, and a vascular network are provided. |
| FILED | Friday, May 27, 2022 |
| APPL NO | 17/827357 |
| CURRENT CPC | Apparatus for Enzymology or Microbiology; C12M 23/16 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0676 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/507 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291207 | Yap et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Michigan Technological University (Houghton, Michigan) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Yoke Khin Yap (Houghton, Michigan); Dongyan Zhang (Houghton, Michigan); Nazmiye Yapici (South Lyon, Michigan) |
| ABSTRACT | A compound includes a nanomaterial carrier, a first linker having a first end connected to the nanomaterial carrier, a second linker having a second end connected to the nanomaterial carrier, a fluorescent entity connected to a second end of the first linker, and a biomolecule connected to a second end of the second linker. The biomolecule is configured to connect to a cluster of differentiation (CD) of an extracellular vesicle (EV). A method is also disclosed. |
| FILED | Friday, August 21, 2020 |
| APPL NO | 17/637018 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 15/00 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/533 (20130101) Original (OR) Class G01N 33/5076 (20130101) G01N 33/54346 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291211 | KIM et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, Utah); TEXAS TECH UNIVERSITY SYSTEM (Lubbock, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jungkyu KIM (Salt Lake City, Utah); Ali Khodayari BAVIL (Salt Lake City, Utah) |
| ABSTRACT | Described herein are devices and methods for improved detection and quantitation of biomolecules. Devices and methods may include a microfluidic biosensing platform for measuring electrical impedance changes in the presence of target analytes from sinusoidal input voltages to improve the sensitivity of immunoassays. In one embodiment, the described devices and methods may provide a point-of-care immunoassay platform for quantitative diagnostics using signal-enhancing microparticles to improve sensitivity and the limit-of-detection. |
| FILED | Thursday, March 10, 2022 |
| APPL NO | 17/691972 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502715 (20130101) B01L 3/502761 (20130101) B01L 2300/0645 (20130101) B01L 2300/0883 (20130101) B01L 2400/0406 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 27/125 (20130101) G01N 33/5438 (20130101) Original (OR) Class G01N 33/54306 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291293 | Wang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Tennessss Research Foundation. (Knoxville, Tennessee) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Fei Wang (Knoxville, Tennessee); Jingxin Wang (Knoxville, Tennessee); Yiwei Ma (Knoxville, Tennessee) |
| ABSTRACT | An apparatus for testing components for use in a power system includes at least one power amplifier circuit configured to be coupled to the component and a control circuit configured to operate the power amplifier circuit responsive to at least one state of a component emulator for the component included in a system emulator for the power system. The component emulator may include at least one power electronics converter circuit and the control circuit may be configured to control at least one of a voltage and a current of the at least one power amplifier circuit responsive to at least one of a voltage and a current of the at least one power electronics converter circuit. The control circuit may be further configured to control the component emulator responsive to at least one state of the at least one power amplifier circuit. |
| FILED | Wednesday, March 10, 2021 |
| APPL NO | 17/197147 |
| CURRENT CPC | Measuring Electric Variables; Measuring Magnetic Variables G01R 31/42 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291300 | Javor et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Trustees of Boston University (Boston, Massachusetts) |
| ASSIGNEE(S) | Trustees of Boston University (Boston, Massachusetts) |
| INVENTOR(S) | Joshua Javor (Cambridge, Massachusetts); David Bishop (Brookline, Massachusetts); David Campbell (Brookline, Massachusetts); Matthias Imboden (St. Blaise, Switzerland) |
| ABSTRACT | A system and method of effectively measuring a change in a gradient of a magnetic field. The systems include a first magnet and a second magnet mechanically coupled together and aligned along a polarization axis. The first magnet and the second magnet are positioned such that a pair of like magnetic poles of the first magnet and the second magnet face in opposite directions. Further, the first magnet and the second magnet are configured to move along the polarization axis in response to a magnetic field. A sensing system is configured to measure a change in a gradient of the magnetic field based on the movement of the first magnet and second magnet along the polarization axis in response to the magnetic field. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692651 |
| CURRENT CPC | Measuring Electric Variables; Measuring Magnetic Variables G01R 33/022 (20130101) Original (OR) Class G01R 33/038 (20130101) G01R 33/0052 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291301 | Javor et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Trustees of Boston University (Boston, Massachusetts) |
| ASSIGNEE(S) | Trustees of Boston University (Boston, Massachusetts) |
| INVENTOR(S) | Joshua Javor (Cambridge, Massachusetts); David Bishop (Brookline, Massachusetts); David Campbell (Brookline, Massachusetts); Matthias Imboden (St. Blaise, Switzerland) |
| ABSTRACT | A gradiometer includes a at least one magnet attached to a beam. The magnet moves in response to a magnetic force. A sensing element is configured to measure movement or deflection of the beam or magnet. The gradiometer is configured to determine a gradient of a magnetic field acting on the first magnet based on movement of the magnet. The gradiometer can further measure higher order gradients. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692692 |
| CURRENT CPC | Measuring Electric Variables; Measuring Magnetic Variables G01R 33/022 (20130101) Original (OR) Class G01R 33/0385 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291450 | ZHONG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE UNIVERSITY OF CHICAGO (Chicago, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Tian ZHONG (Chicago, Illinois); Christina WICKER (Chicago, Illinois) |
| ABSTRACT | Technologies for a strong rare-earth-ion interactions are disclosed. In the illustrative embodiment, a heterogeneous slot waveguide is formed with two layers of silicon surrounding a layer of Er:Y2O3, resulting in a waveguide that supports a TM mode with a strong confinement of electromagnetic field near the erbium dopants. The strong concentration of electromagnetic field and small mode volume allows for strong interactions between optical fields and the erbium dopants. In some embodiments, the slot waveguide structure may be configured as a microring resonator or a photonic crystal, resulting in small-mode-volume resonators with high Q-factors. In some embodiments, strong electro-optic and/or acousto-optic coupling may be achieved, resulting in quantum transducer able to coherently convert between signals in different systems. |
| FILED | Friday, August 14, 2020 |
| APPL NO | 17/635088 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 20/00 (20130101) Chemical Composition of Glasses, Glazes or Vitreous Enamels; Surface Treatment of Glass; Surface Treatment of Fibres or Filaments Made From Glass, Minerals or Slags; Joining Glass to Glass or Other Materials C03C 3/095 (20130101) Optical Elements, Systems, or Apparatus G02B 6/1225 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291495 | PREZA et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CHRYSANTHE PREZA (MEMPHIS, Tennessee); ANA DOBLAS (MEMPHIS, Tennessee); GENARO SAAVEDRA-TORTOSA (VALENCIA, Spain); MANUEL MARTINEZ-CORRAL (VALENCIA, Spain); JUAN CARLOS BARREIRO (VALENCIA, Spain) |
| ASSIGNEE(S) | |
| INVENTOR(S) | CHRYSANTHE PREZA (MEMPHIS, Tennessee); ANA DOBLAS (MEMPHIS, Tennessee); GENARO SAAVEDRA-TORTOSA (VALENCIA, Spain); MANUEL MARTINEZ-CORRAL (VALENCIA, Spain); JUAN CARLOS BARREIRO (VALENCIA, Spain) |
| ABSTRACT | A multi-focal light-sheet structured illumination system that can be implemented as a part of a commercial fluorescence microscope or a module that is adaptable to fit a number of commercially available microscopes. The system provides simultaneous capture of 2D images from multiple planes within a 3D volume, which are resolved laterally and axially to provide improved resolution along the three dimensions (x,y,z). A Wollaston prism allows several axially-localized high-contrast structured illumination patterns to be generated. |
| FILED | Tuesday, March 29, 2022 |
| APPL NO | 17/707628 |
| CURRENT CPC | Optical Elements, Systems, or Apparatus G02B 21/0032 (20130101) G02B 21/0064 (20130101) G02B 21/0076 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292648 | Menon et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Utah Research Foundation (Salt Lake City, Utah) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Rajesh Menon (Salt Lake City, Utah); Ganghun Kim (Salt Lake City, Utah); Kyle Isaacson (Salt Lake City, Utah) |
| ABSTRACT | Technology is described for methods and systems for imaging an object (110). The method can include an image sensor (116) exposed to light (114) from an object (110) without passing the light through an image modification element. Light intensity of the light (114) can be stored as data in a medium. The image data can be analyzed at a processor (902) as a reconstructed image of the object (110). |
| FILED | Tuesday, May 31, 2022 |
| APPL NO | 17/828645 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 5/003 (20130101) Original (OR) Class G06T 5/50 (20130101) Pictorial Communication, e.g Television H04N 5/232 (20130101) H04N 5/2171 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292761 | Jung et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Oregon State University (Corvallis, Oregon) |
| ASSIGNEE(S) | Oregon State University (Corvallis, Oregon) |
| INVENTOR(S) | Jaehoon Jung (Corvallis, Oregon); Michael J. Olsen (Corvallis, Oregon); Erzhuo Che (Corvallis, Oregon) |
| ABSTRACT | An efficient and robust approach for powerline point extraction and refinement is described. In the candidate powerline point extraction step, a voxel-based subsampling structure temporarily substitutes the original scan points with regularly spaced subsampled points that still preserve key details present within the point cloud but significantly reduce the dataset size. After removing the ground surface and adjacent objects, candidate powerline points are efficiently extracted through a hierarchical, feature-based filtering process. In the refinement step, the link between the subsampled candidate powerline points and original scan point cloud enable the original points to be segmented and grouped into clusters. By fitting mathematical models, an individual powerline is re-clustered and used to reconstruct the broken sections in the powerlines. |
| FILED | Monday, March 07, 2022 |
| APPL NO | 17/653720 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 7/11 (20170101) G06T 7/187 (20170101) G06T 15/08 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292819 | Raychaudhuri et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| ASSIGNEE(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| INVENTOR(S) | Dipankar Raychaudhuri (Princeton Junction, New Jersey); Wuyang Zhang (Bellevue, Washington); Yanyong Zhang (Metuchen, New Jersey); Yunxin Liu (Haidian District, China PRC); Marco Gruteser (Princeton, New Jersey) |
| ABSTRACT | Computer vision systems and methods for acceleration of high-resolution mobile deep vision with content-aware parallel offloading are provided. The system allows for acceleration of deep vision applications running on mobile devices via offloading of machine learning computations on edge cloud infrastructure, and speeds up computation via parallel processing on the edge cloud, employing one or more of the following processes: recurrent region proposal prediction, region proposal centric frame partitioning, and resource-aware offloading to multiple processors. Mobile deep vision applications can utilize the systems and methods disclosed herein to accelerate application processing. The system offloads computation to multiple servers to minimize the end-to-end latency, and includes a high-resolution mobile deep vision task acceleration system that offloads computation to multiple (edge located) servers. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689089 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 3/4046 (20130101) G06T 7/11 (20170101) G06T 11/00 (20130101) G06T 2207/20021 (20130101) G06T 2207/20084 (20130101) Image or Video Recognition or Understanding G06V 10/22 (20220101) G06V 10/74 (20220101) G06V 10/82 (20220101) G06V 20/20 (20220101) Original (OR) Class G06V 2201/10 (20220101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293768 | Brueck et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNM RAINFOREST INNOVATIONS (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Steven R.J. Brueck (Albuquerque, New Mexico); Stephen D. Hersee (Albuquerque, New Mexico); Seung-Chang Lee (Albuquerque, New Mexico); Daniel Feezell (Albuquerque, New Mexico) |
| ABSTRACT | A method for making a heteroepitaxial layer. The method comprises providing a semiconductor substrate. A seed area delineated with a selective growth mask is formed on the semiconductor substrate. The seed area comprises a first material and has a linear surface dimension of less than 100 nm. A heteroepitaxial layer is grown on the seed area, the heteroepitaxial layer comprising a second material that is different from the first material. Devices made by the method are also disclosed. |
| FILED | Tuesday, May 31, 2022 |
| APPL NO | 17/828849 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 10/00 (20130101) B82Y 40/00 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 21/02107 (20130101) H01L 21/02381 (20130101) H01L 21/02532 (20130101) H01L 21/02538 (20130101) H01L 21/02639 (20130101) H01L 27/1211 (20130101) H01L 29/04 (20130101) H01L 29/16 (20130101) H01L 29/20 (20130101) H01L 29/0665 (20130101) H01L 29/0673 (20130101) H01L 29/0676 (20130101) H01L 29/775 (20130101) H01L 29/785 (20130101) H01L 29/7783 (20130101) H01L 29/7827 (20130101) H01L 29/7851 (20130101) H01L 29/66462 (20130101) Original (OR) Class H01L 29/66469 (20130101) H01L 29/66666 (20130101) H01L 29/66795 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293802 | HAN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNM RAINFOREST INNOVATIONS (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sang Eon HAN (Albuquerque, New Mexico); Sang M. HAN (Albuquerque, New Mexico); Seok Jun HAN (Albuquerque, New Mexico); Pauls STRADINS (Albuquerque, New Mexico) |
| ABSTRACT | A flexible, non-flat solar cell comprises a flexible substrate. A pn junction is on or in the flexible substrate. The solar cell has been flexed so as to have a non-flat geometry that results in an increased surface area of the flexed solar cell with respect to the surface area of a flat solar cell that is the same as the flexed solar cell except that the flat solar cell has a flat surface geometry that has the same projected area on a lateral plane as does the flexed solar cell. |
| FILED | Thursday, September 03, 2020 |
| APPL NO | 17/636271 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 31/0745 (20130101) H01L 31/02363 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293988 | Wang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Louis S. Wang (Chicago, Illinois); Sossina M. Haile (Evanston, Illinois); Sheel S. Sanghvi (Kendall Park, New Jersey) |
| ABSTRACT | Proton conducting materials and membranes and electrochemical devices incorporating the materials and membranes are provided. Also provided are methods of making the materials and membranes and methods of operating the electrochemical devices. The proton conducting materials are solid acids that form superprotonic phases at elevated temperatures. The superprotonic phases have a cubic structure and the general formula: M(1−x)Hy]H2PO4, where M represents one or more monovalent cations or a combination of monovalent cations and divalent cations, 0<x≤2/9, and y is a number that provides charge balancing. |
| FILED | Thursday, September 03, 2020 |
| APPL NO | 17/639706 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 8/1034 (20130101) Original (OR) Class H01M 8/1048 (20130101) H01M 8/1081 (20130101) H01M 2008/1095 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294390 | Lal et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Amit LAL (Ithaca, New York); Justin KUO (Ithaca, New York); GEEGAH LLC (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Amit Lal (Ithaca, New York); Justin Kuo (Ithaca, New York) |
| ABSTRACT | A temperature insensitive oscillator system. The system includes a substrate having a first surface and an opposing second surface, a CMOS device with one or more CMOS circuits attached to the first surface of the substrate, one or more piezoelectric transducers attached to an outer surface of the CMOS device, a voltage-controlled oscillator generating a RF frequency, which is transmitted as a plurality of short pulses to the one or more piezoelectric transducers, and one or more delays and oscillators using resistor and active components arranged alongside the piezoelectric transducers or on the CMOS device such that the voltage-controlled oscillator has minimal dependence on temperature, and has minimal deviation from a programmed frequency. |
| FILED | Friday, August 21, 2020 |
| APPL NO | 17/637321 |
| CURRENT CPC | Measuring Length, Thickness or Similar Linear Dimensions; Measuring Angles; Measuring Areas; Measuring Irregularities of Surfaces or Contours G01B 17/02 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 29/348 (20130101) G01N 29/2437 (20130101) G01N 29/4409 (20130101) G01N 2291/2697 (20130101) G01N 2291/02854 (20130101) Generation of Oscillations, Directly or by Frequency-changing, by Circuits Employing Active Elements Which Operate in a Non-switching Manner; Generation of Noise by Such Circuits H03B 5/04 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294394 | Roblin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Ohio State Innovation Foundation (Columbus, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Patrick Roblin (Columbus, Ohio); Ruwaybih Alsulami (Columbus, Ohio) |
| ABSTRACT | A multi-band Doherty power amplifier (DPA) is provided. A dual-band Doherty power amplifier (DB-DPA) is based on a 3-way architecture and comprises a main amplifier for each band and an auxiliary amplifier handling both bands. The 3-Way DB-DPA improves the average drain efficiency in concurrent dual-band operation compared to the traditional 2-Way DB-DPA, by avoiding early clipping in the main amplifiers, while benefiting from load-pulling from the auxiliary power amplifier. |
| FILED | Monday, January 10, 2022 |
| APPL NO | 17/572016 |
| CURRENT CPC | Amplifiers H03F 1/0288 (20130101) Original (OR) Class H03F 3/211 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294448 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) XNOR logic gate device includes a conducting device; and a ME-FET coupled to the conducting device. The ME-FET can be formed of a split gate; a first gate terminal coupled to a first portion of the split gate for receiving a first input signal; a second gate terminal coupled to a second portion of the split gate for receiving a second input signal; a source terminal coupled to a ground line; and a drain terminal coupled to the conducting device. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827742 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294449 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) majority gate device includes a conducting device and a plurality of ME transistors coupled to the conducting device. In one implementation, the plurality of ME transistors include a ME AND gate device with downward interface polarization, a ME-transmission gate device with downward interface polarization, and a ME-XNOR gate device. In another implementation, the plurality of ME transistors is five single-input ME-FETs. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827744 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294450 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) inverter includes two anti-ferromagnetic spin orbit read (AFSOR) circuit elements, each AFSOR circuit element has a CMOS inverter; and an AFSOR device with a ME base layer; a semiconductor channel layer on the ME base layer and comprising a source terminal and a drain terminal, where the source terminal is coupled to an output of the CMOS inverter; and a gate electrode on the semiconductor channel layer. The gate electrode of a second AFSOR device of the two AFSOR circuit elements is coupled to the drain terminal of a first AFSOR device of the two AFSOR circuit elements. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827747 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Defense (DOD)
| US 20220287969 | Sayour et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Inc. (Gainesville, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Elias Sayour (Newberry, Florida); Hector Ruben Mendez-Gomez (Gainesville, Florida); Duane Mitchell (Gainesville, Florida); Carlos Rinaldi (Gainesville, Florida) |
| ABSTRACT | The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided. |
| FILED | Friday, July 17, 2020 |
| APPL NO | 17/626674 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/1272 (20130101) Original (OR) Class A61K 39/39 (20130101) A61K 48/0033 (20130101) A61K 2039/53 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/88 (20130101) C12N 15/113 (20130101) C12N 2310/351 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288051 | Mitsiades et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Constantine S. MITSIADES (Brookline, Massachusetts); Ryosuke SHIRASAKI (, None); Geoffrey M. MATTHEWS (Malvern East, Australia); Sara GANDOLFI (Carnago, Italy); Ricardo DE MATOS SIMOE (Boston, Massachusetts); Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Constantine S. Mitsiades (Brookline, Massachusetts); Ryosuke Shirasaki (, None); Geoffrey M. Matthews (Malvern East, Australia); Sara Gandolfi (Carnago, Italy); Ricardo de Matos Simoes (Boston, Massachusetts) |
| ABSTRACT | The present invention relates, in part, to methods for treating cancer using serial administration of E3 ubiquitin ligase degraders. |
| FILED | Friday, September 11, 2020 |
| APPL NO | 17/641288 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/551 (20130101) A61K 31/4545 (20130101) Original (OR) Class A61K 45/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288108 | Landgrebe et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | 3M INNOVATIVE PROPERTIES COMPANY (St. Paul, Minnesota) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kevin D. Landgrebe (Woodbury, Minnesota); Ranjani V. Parthasarathy (Woodbury, Minnesota); Katie F. Wlaschin (St. Paul, Minnesota) |
| ABSTRACT | Aspects of the present disclosure relate to a method of preventing transmission of an enveloped RNA virus. The method includes applying to a mucosal tissue of a first mammalian subject not substantially colonized by the enveloped RNA virus an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan. The first mammalian subject not substantially colonized by the enveloped RNA virus interacts with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction, the second viral load is no greater than 0.5 log increase over an initial viral load over a duration of the treatment plan. The mucosal tissue is in the nasopharynx, nasal cavity, or anterior nares of the mammalian subject. The antiseptic composition comprises iodine, iodophor, or combinations thereof. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/633377 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0043 (20130101) A61K 31/79 (20130101) Original (OR) Class A61K 33/18 (20130101) A61K 2121/00 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/16 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288181 | Mirkin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NORTHWESTERN UNIVERSITY (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Chad A. Mirkin (Wilmette, Illinois); Michelle Hope Teplensky (Evanston, Illinois); Max Everett Distler (Evanston, Illinois); Caroline Danielle Kusmierz (San Antonio, Texas); Cassandra Elizabeth Callmann (Evanston, Illinois) |
| ABSTRACT | Spherical Nucleic Acids (SNAs) are chemically well-defined nanoscale architectures comprised of nucleic acids densely arranged around a spherical nanoparticle core in a highly oriented fashion. SNAs are highly modular structures produced by chemical synthesis and programmed assembly, allowing for their rapid modification to incorporate novel viral antigens. The present disclosure provides a SNA comprising (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a viral antigen encapsulated in the nanoparticle core. |
| FILED | Tuesday, March 01, 2022 |
| APPL NO | 17/684269 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/39 (20130101) A61K 39/001192 (20180801) Original (OR) Class A61K 2039/55555 (20130101) A61K 2039/55561 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1138 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288351 | FRANKLIN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Prytime Medical Devices, Inc. (Boerne, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Curtis J. FRANKLIN (Lakewood, Colorado); David SPENCER (Boerne, Texas); Todd J. KRUMMENACHER (Lakewood, Colorado) |
| ABSTRACT | An occlusion catheter system includes a proximal hub having an inflation connection port and an inflation pathway. An inflation catheter member is connected to the proximal hub and has an inflation lumen. A stiffener member defines a longitudinal axis. The proximal end of the stiffener member is connected to the proximal hub. The stiffener member extends through a portion of the inflation lumen. An occlusion balloon has a proximal balloon end and a distal balloon end. A distal catheter member is positioned substantially on the longitudinal axis and is connected to the distal end of the stiffener member. An atraumatic tip is positioned on a distal end of the distal catheter member. The atraumatic tip has a substantially circular profile in a relaxed configuration. A pressure sensor is connected to the occlusion catheter system distally relative to the occlusion balloon and is connected to a processor by electrical wiring. |
| FILED | Tuesday, December 28, 2021 |
| APPL NO | 17/563629 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 17/12036 (20130101) A61B 2017/00017 (20130101) Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 25/007 (20130101) A61M 25/008 (20130101) A61M 25/0068 (20130101) Original (OR) Class A61M 25/0074 (20130101) A61M 25/104 (20130101) A61M 25/1002 (20130101) A61M 25/1006 (20130101) A61M 25/10182 (20131105) A61M 2025/0002 (20130101) A61M 2025/1052 (20130101) A61M 2025/1086 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289368 | HALDEMAN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Bell Textron Inc. (Fort Worth, Texas) |
| ASSIGNEE(S) | Bell Textron Inc. (Fort Worth, Texas) |
| INVENTOR(S) | Andrew Paul HALDEMAN (Fort Worth, Texas); Michael SEIFERT (Southlake, Texas); Timothy McClellan MOSIG (Richland Hills, Texas); Aaron ACEE (Flower Mound, Texas); Diana R. TINLIN (Fort Worth, Texas); Andrew Thomas CARTER (Richland Hills, Texas); Glenn Thornton LANCASTER (Fort Worth, Texas) |
| ABSTRACT | A blade pitch adjustment mechanism includes a pitch cylinder having a first face and pitch slots extending longitudinally from the first face, a blade sleeve having a second face and a blade slot extending longitudinally from the second face, the blade sleeve is configured to be rotationally positioned in the pitch cylinder with the second face located with the first face, wherein the blade slot and the pitch slots are cooperative to form keyway, corresponding to a discrete blade pitch, when the blade slot is aligned with a pitch slot. |
| FILED | Wednesday, March 10, 2021 |
| APPL NO | 17/198007 |
| CURRENT CPC | Aeroplanes; Helicopters B64C 27/59 (20130101) Original (OR) Class Non-positive Displacement Machines or Engines, e.g Steam Turbines F01D 5/02 (20130101) F01D 5/30 (20130101) F01D 7/00 (20130101) Indexing Scheme for Aspects Relating to Non-positive-displacement Machines or Engines, Gas-turbines or Jet-propulsion Plants F05D 2220/90 (20130101) F05D 2260/70 (20130101) F05D 2260/83 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289775 | LI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Lingyin LI (Menlo Park, California); Mark Smith (San Francisco, California); Jacqueline Ann CAROZZA (Palo Alto, California); Volker BOEHNERT (Palo Alto, California) |
| ABSTRACT | Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response. |
| FILED | Thursday, January 30, 2020 |
| APPL NO | 17/423389 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/44 (20130101) A61K 31/69 (20130101) A61K 31/517 (20130101) A61K 31/675 (20130101) A61K 31/4706 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 215/46 (20130101) C07D 401/04 (20130101) Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium C07F 5/02 (20130101) C07F 9/60 (20130101) C07F 9/65128 (20130101) Original (OR) Class C07F 9/65583 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289796 | Kuhlman et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The University of North Carolina at Chapel Hill (Chapel Hill, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Brian Kuhlman (Chapel Hill, North Carolina); Stephan T. Kudlacek (Katy, Texas); Aravinda De Silva (Chapel Hill, North Carolina); Alexander Payne (New York, New York); Thanh Phan (Carrboro, North Carolina); Stefan Metz (Durham, North Carolina) |
| ABSTRACT | The present invention provides compositions and methods of use comprising a stabilized recombinant E glycoprotein comprising a flavivirus E glycoprotein backbone, which comprises amino acid substitutions that stabilize the E glycoprotein in dimer conformation under physiological conditions. |
| FILED | Thursday, August 06, 2020 |
| APPL NO | 17/632542 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/12 (20130101) A61K 2039/5258 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/14 (20180101) Peptides C07K 14/005 (20130101) Original (OR) Class Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 2770/24122 (20130101) C12N 2770/24123 (20130101) C12N 2770/24134 (20130101) C12N 2770/24171 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289840 | Connolly et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Denise C. Connolly (Philadelphia, Pennsylvania); Alana M. O'Reilly (Philadelphia, Pennsylvania); Tiffiney R. Hartman (Philadelphia, Pennsylvania); Valerie L. Sodi (Philadelphia, Pennsylvania) |
| ABSTRACT | The present disclosure provides antibodies specifically binding N-terminal or C-terminal regions of Cell Adhesion Molecule-Related/Down-Regulated By Oncogenes (CDON) polypeptide, methods of making the same, and methods of treating humans having tumors by administering the antibody. |
| FILED | Wednesday, February 12, 2020 |
| APPL NO | 17/430227 |
| CURRENT CPC | Peptides C07K 16/2803 (20130101) Original (OR) Class C07K 2317/34 (20130101) C07K 2317/73 (20130101) C07K 2317/76 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/57449 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289902 | Martin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | David C. Martin (Lincoln University, Pennsylvania); Samadhan Suresh Nagane (Maharashtra, India); Peter Sitarik (Fleetwood, Pennsylvania) |
| ASSIGNEE(S) | University of Delaware (Newark, Delaware) |
| INVENTOR(S) | David C. Martin (Lincoln University, Pennsylvania); Samadhan Suresh Nagane (Maharashtra, India); Peter Sitarik (Fleetwood, Pennsylvania) |
| ABSTRACT | Disclosed herein are functionalized 3,4-alkylenedioxythiophene (ADOT+) monomers represented by a chemical formula (CR1R2)(CR3R4)(CR4R6)xO2H2S, wherein x=0 or 1; wherein each of R1, R2, R3, R4, R5, and R6 is independently selected from hydrogen, a hydrocarbyl moiety, and a heteroatom-containing functional group; and wherein at least one of R1, R2, R3, R4, R5, and R6 comprises the heteroatom-containing functional group selected from an aldehyde, a maleimide, and their derivatives thereof. Also, disclosed herein are aldehyde derivatives represented by (ADOT-CH2—NH)pY and a maleimide derivative represented by (ADOT-(CH2)q—N)pZ where p=1-2 and each of Y and Z is a hydrocarbyl moiety or a biofunctional hydrocarbyl moiety. In an embodiment of the ADOT+ monomers, one of R1, R2, R3, R4, R5, and R6 is replaced by a direct bond to an amide group, an azide group, or an ester group of a biofunctional hydrocarbyl moiety. Also, disclosed herein are polymers and copolymers made therefrom. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/637108 |
| CURRENT CPC | Heterocyclic Compounds C07D 495/04 (20130101) C07D 519/00 (20130101) Steroids C07J 33/002 (20130101) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 61/126 (20130101) Original (OR) Class C08G 2261/44 (20130101) C08G 2261/94 (20130101) C08G 2261/122 (20130101) C08G 2261/148 (20130101) C08G 2261/334 (20130101) C08G 2261/1424 (20130101) C08G 2261/1426 (20130101) C08G 2261/1428 (20130101) C08G 2261/1432 (20130101) Cables; Conductors; Insulators; Selection of Materials for Their Conductive, Insulating or Dielectric Properties H01B 1/124 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289995 | Holmes |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America, as represented by the Secretary of the Navy (Crane, Indiana) |
| ASSIGNEE(S) | The United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| INVENTOR(S) | Harrison E. Holmes (Bloomington, Indiana) |
| ABSTRACT | Disclosed is a conductive ink composition and a manufacturing method thereof. The composition includes about 50 to about 99 wt % copper nanoparticles and about 1 to about 50 wt % tin. Copper nanoparticles are atomized and suspended in a tin bath, wherein the copper nanoparticles are evenly dispersed within the bath through sonification. The composition is cooled, extracted, and formed into a filament for use as a conductive ink. The ink has a resistivity of about 46.2×E-9 Ω*m to about 742.5×E-9 Ω*m. Once in filament form, the tin-copper mix will be viable for material extrusion, thus allowing for a lower cost, electrically conductive traces to be used in additive manufacturing. |
| FILED | Tuesday, March 09, 2021 |
| APPL NO | 17/196173 |
| CURRENT CPC | Working Metallic Powder; Manufacture of Articles From Metallic Powder; Making Metallic Powder B22F 1/0018 (20130101) B22F 1/0088 (20130101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 40/00 (20130101) Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor C09D 11/52 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290115 | Liu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | President and Fellows of Harvard College (Cambridge, Massachusetts) |
| ASSIGNEE(S) | President and Fellows of Harvard College (Cambridge, Massachusetts) |
| INVENTOR(S) | David R. Liu (Cambridge, Massachusetts); Kevin Tianmeng Zhao (Cambridge, Massachusetts); Yongjoo Kim (Cambridge, Massachusetts) |
| ABSTRACT | Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins comprise a Gam protein, a napDNAbp, and a cytidine deaminase. In some embodiments, the fusion proteins further comprise a UGI domain. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a Gam protein, a cytidine deaminase and nucleic acid editing proteins or domains, are provided. |
| FILED | Monday, March 21, 2022 |
| APPL NO | 17/700109 |
| CURRENT CPC | Peptides C07K 2319/09 (20130101) C07K 2319/80 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 9/78 (20130101) Original (OR) Class C12N 15/62 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290121 | Joung et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The General Hospital Corporation (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | J. Keith Joung (Winchester, Massachusetts); Ronghao Zhou (Charlestown, Massachusetts); Julian Grunewald (Charlestown, Massachusetts) |
| ABSTRACT | Engineered bifunctional adenine and cytosine base editor (BACE) variants that enable expanded amino acid modifications and methods of using the same. Described herein are fusion proteins containing adenosine deaminases, cytidine deaminases, catalytically impaired CRISPR-Cas proteins (e.g., Cas9, CasX or Cas12 nucleases), linkers, nuclear localization signals (NLSs) and uracil-n-glycosylase inhibitors (UGIs) that enable the CRISPR-guided programmable introduction of simultaneous A-to-G (T-to-C) and C-to-T (G-to-A) substitutions in DNA. |
| FILED | Monday, August 31, 2020 |
| APPL NO | 17/638133 |
| CURRENT CPC | Peptides C07K 2319/09 (20130101) C07K 2319/80 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 9/78 (20130101) C12N 15/102 (20130101) Original (OR) Class C12N 2310/20 (20170501) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 19/34 (20130101) C12P 21/02 (20130101) Enzymes C12Y 305/04004 (20130101) C12Y 305/04005 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290123 | FUNKNER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CureVac AG (Tübingen, Germany) |
| ASSIGNEE(S) | CureVac AG (Tübingen, Germany) |
| INVENTOR(S) | Andreas FUNKNER (Tübingen, Germany); Stefanie SEWING (Tübingen, Germany); Isabel STROBEL (Tübingen, Germany); Thorsten MUTZKE (Tübingen, Germany) |
| ABSTRACT | The present invention relates to methods for purifying RNA by chromatography under high salt conditions, e.g. by hydrophobic interaction chromatography. |
| FILED | Wednesday, February 09, 2022 |
| APPL NO | 17/668322 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/101 (20130101) C12N 15/1006 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290132 | Salis et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Howard Salis (State College, Pennsylvania); Alexander Reis (Austin, Texas); Sean Halper (Beltsville, Maryland); Phillip Clauer (State College, Pennsylvania); Grace E. Vezeau (Bellefonte, Pennsylvania); Daniel P. Cetnar (Bellefonte, Pennsylvania); Ayaan Hossain (State College, Pennsylvania) |
| ABSTRACT | The invention provides CRISPR-based compositions and methods comprising non-repetitive sgRNA promoter and handle sequences for simultaneous, stable expression of multiple sgRNAs. |
| FILED | Thursday, August 06, 2020 |
| APPL NO | 17/633321 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 15/11 (20130101) Original (OR) Class C12N 15/907 (20130101) C12N 2310/20 (20170501) C12N 2800/80 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290162 | Abedi et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | California Institute of Technology (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Mohamad H. Abedi (Pasadena, California); Mikhail G. Shapiro (Pasadena, California); Michael S. Yao (Pasadena, California) |
| ABSTRACT | Disclosed herein include methods, compositions, and kits suitable for use in spatiotemporal regulation of probiotic cells. There are provided, in some embodiments, thermal bioswitches that allow probiotic cells to sense small changes in temperature and use them as inputs for the actuation of genetic circuits. Genetic circuits capable of inducing expression of a payload upon thermal stimulation are provided. Thermally actuated probiotic cells and methods of use for the treatment of diseases or disorders are also provided. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692778 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 15/635 (20130101) Original (OR) Class C12N 15/907 (20130101) C12N 2800/30 (20130101) C12N 2830/008 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290257 | LUO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania) |
| INVENTOR(S) | Jianhua LUO (Wexford, Pennsylvania); Zhanghui CHEN (Huzhou City, China PRC); Yanping YU (Wexford, Pennsylvania); George MICHALOPOULOS (Pittsburgh, Pennsylvania); Joel B. NELSON (Pittsburgh, Pennsylvania) |
| ABSTRACT | The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer. |
| FILED | Monday, May 23, 2022 |
| APPL NO | 17/751152 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/4545 (20130101) A61K 31/5377 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 7/00 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1137 (20130101) C12N 2310/14 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6886 (20130101) Original (OR) Class C12Q 2600/106 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290282 | Holder et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Boeing Company (Chicago, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Scott M. Holder (Cherry Hill, New Jersey); Dale J. Weires (Hockessin, Delaware) |
| ABSTRACT | Methods of hardening a case-nitrided metal article, methods of producing a hardened case-nitrided metal article, and hardened case-nitrided metal articles. The methods of hardening a case-nitrided metal article include heating the case-nitrided metal article to an aging temperature, maintaining the case-nitrided metal article at the aging temperature for an aging time, and cooling the case-nitrided metal article from the aging temperature. The methods of producing a hardened case-nitrided metal article include case-nitriding a metal article to produce a case-nitrided metal article and subsequently hardening the case-nitrided metal article. The hardened case-nitrided metal article comprises a body formed of a metal or a metal alloy, a surface surrounding the body, and a nitrided case layer formed in the body and extending inwardly from the surface of the body toward the core that includes a hardness that is greater than that of an otherwise equivalent case-nitrided metal article. |
| FILED | Wednesday, November 17, 2021 |
| APPL NO | 17/528996 |
| CURRENT CPC | Changing the Physical Structure of Non-ferrous Metals and Non-ferrous Alloys C22F 1/183 (20130101) Original (OR) Class Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General C23C 8/24 (20130101) C23C 8/80 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290660 | Myers et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jason D. Myers (Alexandria, Virginia); Jesse A. Frantz (Washington, District of Columbia); Jasbinder S. Sanghera (Ashburn, Virginia); Daniel Rhonehouse (Huntingtown, Maryland); Christopher Bardeen (Riverside, California); Colin Baker (Alexandria, Virginia); Geoffrey Chin (Oakton, Virginia); Peter Alexander Morrison (Alexandria, Virginia) |
| ABSTRACT | Systems and methods are provided for a mechanical actuator based on a fiber optic platform. A material that is configured to be activated by light may be incorporated into an optical fiber that serves as both an actuator and a power delivery network. This platform is adaptable to different materials, types of motions, and length scales and allows for precise delivery of photons to the material. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689843 |
| CURRENT CPC | Spring, Weight, Inertia or Like Motors; Mechanical-power Producing Devices or Mechanisms, Not Otherwise Provided for or Using Energy Sources Not Otherwise Provided for F03G 7/0614 (20210801) Original (OR) Class Optical Elements, Systems, or Apparatus G02B 6/02342 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290948 | Furlong et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America, as represented by the Secretary of the Navy (Crane, Indiana) |
| ASSIGNEE(S) | The United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| INVENTOR(S) | Steven Craig Furlong (Bloomington, Indiana); Timothy Michael Lang (Bloomington, Indiana) |
| ABSTRACT | In general, the present invention is directed to airborne security measures and more specifically to a device and method to defeat in total a plurality of approaching Unmanned Aerial Vehicles (UAVs) with a single sacrificial intercepting drone. In a preferred embodiment of the invention the intercepting drone may be configured with an attached Electro-Magnetic Pulse (EMP) generation device capable of producing a sufficiently intense EMP burst to completely disable all approaching UAVs. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/752114 |
| CURRENT CPC | Aeroplanes; Helicopters B64C 39/024 (20130101) B64C 2201/121 (20130101) B64C 2201/146 (20130101) Armour; Armoured Turrets; Armoured or Armed Vehicles; Means of Attack or Defence, e.g Camouflage, in General F41H 11/02 (20130101) F41H 13/0093 (20130101) Original (OR) Class Systems for Controlling or Regulating Non-electric Variables G05D 1/0016 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291139 | Nicholas et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Andrew Nicholas (Glenelg, Maryland); Theodore Finne (Vienna, Virginia); Charles Brown (Beltsville, Maryland); Christoph Englert (Springfield, Virginia) |
| ABSTRACT | Methods and systems are provided for foreign object debris monitoring in an environment with a dynamic debris field, such as an environment for operating an aircraft. The debris monitoring technique includes generating a light beam and dispersing it to create a virtual witness plate, which is a two-dimensional sheet of light that covers a detection area. The technique also include detecting scattered light from the virtual witness plate caused by debris passing through it. A debris event may be generated based on the scattered light, indicating the presence of debris in the detection area. |
| FILED | Saturday, March 12, 2022 |
| APPL NO | 17/654581 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/47 (20130101) G01N 21/94 (20130101) Original (OR) Class G01N 21/8851 (20130101) Geophysics; Gravitational Measurements; Detecting Masses or Objects; Tags G01V 8/20 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291183 | Dipple et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | US Gov't as represented by Sec'y of Air Force (Wright-Patterson AFB, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kathleen Dipple (Destin, Florida); Jimmy E. Touma (Shalimar, Florida) |
| ABSTRACT | An odor-localizing autonomous air vehicle includes an airborne robotic platform having a navigation platform, a wireless transmitter communicatively coupled to a management console, and an olfactory sensor mounted on the airborne robotic platform that reacts to at least one olfactory odor. A controller is communicatively coupled to the airborne robotic platform, the navigation platform, and the biological sensor. The controller monitors the olfactory sensor. In response to the biological sensor detecting the at least one olfactory odor, the controller directs the airborne platform to three-dimensionally map an olfactory plume of the at least one olfactory odor using an olfactory-driven search pattern. The controller stores the three-dimensional map for later retrieval or transmits the three-dimensional map of the olfactory plume to the management console via the wireless transmitter. The olfactory sensor is a photonic crystal enclosure that contains plasmonic nanoparticles. |
| FILED | Monday, March 07, 2022 |
| APPL NO | 17/687777 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 20/00 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/0001 (20130101) Original (OR) Class G01N 33/0062 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291552 | Basu |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| ASSIGNEE(S) | The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| INVENTOR(S) | Rajratan Basu (Columbia, Maryland) |
| ABSTRACT | An electro-optical liquid crystal cell comprising a first substrate, a first layer of chromium (Cr), a first layer of vertically aligned carbon nanotubes (VA-CNT) capped with nickel nanoparticles, and a layer of liquid crystal. Furthermore, the electro-optical liquid crystal cell can comprise a second layer of VA-CNT capped with nickel nanoparticles, a second layer of Cr, and a second substrate. This electro-optic VA-CNT-based liquid crystal cell exhibits the required electro-optic effect needed for a liquid crystal display. |
| FILED | Monday, November 15, 2021 |
| APPL NO | 17/526395 |
| CURRENT CPC | Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 1/0018 (20130101) G02F 1/061 (20130101) G02F 1/133715 (20210101) G02F 1/133719 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292199 | Mosko |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Palo Alto Research Center Incorporated (Palo Alto, California) |
| ASSIGNEE(S) | Palo Alto Research Center Incorporated (Palo Alto, California) |
| INVENTOR(S) | Marc E. Mosko (Santa Cruz, California) |
| ABSTRACT | Embodiments provide a system and method for modeling a shared resource in a multi-layer reasoning graph based on configuration security. During operation, the system can obtain a multi-layer graph for a system with a plurality of components that can include a set of subgroups of components. The system can generate, based on the multi-layer graph, an abstract component to represent a shared resource model for a respective subgroup of components. The shared resource model can be associated with a set of resource constraints. The system can generate a set of values for resource configuration parameters that satisfy the resource constraints. The system can map the shared resource model to a respective component and can then determine, based on the mapping and the set of values for the resource configuration parameters, a set of values for the component configuration parameters thereby facilitating optimization of a security objective function. |
| FILED | Friday, March 12, 2021 |
| APPL NO | 17/199988 |
| CURRENT CPC | Electric Digital Data Processing G06F 21/577 (20130101) Original (OR) Class G06F 2221/034 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292729 | Mullen et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America, as represented by the Secretary of the Navy (Crane, Indiana) |
| ASSIGNEE(S) | The United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| INVENTOR(S) | Robert E. Mullen (Bloomington, Indiana); James A. Hammack (Huntsville, Alabama) |
| ABSTRACT | Provided are methods and apparatus for creating super-compressed map files. Using free and open-source software (FOSS), the tool create a super-compressed internally tiled Geo Tag Image File Format (TIFF) in a WGS84 datum (WGS84) similar in size to the original LizardTech's MrSID (SID) imagery from the National Geospatial-Intelligence Agency (NGA). Converting NGA data to WGS84 allows mapping systems like NASA Worldwind (WW) to eliminate the step of re-projecting on the fly from non-native projections, thus reducing processing time. The disclosed method includes removing all pure-black pixels by setting them to black+1, changing all near-black border pixels with values less than 15 to 0 (pure black), setting pure black values to “no-data,” compressing the image with a compression scheme, and translating the compressed image to JPEG and a YCbCr color space to achieve greater compression. |
| FILED | Thursday, March 10, 2022 |
| APPL NO | 17/691712 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 7/90 (20170101) G06T 9/20 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293768 | Brueck et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNM RAINFOREST INNOVATIONS (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Steven R.J. Brueck (Albuquerque, New Mexico); Stephen D. Hersee (Albuquerque, New Mexico); Seung-Chang Lee (Albuquerque, New Mexico); Daniel Feezell (Albuquerque, New Mexico) |
| ABSTRACT | A method for making a heteroepitaxial layer. The method comprises providing a semiconductor substrate. A seed area delineated with a selective growth mask is formed on the semiconductor substrate. The seed area comprises a first material and has a linear surface dimension of less than 100 nm. A heteroepitaxial layer is grown on the seed area, the heteroepitaxial layer comprising a second material that is different from the first material. Devices made by the method are also disclosed. |
| FILED | Tuesday, May 31, 2022 |
| APPL NO | 17/828849 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 10/00 (20130101) B82Y 40/00 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 21/02107 (20130101) H01L 21/02381 (20130101) H01L 21/02532 (20130101) H01L 21/02538 (20130101) H01L 21/02639 (20130101) H01L 27/1211 (20130101) H01L 29/04 (20130101) H01L 29/16 (20130101) H01L 29/20 (20130101) H01L 29/0665 (20130101) H01L 29/0673 (20130101) H01L 29/0676 (20130101) H01L 29/775 (20130101) H01L 29/785 (20130101) H01L 29/7783 (20130101) H01L 29/7827 (20130101) H01L 29/7851 (20130101) H01L 29/66462 (20130101) Original (OR) Class H01L 29/66469 (20130101) H01L 29/66666 (20130101) H01L 29/66795 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293927 | Allen |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | U.S. Army Combat Capabilities Development Command, Army Research Laboratory (Adelphi, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jan L. Allen (Silver Spring, Maryland) |
| ABSTRACT | A composition of matter and method includes Li1+x+zM(II)0.5−2x−zM(III)x+yM(IV)1.5−2y−zM(V)yM(V)zO4. M(II) includes any of Mg, Co, Ni, Cu, and Zn. M(III) includes any of Al, Cr, Fe, Ga, and In. M(IV) includes any of Ti, Mn, and Ge. M(V) includes any of Nb, Ta, Sb, and Bi. Additionally, 0≤x≤0.25, 0≤y≤0.75, 0≤z≤0.5, and (x+z)>0. |
| FILED | Wednesday, March 03, 2021 |
| APPL NO | 17/190911 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/0471 (20130101) H01M 4/505 (20130101) Original (OR) Class H01M 4/525 (20130101) H01M 10/0562 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294246 | Temkin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Johns Hopkins University (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Deanna K. Temkin (Silver Spring, Maryland); Tyler J. Boehmer (Columbia, Maryland) |
| ABSTRACT | An active filter system for filtering power on a power system may include a converter, an energy storage device, and control circuitry. The converter may be configured to be electrically coupled to a power source at a converter input and an active filter system bus at a converter output. The converter may be configured to deliver power to the active filter system bus that serves a dynamic load. The energy storage device may be electrically coupled to the active filter system bus and configured to filter the power via charge and discharge of an energy storage device. The control circuitry may be configured to control the converter to condition power drawn from the power source to create a filtered load based on programmable active filter controls. The programmable active filter controls may be based on a measurement of a load current being supplied to the dynamic load and a state of charge of the energy storage device. |
| FILED | Tuesday, August 31, 2021 |
| APPL NO | 17/462951 |
| CURRENT CPC | Circuit Arrangements or Systems for Supplying or Distributing Electric Power; Systems for Storing Electric Energy H02J 4/00 (20130101) H02J 7/0063 (20130101) Original (OR) Class H02J 7/007182 (20200101) H02J 2207/10 (20200101) H02J 2207/20 (20200101) H02J 2207/40 (20200101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294448 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) XNOR logic gate device includes a conducting device; and a ME-FET coupled to the conducting device. The ME-FET can be formed of a split gate; a first gate terminal coupled to a first portion of the split gate for receiving a first input signal; a second gate terminal coupled to a second portion of the split gate for receiving a second input signal; a source terminal coupled to a ground line; and a drain terminal coupled to the conducting device. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827742 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294449 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) majority gate device includes a conducting device and a plurality of ME transistors coupled to the conducting device. In one implementation, the plurality of ME transistors include a ME AND gate device with downward interface polarization, a ME-transmission gate device with downward interface polarization, and a ME-XNOR gate device. In another implementation, the plurality of ME transistors is five single-input ME-FETs. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827744 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294450 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) inverter includes two anti-ferromagnetic spin orbit read (AFSOR) circuit elements, each AFSOR circuit element has a CMOS inverter; and an AFSOR device with a ME base layer; a semiconductor channel layer on the ME base layer and comprising a source terminal and a drain terminal, where the source terminal is coupled to an output of the CMOS inverter; and a gate electrode on the semiconductor channel layer. The gate electrode of a second AFSOR device of the two AFSOR circuit elements is coupled to the drain terminal of a first AFSOR device of the two AFSOR circuit elements. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827747 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294942 | Rixman |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | FLIR Commercial Systems, Inc. (Goleta, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Todd E. Rixman (Goleta, California) |
| ABSTRACT | Light weight lens barrel systems and methods are provided. In one example, an imaging device includes a lens barrel including a body and a plurality of focusing fins extending from the body. The imaging device further includes a lens system disposed within the lens barrel and configured to receive electromagnetic radiation and direct the electromagnetic radiation. The imaging device further includes a detector array including a plurality of detectors. Each of the plurality of detectors is configured to receive the electromagnetic radiation from the lens system and generate an image based on the electromagnetic radiation. Related methods and systems are also provided. |
| FILED | Monday, December 27, 2021 |
| APPL NO | 17/562860 |
| CURRENT CPC | Optical Elements, Systems, or Apparatus G02B 7/04 (20130101) G02B 7/021 (20130101) G02B 13/14 (20130101) Pictorial Communication, e.g Television H04N 5/2252 (20130101) H04N 5/2254 (20130101) Original (OR) Class H04N 5/23229 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Energy (DOE)
| US 20220288195 | BRUENING et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Vir Biotechnology, Inc. (San Francisco, California); Triad National Security, LLC (Los Alamos, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Eric BRUENING (San Francisco, California); Janet DOUGLAS (San Francisco, California); Emily MARSHALL (San Francisco, California); Karina YUSIM (Santa Fe, New Mexico); Bette KORBER (Santa Fe, New Mexico); James THEILER (Santa Fe, New Mexico) |
| ABSTRACT | The present disclosure relates to isolated polynucleotides and polypeptides, and related hepatitis B virus (HBV)vaccines. The present disclosure also relates to viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines described herein. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area are also provided herein. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/638344 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/292 (20130101) Original (OR) Class A61K 2039/5256 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/20 (20180101) Peptides C07K 14/005 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/86 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288570 | Kuhn et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of South Florida (Tampa, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | John Kuhn (Wesley Chapel, Florida); Babu Joseph (Tampa, Florida); Yang He (Tampa, Florida) |
| ABSTRACT | The present disclosure provides a composition. In an embodiment, a catalyst composition is provided and includes from 85 mol % to 95 mol % iron metal, and from 15 mol % to 5 mol % indium metal, wherein mol % is based on total moles of iron metal and indium metal. Also provided is a process of contacting, under reaction conditions, a gaseous mixture of carbon monoxide, hydrogen and optionally water with the catalyst composition. The process includes forming a reaction product composed of light olefins. |
| FILED | Wednesday, March 09, 2022 |
| APPL NO | 17/691082 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 21/04 (20130101) B01J 23/825 (20130101) Original (OR) Class B01J 37/18 (20130101) Acyclic or Carbocyclic Compounds C07C 1/041 (20130101) C07C 1/044 (20130101) C07C 1/048 (20130101) C07C 1/0445 (20130101) C07C 2521/04 (20130101) C07C 2523/825 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288606 | Siler et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David Michael Siler (Albuquerque, New Mexico); Michael Edward Ferdinand (Placitas, New Mexico) |
| ABSTRACT | A method for isolating vibrations for centrifuge testing devices is provided. The method comprises coupling a test payload platform to a number of piezoelectric actuators and coupling the piezoelectric actuators to a reaction mass coupled to a centrifuge arm. A layer of vibration-absorbing material is sandwiched between the reaction mass and the centrifuge arm. The centrifuge arm is rotated around an axis, and the test payload platform is vibrated with the piezoelectric actuators as the centrifuge rotates, wherein the layer of vibration-absorbing material prevents vibrations from traveling down the centrifuge arm. |
| FILED | Monday, March 15, 2021 |
| APPL NO | 17/202158 |
| CURRENT CPC | Centrifuges B04B 5/10 (20130101) Original (OR) Class Methods or Apparatus for Generating or Transmitting Mechanical Vibrations of Infrasonic, Sonic, or Ultrasonic Frequency, for Performing Mechanical Work in General B06B 1/0629 (20130101) Springs; Shock-absorbers; Means for Damping Vibration F16F 15/08 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288822 | Rodriguez et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (Livermore, California); The Texas A and M University System (College Station, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jennifer N. Rodriguez (Lathrop, California); Duncan J. Maitland (College Station, Texas); Thomas S. Wilson (San Leandro, California) |
| ABSTRACT | Polymeric based closed cell foams, such as shape memory polymer foams, contain bubbles. Making these bubbles continuous is called reticulation. Disclosed are embodiments of a device and method to controllably reticulate polymer-based closed cell foams by puncturing the membranes of these polymer-based closed cell foams. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/752275 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 31/06 (20130101) A61L 31/146 (20130101) Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing B29C 44/5663 (20130101) Original (OR) Class Indexing Scheme Associated With Subclasses B29B, B29C or B29D, Relating to Moulding Materials or to Materials for Reinforcements, Fillers or Preformed Parts, e.g Inserts B29K 2075/00 (20130101) Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form B32B 5/18 (20130101) B32B 5/32 (20130101) B32B 2266/08 (20130101) B32B 2266/0278 (20130101) B32B 2535/00 (20130101) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 18/73 (20130101) C08G 18/3228 (20130101) C08G 18/3278 (20130101) C08G 18/3284 (20130101) Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H C08J 9/38 (20130101) C08J 2205/052 (20130101) C08J 2207/10 (20130101) C08J 2375/04 (20130101) Compositions of Macromolecular Compounds C08L 75/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289347 | Latham |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Tridentis Advanced Marine Vehicles, LLC (Kailua Kona, Hawaii) |
| ASSIGNEE(S) | |
| INVENTOR(S) | William Latham (Stafford, Virginia) |
| ABSTRACT | Devices and methods for recovering an unmanned underwater vehicle. The device includes a gantry mounted on a recovery vehicle, a frame, and a shaft extending between the gantry and the frame and configured to vertically move the frame relative to the gantry. Attached to the frame are a plurality of rotatable arms movable between an opened position and a closed position. A first end of each arm is attached to the frame at a pivot. A flexible strap extends between each of the second ends of the arm and the frame. As the arms are moved to the closed position around the unmanned underwater vehicle, the straps will support the unmanned underwater vehicle. |
| FILED | Monday, March 15, 2021 |
| APPL NO | 17/201491 |
| CURRENT CPC | Ships or Other Waterborne Vessels; Equipment for Shipping B63B 27/12 (20130101) Launching, Hauling-out, or Dry-docking of Vessels; Life-saving in Water; Equipment for Dwelling or Working Under Water; Means for Salvaging or Searching for Underwater Objects B63C 7/16 (20130101) Original (OR) Class B63C 7/24 (20130101) Offensive or Defensive Arrangements on Vessels; Mine-laying; Mine-sweeping; Submarines; Aircraft Carriers B63G 8/001 (20130101) B63G 2008/002 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289642 | Forrest et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Eric Christopher Forrest (Albuquerque, New Mexico); Robert Knepper (Albuquerque, New Mexico); Alexander S. Tappan (Albuquerque, New Mexico); Michael P. Marquez (Albuquerque, New Mexico) |
| ABSTRACT | An explosive device is described herein, wherein the explosive device includes a substrate that has a surface, wherein surface energy of a portion of the surface of the substrate has been modified in a vacuum chamber from a first surface energy to a second surface energy. The explosive device additionally includes explosive material that has been deposited on the surface of the substrate in the vacuum chamber by way of physical vapor deposition (PVD), wherein the explosive material is deposited on the portion of the surface of the substrate subsequent to the surface energy of the portion of the surface of the substrate being modified from the first surface energy to the second surface energy. |
| FILED | Thursday, May 05, 2022 |
| APPL NO | 17/737173 |
| CURRENT CPC | Explosives or Thermic Compositions; Manufacture Thereof; Use of Single Substances as Explosives C06B 45/00 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289695 | HOYT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Alliance for Sustainable Energy, LLC (Golden, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Caroline Bradshaw HOYT (Denver, Colorado); Gregg Tyler BECKHAM (Golden, Colorado) |
| ABSTRACT | The present disclosure relates to a composition having a structure that includes where R1 includes at least one of hydrogen, carbon, and/or fluorine, and |
| FILED | Wednesday, March 09, 2022 |
| APPL NO | 17/690131 |
| CURRENT CPC | Heterocyclic Compounds C07D 263/57 (20130101) C07D 263/58 (20130101) Original (OR) Class C07D 413/10 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290193 | JOHNSON et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Alliance for Sustainable Energy, LLC (Golden, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Christopher W. JOHNSON (Denver, Colorado); Gregg Tyler BECKHAM (Golden, Colorado); Allison Jean ZIMONT WERNER (Denver, Colorado) |
| ABSTRACT | Disclosed herein are engineered Pseudomonas useful to relieve the metabolic bottleneck of 4-hydroxybenzoate transformation in a muconate accumulating strain on an engineered Pseudomonas by swapping its endogenous para-hydroxybenzoate-3-hydroxylase (PHBH), PobA, with a homolog, PraI, that has a broader cofactor preference. |
| FILED | Wednesday, March 09, 2022 |
| APPL NO | 17/691075 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/0036 (20130101) C12N 15/52 (20130101) C12N 15/63 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 7/42 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290301 | Zhao et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Ohio State Innovation Foundation (Columbus, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Hongping Zhao (Columbus, Ohio); Zhaoying Chen (Columbus, Ohio); Yuxuan Zhang (Columbus, Ohio) |
| ABSTRACT | Disclosed herein are laser-assisted metal-organic chemical vapor deposition devices and methods of use thereof for suppressing background carbon incorporation. |
| FILED | Monday, March 15, 2021 |
| APPL NO | 17/201815 |
| CURRENT CPC | Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General C23C 16/46 (20130101) C23C 16/483 (20130101) Original (OR) Class Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 21/0254 (20130101) H01L 21/0262 (20130101) H01L 21/67023 (20130101) H01L 21/67115 (20130101) H01L 21/67207 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290328 | ALBIN |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Alliance for Sustainable Energy, LLC (Golden, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David Scott ALBIN (Denver, Colorado) |
| ABSTRACT | Disclosed herein are compositions and methods for making polycrystalline thin films having very large grains sizes and exhibiting improved properties over existing thin films. |
| FILED | Monday, July 27, 2020 |
| APPL NO | 17/630292 |
| CURRENT CPC | Non-metallic Elements; Compounds Thereof; C01B 19/007 (20130101) Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds C01P 2002/60 (20130101) C01P 2006/40 (20130101) Single-crystal-growth; Unidirectional Solidification of Eutectic Material or Unidirectional Demixing of Eutectoid Material; Refining by Zone-melting of Material; Production of a Homogeneous Polycrystalline Material With Defined Structure; Single Crystals or Homogeneous Polycrystalline Material With Defined Structure; After-treatment of Single Crystals or a Homogeneous Polycrystalline Material With Defined Structure; Apparatus Therefor C30B 31/08 (20130101) Original (OR) Class C30B 33/02 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 31/0296 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290349 | Bowland et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UT-Battelle, LLC (Oak Ridge, Tennessee) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Christopher C. Bowland (Knoxville, Tennessee); Amit K. Naskar (Knoxville, Tennessee); Sumit Gupta (Knoxville, Tennessee) |
| ABSTRACT | A composition comprising: (i) an electrically non-conductive fiber having a surface; and (ii) piezoelectric particles adhered to the surface of said electrically non-conductive fiber, and optionally, (iii) a sizing agent (e.g., epoxy) coated over the piezoelectric particles and surface of the electrically non-conductive fiber. Also described are composites in which the above fiber composition is embedded within a matrix, e.g., a polymer, ceramic, or glassy carbon matrix. Also described is a method for producing a passive sensing fiber composition by: coating a fiber having a surface with a liquid suspension containing piezoelectric particles suspended in a solvent; and removing the solvent to result in the piezoelectric particles adhered to the surface of the fiber. Also described are methods for detecting formation of defects in a material and methods of generating electrical energy from ambient vibration by use of the above described fiber compositions and composites thereof. |
| FILED | Wednesday, March 09, 2022 |
| APPL NO | 17/690432 |
| CURRENT CPC | Treating Textile Materials Using Liquids, Gases or Vapours D06B 3/02 (20130101) Original (OR) Class D06B 21/00 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 27/20 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290845 | Gladden et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Glint Photonics, Inc. (Burlingame, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Christopher Gladden (San Mateo, California); Victor Chub (Hayward, California); Peter Kozodoy (Palo Alto, California) |
| ABSTRACT | A mechanical actuation system for a light fixture that allows for translation of an array of optics relative to an array of light sources in a defined plane. The system can prevent undesired movement such as rotation or out-of-plane motion. A simple and intuitive user interface enables a user to point a resulting light beam in a desired direction without requiring an understanding of the internal mechanical system. The user interface may include a manually manipulated touch point such as a joystick, knob, or other interface. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689060 |
| CURRENT CPC | Functional Features or Details of Lighting Devices or Systems Thereof; Structural Combinations of Lighting Devices With Other Articles, Not Otherwise Provided for F21V 5/007 (20130101) F21V 14/06 (20130101) Original (OR) Class F21V 17/02 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291106 | McDaniel et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Florida International University Board of Trustees (Miami, Florida); Savannah River Nuclear Solutions, LLC (Aiken, South Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dwayne E. McDaniel (Miami, Florida); Ahmadreza Abbasi Baharanchi (Miami, Florida); Michael Poirier (Aiken, South Carolina); Shervin Tashakori (Miami, Florida) |
| ABSTRACT | Systems and methods for determining the yield stress of a non-Newtonian fluid in real time are provided. A pressure loss and/or liquid rise technique, an ultrasonic technique, and/or a penetrometer technique can be used to determine the yield stress of a non-Newtonian fluid. The ultrasonic technique can include a longitudinal wave approach and/or a shear wave approach. The methods and systems are non-invasive and only require slight modifications to the piping containing the non-Newtonian fluid in order to measure the yield stress. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/654006 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 11/08 (20130101) Original (OR) Class G01N 2011/0033 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291429 | Michel et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Pierre Michel (Oakland, California); Matthew Reid Edwards (Livermore, California) |
| ABSTRACT | A diffractive optical element, such as a holographic plasma lens, can be made by direction two laser beams so that they overlap in a nonlinear material, to form an interference pattern in the nonlinear material. The interference pattern can modify the index of refraction in the nonlinear material to produce the diffractive optical element. The interference pattern can modify the distribution of plasma for the nonlinear material, which can adjust the index of refraction. A third laser beam can be directed through the diffractive optical element to modify the third laser beam, such as to focus, defocus, or collimate the third laser beam. |
| FILED | Friday, March 12, 2021 |
| APPL NO | 17/200688 |
| CURRENT CPC | Optical Elements, Systems, or Apparatus G02B 5/1857 (20130101) Original (OR) Class Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 1/355 (20130101) Holographic Processes or Apparatus G03H 1/0402 (20130101) G03H 1/0465 (20130101) G03H 2001/0439 (20130101) G03H 2222/45 (20130101) G03H 2224/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292018 | Walker et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Micron Technology, Inc. (Boise, Idaho) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dean Walker (Allen, Texas); Bryan D. Hornung (Plano, Texas); Tony M. Brewer (Plano, Texas); David M. Patrick (McKinney, Texas); Christopher A. Baronne (Allen, Texas) |
| ABSTRACT | Methods, systems, and devices for bias control for a memory device are described. A memory system may store indication of whether data is coherent. In some examples, the indication may be stored as metadata, where a first value indicates that the data is not coherent and a second value or a third value indicate that the data is coherent. When a processing unit or other component of the memory system processes a command to access data, the memory system may operate according to a device bias mode when the indication is the first value, and according to a host bias mode when the indication is the second value or the third value. |
| FILED | Wednesday, March 10, 2021 |
| APPL NO | 17/198084 |
| CURRENT CPC | Electric Digital Data Processing G06F 12/0815 (20130101) Original (OR) Class G06F 2212/1041 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292278 | Roberts et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Randy S. Roberts (Livermore, California); John Goforth (Carlsbad, California) |
| ABSTRACT | A system is provided for identifying and quantizing a change in a scene having objects based on comparison of features representing a target object derived from a first image and a second image that includes the target object. The system segments, based on a scene model of the scene, a second image that includes the target object to identify a second area representing the target object within the second image. The system extracts, from the second image, second features for the target object based on the second area. The system determines determine a second effectiveness of the second features indicating effectiveness of the second features in representing the target object. The system detects a change based on a difference between first features and the second features factoring in a first effectiveness and the second effectiveness. |
| FILED | Friday, March 12, 2021 |
| APPL NO | 17/199678 |
| CURRENT CPC | Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers G06K 9/0063 (20130101) Original (OR) Class G06K 9/4604 (20130101) G06K 9/4661 (20130101) G06K 9/4671 (20130101) G06K 9/6256 (20130101) G06K 9/6262 (20130101) G06K 2209/21 (20130101) Image Data Processing or Generation, in General G06T 7/174 (20170101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292338 | Nair et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Chevron U.S.A. Inc. (San Ramon, California); Triad National Security, LLC (Los Alamos, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Rajesh S. Nair (Houston, Texas); Karim Shafik Zaki (Houston, Texas); Yan Li (Houston, Texas); Margaretha Catharina Maria Rijken (Houston, Texas); Velimir Valentinov Vesselinov (Los Alamos, New Mexico) |
| ABSTRACT | A computer implemented method for prediction of geomechanical performance including productivity index decline and completion integrity for a well or a hydrocarbon reservoir using a geomechanics informed machine intelligence (GIMI) algorithm. The method includes running a geomechanical reservoir simulator to generate training datasets for the hydrocarbon reservoir and incorporating physical models and identified variables into the GIMI algorithm. The method further includes training a neural network of the GIMI algorithm by using correlated training datasets that correlate to the physical models to produce a resulting prediction model and performing sensitivity analysis on the resulting prediction model. Additionally, the method includes identifying dominant variables for damage mechanisms through design of experiment statistics and performing history matching and blind test on the resulting prediction model. Lastly, the method includes updating the identified variables and models incorporated into the GIMI algorithm. |
| FILED | Tuesday, March 09, 2021 |
| APPL NO | 17/195755 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 3/04 (20130101) G06N 3/08 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292364 | Aimone et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | James Bradley Aimone (Keller, Texas); William Mark Severa (Placitas, New Mexico); John Darby Smith (Albuquerque, New Mexico) |
| ABSTRACT | A method for simulating a random walk using spiking neuromorphic hardware is provided. The method comprises receiving, by a buffer count neuron, spiking inputs from upstream mesh nodes, wherein the inputs include information packets comprising information associated with a simulation of a random walk process. A buffer generator neuron generates spikes until the buffer count reaches a first predefined threshold, after which it sends buffer spiking outputs to a spike count neuron. The spike count neuron counts the buffer spiking outputs, and a spike generator neuron generates spikes until the spike count neuron reaches a second specified threshold. The spike generator neuron then sends counter spiking outputs to a probability neuron, which selects downstream mesh nodes to receive the counter spiking outputs, wherein the spiking outputs include updated information packets. The probability neuron then sends the spiking outputs to the selected downstream nodes. |
| FILED | Friday, March 12, 2021 |
| APPL NO | 17/200003 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 3/10 (20130101) Original (OR) Class G06N 3/049 (20130101) G06N 3/063 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293810 | STEINER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Alliance for Sustainable Energy, LLC (Golden, Colorado); Georgia Tech Research Corporation (Atlanta, Georgia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Myles Aaron STEINER (Denver, Colorado); Daniel Joseph FRIEDMAN (Lakewood, Colorado); Ryan Matthew FRANCE (Golden, Colorado); Asegun HENRY (Boston, Massachusetts) |
| ABSTRACT | The present disclosure relates to a photovoltaic (PV) device that includes a first junction constructed with a first alloy and having a bandgap between about 1.0 eV and about 1.5 eV, and a second junction constructed with a second alloy and having a bandgap between about 0.9 eV and about 1.3 eV, where the first alloy includes III-V elements, the second alloy includes III-V elements, and the PV device is configured to operate in a thermophotovoltaic system having an operating temperature between about 1500° C. and about 3000° C. |
| FILED | Thursday, May 19, 2022 |
| APPL NO | 17/664085 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 31/0725 (20130101) H01L 31/0735 (20130101) Original (OR) Class H01L 31/1892 (20130101) Generation of Electric Power by Conversion of Infra-red Radiation, Visible Light or Ultraviolet Light, e.g Using Photovoltaic [PV] Modules H02S 10/30 (20141201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220293900 | Mane et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UCHICAGO ARGONNE, LLC (Chicago, Illinois) |
| ASSIGNEE(S) | UCHICAGO ARGONNE, LLC (Chicago, Illinois) |
| INVENTOR(S) | Anil U. Mane (Naperville, Illinois); Jeffrey W. Elam (Elmhurst, Illinois); Pragathi Darapaneni (Lemont, Illinois) |
| ABSTRACT | A process for forming a fluoride-based coating on an electrode material that is at least partially covered with a surface carbonate, includes disposing the electrode material in a reactor. The electrode material is exposed to a vapor of a fluoride-based precursor material such that the fluoride-based precursor material dopes the surface carbonate so as to form a layer of a fluoride coating on the electrode material. |
| FILED | Tuesday, May 18, 2021 |
| APPL NO | 17/323673 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/58 (20130101) H01M 4/366 (20130101) H01M 4/0428 (20130101) Original (OR) Class H01M 4/505 (20130101) H01M 4/525 (20130101) H01M 10/0525 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294267 | LETHELLIER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wireless Advanced Vehicle Electrification, LLC (Salt Lake City, Utah) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Patrice LETHELLIER (Salt Lake City, Utah); Kelly WARDELL (Stansbury Park, Utah); Adeel ZAHEER (West Valley, Utah) |
| ABSTRACT | Described herein is a wireless transfer system that includes multiple charging pads. Each of the wireless power transfer pads (WPT) includes a first winding comprising conductive wiring, the first winding positioned a distance from a center of the respective WPT pad, a second winding comprising conductive wiring, the second winding positioned the distance from the center of the WPT pad, and a third winding comprising conductive wiring, the third winding positioned the distance from the center of the WPT pad, wherein the individual windings are positioned at equal distances from the other of the three windings. |
| FILED | Wednesday, May 11, 2022 |
| APPL NO | 17/742250 |
| CURRENT CPC | Propulsion of Electrically-propelled Vehicles; Supplying Electric Power for Auxiliary Equipment of Electrically-propelled Vehicles; Electrodynamic Brake Systems for Vehicles in General; Magnetic Suspension or Levitation for Vehicles; Monitoring Operating Variables of Electrically-propelled Vehicles; Electric Safety Devices for Electrically-propelled Vehicles B60L 53/12 (20190201) Magnets; Inductances; Transformers; Selection of Materials for Their Magnetic Properties H01F 27/36 (20130101) H01F 38/14 (20130101) Circuit Arrangements or Systems for Supplying or Distributing Electric Power; Systems for Storing Electric Energy H02J 50/005 (20200101) Original (OR) Class H02J 50/12 (20160201) H02J 50/70 (20160201) H02J 50/90 (20160201) H02J 50/402 (20200101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294365 | Jahns et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Thomas Merlin Jahns (Madison, Wisconsin); Hang Dai (Madison, Wisconsin); Bulent Sarlioglu (Madison, Wisconsin); Renato Amorim Torres (Madison, Wisconsin); Woongkul Lee (Madison, Wisconsin) |
| ABSTRACT | A switching circuit includes a reverse-voltage-blocking (RB) commutation switch, a first inverter leg, and a second inverter leg. The first inverter leg includes a first dual-gate bidirectional (DGBD) and a second DGBD switch connected in series. The second inverter leg includes a third and a fourth DGBD switch connected in series. A pair of the first DGBD switch, the second DGBD switch, the third DGBD switch, and the fourth DGBD switch that are in different inverter legs of the first inverter leg and the second inverter leg are configured to switch between a first DGBD on-state and a second DGBD on-state when in an inverting operating mode. A current with a positive or a negative polarity is conducted when in the first DGBD on-state. When in the second DGBD on-state, a reverse voltage is blocked by and a current with a positive polarity is conducted through the respective DGBD switch. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692332 |
| CURRENT CPC | Apparatus for Conversion Between AC and AC, Between AC and DC, or Between DC and DC, and for Use With Mains or Similar Power Supply Systems; Conversion of DC or AC Input Power into Surge Output Power; Control or Regulation Thereof H02M 7/53871 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294808 | Ramanujan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Architecture Technology Corporation (Minneapolis, Minnesota) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ranga Ramanujan (Medina, Minnesota); Benjamin L. Burnett (Prior Lake, Minnesota) |
| ABSTRACT | This disclosure is directed to monitoring a crypto-partitioned, or cipher-text, wide-area network (WAN). A first computing device may be situated in a plain-text portion of a first enclave behind a first inline network encryptor (INE). A second device may be positioned in a plain-text portion of a second enclave behind a second INE. The two enclaves may be separated by a cipher-text WAN, over which the two enclaved may communicate. The first computing device may receive a data packet from the second computing device. The first computing device may then determine contents of a header of the data packet. The first computing device may, based at least in part on the contents of the header of the data packet, determine a status of the cipher-text WAN. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/663597 |
| CURRENT CPC | Transmission of Digital Information, e.g Telegraphic Communication H04L 12/2854 (20130101) H04L 63/1408 (20130101) Original (OR) Class H04L 63/1441 (20130101) H04L 63/1458 (20130101) H04L 63/1483 (20130101) H04L 69/22 (20130101) H04L 2463/121 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Agriculture (USDA)
| US 20220287299 | Kaeppler et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shawn Kaeppler (Middleton, Wisconsin); Heidi Kaeppler (Middleton, Wisconsin); Michael William Petersen (Merrimac, Wisconsin); Brian Joseph Martinell (Mount Horeb, Wisconsin); Frank McFarland (Middleton, Wisconsin) |
| ABSTRACT | The present invention provides pollen compositions, methods and kits for making said compositions, and methods of using said compositions to fertilize a plant. The pollen within these compositions has increased longevity and can be used to fertilize plants for an extended period of time as compared to pollen prepared using conventional methods. Also provided are methods of collecting pollen from a maize plant by maturing individual tassel branches off of the plant and vessels for collecting the pollen from these individual branches. |
| FILED | Monday, March 14, 2022 |
| APPL NO | 17/694200 |
| CURRENT CPC | New Plants or Processes for Obtaining Them; Plant Reproduction by Tissue Culture Techniques A01H 5/10 (20130101) A01H 6/4684 (20180501) Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 3/00 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287769 | Knecht et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sean David Knecht (State College, Pennsylvania); Christopher A. Siedlecki (Harrisburg, Pennsylvania); Sven Gunnar Bilen (State College, Pennsylvania); Michael Matthew Micci (Lemont, Pennsylvania); Ian Gilchrist (Hummelstown, Pennsylvania); Girish Soorappa Kirimanjeswara (State College, Pennsylvania) |
| ABSTRACT | Various aspects of the invention relate to methods and devices for treating diseases and conditions including atherosclerosis and endocarditis using low-temperature, non-equilibrium plasmas. A device may be, for example, a catheter that carries electrodes and a dielectric material for generating a localized, non-equilibrium plasma in a bodily fluid such as blood. |
| FILED | Wednesday, April 13, 2022 |
| APPL NO | 17/719833 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 18/1492 (20130101) Original (OR) Class A61B 2018/00357 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 1/44 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287965 | Ibrahim et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | North Carolina Agricultural and Technical State University (Greensboro, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Salam Ibrahim (Greensboro, North Carolina); Tahl Zimmerman (Greensboro, North Carolina); Roberta Claro da Silva (Greensboro, North Carolina) |
| ABSTRACT | The presently disclosed subject matter relates generally to oleogels, particularly to oleogels that can be used for delivering active ingredients such as probiotics. Also described herein are methods for preparing and using such delivery systems. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/692288 |
| CURRENT CPC | Foods, Foodstuffs, or Non-alcoholic Beverages, Not Covered by Subclasses A23B - A23J; Their Preparation or Treatment, e.g Cooking, Modification of Nutritive Qualities, Physical Treatment; Preservation of Foods or Foodstuffs, in General A23L 33/135 (20160801) Preparations for Medical, Dental, or Toilet Purposes A61K 9/06 (20130101) Original (OR) Class A61K 35/741 (20130101) A61K 45/06 (20130101) A61K 47/44 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220288809 | Janowiak et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | John J. Janowiak (Julian, Pennsylvania); Karolina Szymona (University Park, Pennsylvania); Kelli Hoover (Pennsylvania Furnace, Pennsylvania); Ronald G. Mack (Chatham, Massachusetts); Mark Hamelin (Midland, Canada) |
| ABSTRACT | A method for treating wood packaging materials using Radio Frequency heating includes the steps of heating wood packaging materials using RF heating and applying a pressure before the heating or incrementally applying a pressure during the heating. The wood packaging materials are heated in a RF operating unit that has a sealed chamber with an inner surface and a liner cover a majority of the inner surface, the liner having a heat-reflective inner face and an insulation layer between the inner face and the inner surface. |
| FILED | Tuesday, September 29, 2020 |
| APPL NO | 17/761358 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 2/08 (20130101) A61L 2202/122 (20130101) Processes, Apparatus or Selection of Substances for Impregnating, Staining, Dyeing, Bleaching of Wood or Similar Materials, or Treating of Wood or Similar Materials With Permeant Liquids, Not Otherwise Provided for; Chemical or Physical Treatment of Cork, Cane, Reed, Straw or Similar Materials B27K 5/001 (20130101) B27K 5/008 (20130101) B27K 5/0055 (20130101) Original (OR) Class B27K 2240/15 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220289948 | Youngblood et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana); United States Department of Agriculture (Washington, District of Columbia) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Jeffrey Paul Youngblood (Crawfordsville, Indiana); Sami Miguel El Awad Azrak (Midland, Michigan); Robert John Moon (Marietta, Georgia); Gregory T. Schueneman (Madison, Wisconsin) |
| ABSTRACT | A substantially homogeneous composition comprising cellulose nanocrystals (CNC) and carboxymethyl cellulose (CMC), wherein said CNC and CMC provide 85-95% of and 5-15% of total dry weight percentage of said CNC and CMC, respectively; a method of preparing a dried composition comprising CNC and CMC, and re-dispersing said dried composition into water to form a substantially homogeneous aqueous suspension without visible precipitate. |
| FILED | Tuesday, March 15, 2022 |
| APPL NO | 17/695443 |
| CURRENT CPC | Compositions of Macromolecular Compounds C08L 1/286 (20130101) Original (OR) Class C08L 2205/025 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290132 | Salis et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Howard Salis (State College, Pennsylvania); Alexander Reis (Austin, Texas); Sean Halper (Beltsville, Maryland); Phillip Clauer (State College, Pennsylvania); Grace E. Vezeau (Bellefonte, Pennsylvania); Daniel P. Cetnar (Bellefonte, Pennsylvania); Ayaan Hossain (State College, Pennsylvania) |
| ABSTRACT | The invention provides CRISPR-based compositions and methods comprising non-repetitive sgRNA promoter and handle sequences for simultaneous, stable expression of multiple sgRNAs. |
| FILED | Thursday, August 06, 2020 |
| APPL NO | 17/633321 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 15/11 (20130101) Original (OR) Class C12N 15/907 (20130101) C12N 2310/20 (20170501) C12N 2800/80 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290170 | PURALEWSKI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Greenlight Biosciences, Inc. (Medford, Massachusetts); United States of America, as represented by the Secretary of Agriculture (Beltsville, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Adriana PURALEWSKI (Cary, North Carolina); Christopher LAWRENCE (Blacksburg, Virginia); Upendra Kumar DEVISETTY (Morrisville, North Carolina); Sambit Kumar MISHRA (Cary, North Carolina); Krishnakumar SRIDHARAN (Cary, North Carolina); Lance E. CADLE DAVIDSON (Geneva, New York); Ann N. UNDERHILL (Geneva, New York); Yufeng FANG (Durham, North Carolina); Wimalanathan KOKULAPALAN (Cambridge, Massachusetts) |
| ABSTRACT | Disclosed herein are compositions and methods that involve recombinant polynucleotide molecules, such as single or double-stranded DNA or RNA molecules, also referred to “triggers”, that are useful for controlling or preventing E. necator infection, or recombinant DNA constructs for making such RNA molecules or for making transgenic grape plants resistant to E. necator infection. In some embodiments, polynucleotide triggers are provided as topically applied agents for controlling or preventing infection of a plant by E. necator. In some embodiments, grape plants with improved resistance to infection by E. necator, such as transgenic grape plants (including seeds or propagatable parts) expressing a polynucleotide trigger are provided. In some embodiments, grape plants (including seeds or propagatable parts) that have been topically treated with a composition comprising a polynucleotide trigger (e.g., grape plants that have been sprayed with a solution of dsRNA molecules) are provided. Also provided are polynucleotide-containing compositions that are topically applied to a E. necator or to a plant, plant part, or seed to be protected from infection by E. necator. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689598 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/113 (20130101) C12N 15/8218 (20130101) Original (OR) Class C12N 15/8286 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290369 | Zhu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States as Represented by the Secretary of Agriculture (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Junyong Zhu (Madison, Wisconsin); Roland Gleisner (Jefferson, Wisconsin) |
| ABSTRACT | Methods of fractionating lignocellulosic biomass using maleic acids are provided. Also provided are methods of forming lignin particles, furans, sugars, and/or lignocellulosic micro- and nanofibrils from the liquid and solid fractions produced by fractionation process. The fractionation can be carried out at low temperatures with short reaction times to carboxylate and dissolve lignin with a low degree of condensation. |
| FILED | Tuesday, August 11, 2020 |
| APPL NO | 16/990459 |
| CURRENT CPC | Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 19/02 (20130101) C12P 19/14 (20130101) Production of Cellulose by Removing Non-cellulose Substances From Cellulose-containing Materials; Regeneration of Pulping Liquors; Apparatus Therefor D21C 3/04 (20130101) Original (OR) Class D21C 9/08 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
National Aeronautics and Space Administration (NASA)
| US 20220291142 | Mookherjea et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); California Institute of Technology (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shayan Mookherjea (San Diego, California); Xiaoxi Wang (San Diego, California); Boris A. Korzh (Altadena, California); Matthew D. Shaw (Los Angeles, California) |
| ABSTRACT | Methods, systems, and devices for testing an electro-optic device such as a modulator or a switch are disclosed. In one implementation, an apparatus includes an optical source to generate light, a first light transmission structure to route the light into the electro-optic device through a first guide segment structured to guide optical waves and optically couplable to the electro-optic device, an electrical probe to apply one or more electrical modulation signals to the electro-optic device to generate modulated light by modulating the light routed into the electro-optic device, a second light transmission structure to collect at least part of the modulated light from a second guide segment structured to guide optical waves and optically couplable to the electro-optic device, a detector to generate an electrical output signal corresponding to the collected light, and a signal processing device to record times at which each photon corresponding to the collected light is detected by processing the electrical output signal. |
| FILED | Friday, March 11, 2022 |
| APPL NO | 17/654561 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/9503 (20130101) G01N 21/9505 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291368 | Beard et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Advent Innovations Limited Company (Columbia, South Carolina) |
| ASSIGNEE(S) | Advent Innovations Limited Company (Columbia, South Carolina) |
| INVENTOR(S) | Shawn Beard (Bishop, California); Ritubarna Banerjee (Irmo, South Carolina) |
| ABSTRACT | Described herein are Compressive Sensing algorithms developed for automated reduction of NDE/SHM data from pitch-catch ultrasonic guided waves as well as a methodology using Compressive Sensing at two stages in the data acquisition and analysis process to detect damage: (1) temporally undersampled sensor signals from (2) spatially undersampled sensor arrays, resulting in faster data acquisition and reduced data sets without any loss in damage detection ability. |
| FILED | Monday, January 10, 2022 |
| APPL NO | 17/571624 |
| CURRENT CPC | Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 7/53 (20130101) G01S 7/52004 (20130101) G01S 7/52022 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220291480 | BRENNAN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Eagle Technology, LLC (Melbourne, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sean A. BRENNAN (Pittsford, New York); Matthew John EAST (Fairport, New York) |
| ABSTRACT | According to one implementation a mount pad is provided that includes a plurality of arcuate flexure members disposed between and connected to top and bottom plates. According to some implementations a majority or all of the arcuate flexure members have a semi-circular cross-section and are arranged to form a plurality of radially spaced-apart concentric rings. Concave surfaces of the arcuate flexure members face radially inward toward a center of the concentric rings. Circumferential adjacent arcuate flexure members in each of the concentric rings are circumferentially spaced apart from one another so that a gap exists between them. According to some implementations the mount pad further includes a coupling unit prolonging from one of the top and bottom plates, the coupling unit facilitating a connection of the mount pad to a support structure. According to some implementations the mount pad is a monolithic structure. According to some implementations the monolithic structure is made using an additive manufacturing method. |
| FILED | Thursday, March 11, 2021 |
| APPL NO | 17/198699 |
| CURRENT CPC | Optical Elements, Systems, or Apparatus G02B 7/182 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220295312 | Barsoum et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Constellation Designs, LLC (Anaheim, California) |
| ASSIGNEE(S) | Constellation Designs, LLC (Anaheim, California) |
| INVENTOR(S) | Maged F. Barsoum (San Jose, California); Christopher R. Jones (Pacific Palisades, California) |
| ABSTRACT | Communication systems are described that use unequally spaced constellations that have increased capacity compared to conventional constellations operating within a similar SNR band. One embodiment is a digital communications system including a transmitter transmitting signals via a communication channel, the transmitter including a coder capable of receiving user bits and outputting encoded bits at a rate, a mapper capable of mapping encoded bits to symbols in a constellation, and a modulator capable of generating a modulated signal for transmission via the communication channel using symbols generated by the mapper, wherein the constellation is unequally spaced and characterizable by assignment of locations and labels of constellation points to maximize parallel decode capacity of the constellation at a given signal-to-noise ratio so that the constellation provides a given capacity at a reduced signal-to-noise ratio compared to a uniform constellation that maximizes the minimum distance between constellation points of the uniform constellation. |
| FILED | Thursday, May 26, 2022 |
| APPL NO | 17/804306 |
| CURRENT CPC | Coding; Decoding; Code Conversion in General H03M 13/255 (20130101) H03M 13/6325 (20130101) Transmission H04B 15/00 (20130101) H04B 17/336 (20150115) Transmission of Digital Information, e.g Telegraphic Communication H04L 1/0003 (20130101) H04L 1/0009 (20130101) H04L 27/3405 (20130101) H04L 27/3483 (20130101) H04L 27/3809 (20130101) Wireless Communication Networks H04W 24/02 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220295313 | Barsoum et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Constellation Designs, LLC (Anaheim, California) |
| ASSIGNEE(S) | Constellation Designs, LLC (Anaheim, California) |
| INVENTOR(S) | Maged F. Barsoum (San Jose, California); Christopher R. Jones (Pacific Palisades, California) |
| ABSTRACT | Communication systems are described that use unequally spaced constellations that have increased capacity compared to conventional constellations operating within a similar SNR band. One embodiment is a digital communications system including a transmitter transmitting signals via a communication channel, the transmitter including a coder capable of receiving user bits and outputting encoded bits at a rate, a mapper capable of mapping encoded bits to symbols in a constellation, and a modulator capable of generating a modulated signal for transmission via the communication channel using symbols generated by the mapper, wherein the constellation is unequally spaced and characterizable by assignment of locations and labels of constellation points to maximize parallel decode capacity of the constellation at a given signal-to-noise ratio so that the constellation provides a given capacity at a reduced signal-to-noise ratio compared to a uniform constellation that maximizes the minimum distance between constellation points of the uniform constellation. |
| FILED | Thursday, May 26, 2022 |
| APPL NO | 17/804307 |
| CURRENT CPC | Coding; Decoding; Code Conversion in General H03M 13/255 (20130101) H03M 13/6325 (20130101) Transmission H04B 15/00 (20130101) H04B 17/336 (20150115) Transmission of Digital Information, e.g Telegraphic Communication H04L 1/0003 (20130101) H04L 1/0009 (20130101) H04L 27/3405 (20130101) H04L 27/3483 (20130101) H04L 27/3809 (20130101) Wireless Communication Networks H04W 24/02 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
United States Postal Service (USPS)
| US 20220291672 | Shiu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Postal Service (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Leung Man Shiu (Gaithersburg, Maryland); Erich Joseph Petre (Gainesville, Virginia) |
| ABSTRACT | Systems and methods for commanding, controlling, and guiding automated guided vehicles (“AGVs”). Automated systems translate AGV commands according to AGV manufacturers. AGVs can be summoned and destinations be determined automatically. |
| FILED | Friday, June 03, 2022 |
| APPL NO | 17/805414 |
| CURRENT CPC | Transport or Storage Devices, e.g Conveyors for Loading or Tipping, shop Conveyor Systems Or pneumatic Tube Conveyors B65G 1/1371 (20130101) B65G 1/1378 (20130101) B65G 2203/041 (20130101) B65G 2203/042 (20130101) Hoisting, Lifting, Hauling or Pushing, Not Otherwise Provided For, e.g Devices Which Apply a Lifting or Pushing Force Directly to the Surface of a Load B66F 9/063 (20130101) Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 15/04 (20130101) Control or Regulating Systems in General; Functional Elements of Such Systems; Monitoring or Testing Arrangements for Such Systems or Elements G05B 19/41895 (20130101) Original (OR) Class G05B 2219/40298 (20130101) G05B 2219/45063 (20130101) Systems for Controlling or Regulating Non-electric Variables G05D 2201/0216 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
20220292439 — SYSTEM AND METHOD OF ELECTRONIC AND PHYSICAL MAIL CATEGORIZATION AND TARGETED DELIVERY
| US 20220292439 | Dearing et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Postal Service (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Stephen M. Dearing (Herndon, Virginia); Carla F. Sherry (Annandale, Virginia) |
| ABSTRACT | Embodiments include systems and methods of a service that allows hard copy and electronic media customers to proactively specify, across a broad range of categories, the hard copy mail and/or electronic media mail that they would or would not like to receive. Embodiments include methods and systems configured to allow customers of delivery services to customize the flow of physical items such as hard copy or other letters or parcels, for delivery or electronic media mail from mailers based on highly specific customer-designated criteria. The delivery service acts as a trusted third party to serve as the intermediary between the recipient of the items and mailers to provide privacy and manage a repository for a customer-selected criteria database. In addition, one embodiment provides verification and/or identification that mail being sent meets the customer's designated criteria. |
| FILED | Tuesday, May 31, 2022 |
| APPL NO | 17/829178 |
| CURRENT CPC | Postal Sorting; Sorting Individual Articles, or Bulk Material Fit to be Sorted Piece-meal, e.g by Picking B07C 3/00 (20130101) Electric Digital Data Processing G06F 16/245 (20190101) Data Processing Systems or Methods, Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes; Systems or Methods Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes, Not Otherwise Provided for G06Q 10/083 (20130101) Original (OR) Class G06Q 2220/00 (20130101) Transmission of Digital Information, e.g Telegraphic Communication H04L 51/212 (20220501) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292452 | Dearing |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Postal Service (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Stephen M. Dearing (Herndon, Virginia) |
| ABSTRACT | A system and method for accurately tracking the delivery of items in an item distribution network using a purpose built confidence event recorder. An item sorter sorts items for delivery based upon route information and preferences for the delivery. Items are tracked while out for delivery through the use of confidence data recorded by a confidence event recorder carried by an item carrier. The confidence data recorder can that can record GPS and time data, as well as scan barcodes, such as a barcode on an item to be delivered. Confidence data can be used to accurately record when and where item carriers deliver items. The system determines if an actual delivery occurred by comparing the confidence data to previously gathered confidence data. An expected delivery window generation system can be used to generate expected delivery windows for the delivery of new items based on the confidence data recorded. |
| FILED | Tuesday, May 31, 2022 |
| APPL NO | 17/804670 |
| CURRENT CPC | Electric Digital Data Processing G06F 16/29 (20190101) Data Processing Systems or Methods, Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes; Systems or Methods Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes, Not Otherwise Provided for G06Q 10/0833 (20130101) Original (OR) Class Wireless Communication Networks H04W 4/021 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220292802 | Simpson |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Postal Service (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ryan J. Simpson (Vienna, Virginia) |
| ABSTRACT | Embodiments of a system and method for sorting and delivering articles in a processing facility based on image data are described. Image processing results such as rotation notation information may be included in or with an image to facilitate downstream processing such as when the routing information cannot be extracted from the image using an unattended system and the image is passed to an attended image processing system. The rotation notation information may be used to dynamically adjust the image before presenting the image via the attended image processing system. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/664837 |
| CURRENT CPC | Postal Sorting; Sorting Individual Articles, or Bulk Material Fit to be Sorted Piece-meal, e.g by Picking B07C 3/20 (20130101) Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers G06K 7/1404 (20130101) Image or Video Recognition or Understanding G06V 10/25 (20220101) Original (OR) Class G06V 10/242 (20220101) G06V 30/40 (20220101) G06V 30/413 (20220101) G06V 30/424 (20220101) G06V 30/1478 (20220101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Commerce (DOC)
| US 20220294448 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) XNOR logic gate device includes a conducting device; and a ME-FET coupled to the conducting device. The ME-FET can be formed of a split gate; a first gate terminal coupled to a first portion of the split gate for receiving a first input signal; a second gate terminal coupled to a second portion of the split gate for receiving a second input signal; a source terminal coupled to a ground line; and a drain terminal coupled to the conducting device. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827742 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294449 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) majority gate device includes a conducting device and a plurality of ME transistors coupled to the conducting device. In one implementation, the plurality of ME transistors include a ME AND gate device with downward interface polarization, a ME-transmission gate device with downward interface polarization, and a ME-XNOR gate device. In another implementation, the plurality of ME transistors is five single-input ME-FETs. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827744 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220294450 | GAUL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas); Intel Corporation (Santa Clara, California) |
| INVENTOR(S) | Nishtha Sharma GAUL (Richardson, Texas); Andrew MARSHALL (Dallas, Texas); Peter A. DOWBEN (Crete, Nebraska); Dmitri E. NIKONOV (Beaverton, Oregon) |
| ABSTRACT | A magneto-electric (ME) inverter includes two anti-ferromagnetic spin orbit read (AFSOR) circuit elements, each AFSOR circuit element has a CMOS inverter; and an AFSOR device with a ME base layer; a semiconductor channel layer on the ME base layer and comprising a source terminal and a drain terminal, where the source terminal is coupled to an output of the CMOS inverter; and a gate electrode on the semiconductor channel layer. The gate electrode of a second AFSOR device of the two AFSOR circuit elements is coupled to the drain terminal of a first AFSOR device of the two AFSOR circuit elements. |
| FILED | Sunday, May 29, 2022 |
| APPL NO | 17/827747 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/42312 (20130101) Pulse Technique H03K 19/10 (20130101) H03K 19/16 (20130101) Original (OR) Class H03K 19/21 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Homeland Security (DHS)
| US 20220292295 | Hastings |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Government of the United States of America, as represented by the Secretary of Homeland Security (Washington, District of Columbia) |
| ASSIGNEE(S) | The Government of the United States of America, as represented by the Secretary of Homeland Security (Washington, District of Columbia) |
| INVENTOR(S) | William Hastings (Alexandria, Virginia) |
| ABSTRACT | An improvement to automatic classifying of threat level of objects in CT scan images of container content, methods include automatic identification of non-classifiable threat level object images, and displaying on a display of an operator a de-cluttered image, to improve operator efficiency. The de-cluttered image includes, as subject images, the non-classifiable threat level object images. Improvement to resolution of non-classifiable threat objects includes computer-directed prompts for the operator to enter information regarding the subject image and, based on same, identifying the object type. Improvement to automatic classifying of threat levels includes incremental updating the classifying, using the determined object type and the threat level of the object type. |
| FILED | Tuesday, May 03, 2022 |
| APPL NO | 17/735684 |
| CURRENT CPC | Electric Digital Data Processing G06F 3/0481 (20130101) G06F 3/0484 (20130101) Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers G06K 9/628 (20130101) Original (OR) Class Image Data Processing or Generation, in General G06T 7/70 (20170101) G06T 2200/24 (20130101) G06T 2207/10081 (20130101) G06T 2207/20092 (20130101) Image or Video Recognition or Understanding G06V 10/764 (20220101) G06V 10/768 (20220101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220295289 | Lim et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Government of the United States of America, as represented by the Secretary of Homeland Security (Washington, District of Columbia) |
| ASSIGNEE(S) | The Government of the United States of America, as represented by the Secretary of Homeland Security (Washington, District of Columbia) |
| INVENTOR(S) | Jason Lim (Alexandria, Virginia); Daniel Boyd (Arlington, Virginia); Chang Ellison (Arlington, Virginia); William Washington (North Potomac, Maryland) |
| ABSTRACT | A provider system is connected to readers disposed at distances from the provider system. A secure local connection is established between the client device and the provider system via one of the readers. Before the client reaches an access touchpoint, the provider system receives from the client device a request for client access, the provider system sends to the client device a request for identification information of the client, and the client device sends client information associated with a first mobile identification credential (MIC) which the client device received from an authorizing party system (APS), the client having consented to release the client information to the provider system, and the client information having been verified. The provider system uses the verified client information associated with the first MIC to verify or not verify the identity of the client before granting or denying the request to the client. |
| FILED | Friday, May 27, 2022 |
| APPL NO | 17/827143 |
| CURRENT CPC | Wireless Communication Networks H04W 12/06 (20130101) H04W 12/08 (20130101) H04W 12/71 (20210101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Justice (DOJ)
| US 20220291163 | XIAO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | YI XIAO (MIAMI, Florida); JUAN CANOURA (HIALEAH GARDENS, Florida) |
| ASSIGNEE(S) | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (MIAMI, Florida) |
| INVENTOR(S) | YI XIAO (MIAMI, Florida); JUAN CANOURA (HIALEAH GARDENS, Florida) |
| ABSTRACT | The subject invention provides materials and methods for single-step fluorescence and electrochemical detection of small molecules, e.g., fentanyl and its analogs, in a sample. The subjection invention provides nucleic acids materials, e.g., aptamers (nucleic acid oligonucleotides) that can bind to fentanyl and its analogs with nanomolar affinity and high specificity against illicit drugs, adulterants, and cutting agents commonly existing in seized samples. The method for detecting fentanyl and/or its analogs in a sample comprises contacting the sample with an aptamer-based sensor selective for fentanyl and its analogs, and sensitively, specifically, and rapidly detecting fentanyl and/or its analogs in the sample. |
| FILED | Friday, May 27, 2022 |
| APPL NO | 17/826891 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/115 (20130101) C12N 2310/16 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/6428 (20130101) G01N 27/3276 (20130101) Original (OR) Class G01N 27/3277 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Veterans Affairs (DVA)
| US 20220287883 | Mbagwu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California); The United States of America as represented by The Department Of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael Mbagwu (Mountain View, California); David Buickians (Glendale, California); David Myung (Saratoga, California) |
| ABSTRACT | Precise concentric, symmetric, and repeatable circular scoring (cutting) of Descemet's membrane is made possible by a handheld surgical ophthalmic device. The precision of the cut is provided by a stabilizing point on a stabilizing arm as well the anchoring insertion point at the limbus. Stabilization through the insertion point and the stabilizing arm provides a two-point fixation thereby establishing a cutting plane. The cutting plane allows for precise depth of cut whereas the rotating blade's consistent radius allows for circularity of the cut. The stabilization arm fixates on tissue, and is then removed when the procedure is completed. Consistent torque and contact pressure of the cutting blade is provided through rotational control via the depression of a button on a handle thereby removing the need to “free-hand” the desemetorhexis. |
| FILED | Tuesday, March 15, 2022 |
| APPL NO | 17/695484 |
| CURRENT CPC | Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits A61F 9/0133 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Non-Profit Organization (NPO)
| US 20220291183 | Dipple et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | US Gov't as represented by Sec'y of Air Force (Wright-Patterson AFB, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kathleen Dipple (Destin, Florida); Jimmy E. Touma (Shalimar, Florida) |
| ABSTRACT | An odor-localizing autonomous air vehicle includes an airborne robotic platform having a navigation platform, a wireless transmitter communicatively coupled to a management console, and an olfactory sensor mounted on the airborne robotic platform that reacts to at least one olfactory odor. A controller is communicatively coupled to the airborne robotic platform, the navigation platform, and the biological sensor. The controller monitors the olfactory sensor. In response to the biological sensor detecting the at least one olfactory odor, the controller directs the airborne platform to three-dimensionally map an olfactory plume of the at least one olfactory odor using an olfactory-driven search pattern. The controller stores the three-dimensional map for later retrieval or transmits the three-dimensional map of the olfactory plume to the management console via the wireless transmitter. The olfactory sensor is a photonic crystal enclosure that contains plasmonic nanoparticles. |
| FILED | Monday, March 07, 2022 |
| APPL NO | 17/687777 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 20/00 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/0001 (20130101) Original (OR) Class G01N 33/0062 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Government Rights Acknowledged
| US 20220289559 | Duan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northrop Grumman Systems Corporation (Falls Church, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dah-Weih Duan (Torrance, California); Elizabeth T. Kunkee (Manhattan Beach, California); Martin E. Roden (Long Beach, California); Laura M. Woo (Rossmoor, California) |
| ABSTRACT | A microelectronics H-frame device includes: a stack of two or more substrates wherein the substrate stack comprises a top substrate and a bottom substrate, wherein bonding of the top substrate to the bottom substrate creates a vertical electrical connection between the top substrate and the bottom substrate, wherein the top surface of the top substrate comprises top substrate top metallization, wherein the bottom surface of the bottom substrate comprises bottom substrate bottom metallization; mid-substrate metallization located between the top substrate and the bottom substrate; a micro-machined top cover bonded to a top side of the substrate stack; and a micro-machined bottom cover bonded to a bottom side of the substrate stack. |
| FILED | Thursday, March 11, 2021 |
| APPL NO | 17/198700 |
| CURRENT CPC | Microstructural Devices or Systems, e.g Micromechanical Devices B81B 7/0006 (20130101) Original (OR) Class B81B 7/0019 (20130101) B81B 2207/07 (20130101) B81B 2207/091 (20130101) Processes or Apparatus Specially Adapted for the Manufacture or Treatment of Microstructural Devices or Systems B81C 3/001 (20130101) B81C 3/005 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220290572 | Gunasekera et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | General Electric Company (Schenectady, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Anthony Michael Gunasekera (New Richmond, Ohio); Nicholas Joseph Kray (Mason, Ohio); Leslie Louis Langenbrunner (Cincinnati, Ohio); Simeon Paul Copple (Wilmington, Ohio) |
| ABSTRACT | A composite airfoil having a non-metallic leading edge protective wrap is provided. In one aspect, the airfoil has a composite core having a pressure sidewall and a suction sidewall each extending between a core leading edge and a core trailing edge. A leading edge protective wrap protects the core leading edge and includes a trailing wrap and a leading wrap. The trailing wrap wraps around the core leading edge and is connected to the composite core. The leading wrap wraps around the core leading edge and is connected to the trailing wrap. The trailing and leading wraps both have leading edges that are spaced from one another. A filler is positioned between the leading edges of the trailing and leading wraps. A protective nose is connected to the leading edge of the leading wrap. The components of the leading edge protective wrap are formed of non-metallic materials. |
| FILED | Thursday, March 11, 2021 |
| APPL NO | 17/198843 |
| CURRENT CPC | Non-positive Displacement Machines or Engines, e.g Steam Turbines F01D 5/282 (20130101) F01D 9/041 (20130101) Original (OR) Class F01D 25/005 (20130101) Indexing Scheme for Aspects Relating to Non-positive-displacement Machines or Engines, Gas-turbines or Jet-propulsion Plants F05D 2220/323 (20130101) F05D 2240/12 (20130101) F05D 2240/30 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220295629 | DUAN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northrop Grumman Systems Corporation (Falls Church, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | DAH-WEIH DUAN (Torrance, California); ELIZABETH T. KUNKEE (Manhattan Beach, California); MARTIN E. RODEN (Long Beach, California); LAURA M. WOO (Rossmoor, California) |
| ABSTRACT | A microelectronics H-frame device comprising an RF crossover includes: a stack of two or more substrates, wherein a bottom surface of a top substrate comprises top substrate bottom metallization, and wherein a top surface of a bottom substrate comprises bottom substrate top metallization, wherein the top substrate bottom metallization and the bottom substrate top metallization form a ground plane that provides isolation to allow a first signal line to traverse one or more of the top substrate and the bottom substrate without being disturbed by a second signal line traversing one or more of the top substrate and the bottom substrate at a non-zero angle relative to the first signal line, at least one of the first signal line and the second signal line passing to a second level with the protection of the ground plane, thereby providing isolation from the other signal line. |
| FILED | Wednesday, March 31, 2021 |
| APPL NO | 17/219103 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 23/04 (20130101) H01L 23/66 (20130101) H01L 23/528 (20130101) H01L 23/5221 (20130101) H01L 23/5226 (20130101) Waveguides; Resonators, Lines, or Other Devices of the Waveguide Type H01P 3/08 (20130101) Printed Circuits; Casings or Constructional Details of Electric Apparatus; Manufacture of Assemblages of Electrical Components H05K 1/0237 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
How To Use This Page
THE FEDINVENT PATENT APPLICATION DETAILS PAGE
Each week, FedInvent analyzes newly granted patents and published patent applications whose origins lead back to funding by the US Federal Government. The FedInvent Patent Details page is a companion to the weekly FedInvents Patents Report.
This week's information is published in the FedInvent Patents report for Thursday, September 15, 2022.
The FedInvent Weekly Patent Details Page contains a subset of patent information to provide a deeper dive into the week's taxpayer-funded patents to help the reader better understand where a patent fits in the federal innovation ecosphere.
HOW IS THE INFORMATION ORGANIZED?
Patents are organized by the funding agency. Within each group, the patents are organized in numeric order. A patent funded by more than one agency will appear in the section of each of the agencies that funded the research and development that resulted in the invention. This approach gives the reader a complete view of the department or agency activity for the week.
WHAT INFORMATION WILL I FIND?
THE PANEL
There is a panel for each patent that contains the patent number and the title of the patent. When you click the panel, it opens to reveal the following information:
FUNDED BY
The agencies that funded the grants, contracts, or other research agreements that resulted in the patent. FedInvent includes as much information on the source of the funding as possible. The information is presented in a hierarchy going from the Federal Department down to the agencies, subagencies, and offices that funded the work. Here are two examples:
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Army Research Office (ARO)
We do our best to provide detailed information about the funding. In some cases, the patent only reports limited information on the origins of the funding. FedInvents presents what it can confirm. We add the patents without the information required by the Bayh-Dole Act to our list of patents worthy of further investigation.
APPLICANT(S) and ASSIGNEES
FedInvent includes both the Applicants and the Assignees because having both provides more information about where the inventive work was done and by what organizations. Many organizations — universities, corporations, and federal agencies — standardize the Assignee/Owner information by the time a patent is granted. In the case of federal patents, many of the patents use the agency headquarters information for patent assignment.
Showing just the headquarters address would make Washington, DC the epicenter of all taxpayer-funded research and development. Providing both the applicant information and the assignee information provides a more accurate picture of where important taxpayer-funded innovation is happening in America. Here are two examples from two different patents:
APPLICANT: U.S. Army Research Laboratory, Adelphi, MD
ASSIGNEE: The United States of America as represented by the Secretary of the Army Washington, DC
APPLICANT: Optech Ventures, LLC (Torrance, California)
ASSIGNEE(S): The Regents of the University of California (Oakland, California); Optech Ventures, LLC (Torrance, California)
INVENTOR(S)
The inventors appear in the same order as they appear on the patent. FedInvents presents the names in first name/last name order because they are easier to read than the last name/first name order of the names on the USPTO patent documents.
ABSTRACT
The abstract is presented as it appears on the patent.
FILED
The date the patent application including the day of the week.
APPL NO
This is the patent application serial number. If you’d like to learn more about how application serial numbers work you can go to the Lists Page.
ART UNIT
Patent data includes the Art Unit where a patent was examined. (The Art Unit isn’t available for published patent applications.) The Art Unit provides insight into what group of patent examiners prosecuted the patent application and the subject matter that the examiners work on. For example:
3793 — Medical Instruments, Diagnostic Equipment, and Treatment Devices
You can learn more about ART UNITS on the FedInvent Patents Weekly panel called About Tech Center or you can find information on the FedInvent Lists Page.
CURRENT CPC
Current CPC provides a list of the Cooperative Patent Classification symbols assigned to the patent. These are the CPC symbols assigned at the time the patent was granted.
The FedInvent Project is a patent classification maximalist endeavor or put another way, we believe that the more you understand about patent classification the more you'll learn about the nature of the invention and the types of work that the federal government is funding.
The symbol presented in BOLD is the symbol identified as the "first" classification which is the most relevant classification on the patent. The date that follows the symbol is the date of the most recent revision to the art classed there.
- A61B 1/149 (20130101)
- A61B 1/71 (20130101)
- A61B 1/105 (20130101)
The CPC symbols match the classifications found on the PDF version of the patent. Over time, the classifications on the full text version of the patent change to reflect how USPTO organizes patent art to support its examiners. The two sets of CPCs don’t always match.
VIEW PATENT
As of June 2021, we include two ways to view a patent at USPTO. FedInvent provides a link to the Full-Text Version of the patent and a link to the PDF version of the patent.
HOW DO I FIND A SPECIFIC PATENT ON A PAGE?
You can use the Command F or Control F to find a specific patent you are interested in.
HOW DO I GET HERE?
You navigate to the details of a patent by clicking the information icon that follows a patent on the FedInvent Patents Weekly Report.
You can also reach this page using the weekly page link that looks like this:
https://wayfinder.digital/fedinvent/patents-2022/fedinvent-applications-20220915.html
Just update the date portion of the URL. Tuesdays for patents. Thursdays for pre-grant publication of patent applications.
Download a copy of the How To Use This Page